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Non-invasive methods for obtaining intact fetal cells would permit accurate prenatal 
diagnosis for aneuploidy and single gene disorders without attendant risks associated 
with invasive procedures.  In chromosomally abnormal fetus such as trisomy 18, 
existence of fetal primitive nucleated erythroblasts during second trimester and at birth 
has not yet been identified.  If proven, it could be of great clinical significance, as the 
existence of these cells could indicate not only the presence of a chromosomally 
abnormal fetus but also imply that the ε-globin primitive fetal nucleated erythroblasts are 
also ideal cell to be targeted in the second trimester for non-invasive prenatal diagnosis.   
 
Various fetal cell enrichment protocols are available; their efficiency has not been tested 
appropriately in an in-vitro model system and it is important to evaluate the intrinsic 
protocol efficiency in-vitro before studying its enrichment efficiency in an in-vivo model.    
 
To date, there is no biological model to determine the in-vivo efficiency of any new fetal 
cell enrichment protocol.   
 
Cell-free fetal DNA has been investigated as a marker for feto-maternal haemorrhage at 
surgical termination of pregnancy and we planned to use this fetal genetic material as 
corroborating evidence of the quantity of feto-maternal haemorrhage. 
 
Study Objectives 
(i) To evaluate the presence of ε-globin-positive primitive fetal nucleated erythroblasts in 
trisomy 18 syndrome fetus during second trimester and at birth.   
 xi 
Trisomy 18 was selected as a model to prove this hypothesis.  The choice of T18 as an 
aueploid model to base our investigations was based upon the assumption that the 
haemoglobin switch is similar in all aneuploidies, and that the placental interface is 
similar in its leakiness for both T18 and T21.  We acknowledge that T18 is rarer than T21 
and choosing T18 will limit our ability to gauge what happens in a T21 pregnancy which 
is more clinically relevant, it was due to the availability of T18 cases in our unit at that 
point in time and lack of any T21 cases, that we chose to undertake T18 to prove our 
hypothesis.     
 
(ii) To evaluate efficiency of a new fetal cell enrichment protocol in in-vitro model 
system.  
 
(iii) To develop an in-vivo model of biological feto-maternal haemorrhage that could be 
used to evaluate efficiency of new fetal cell enrichment protocol for non-invasive 
prenatal diagnosis in the first trimester. 
 
Hypotheses 
1.   Embryonic epsilon-globin positive nucleated red blood cells persists beyond the  
      second trimester using T18 as a model. 
2a. Surgical termination of pregnancy can be used to evaluate efficiency of a new fetal   
      cell enrichment protocol in in-vitro model system. 
2b. Surgical termination of pregnancy can be used as an in-vivo model to study   
      enrichment efficiency of a novel non-invasive prenatal diagnosis method in the first  





To address the first hypothesis pure sample of fetal blood was obtained via cordocentesis 
from a viable trisomy 18 fetus (n = 1) and karyotypically normal fetuses (n = 4) during 
the second trimester.  Cord blood samples were obtained from three trisomy 18 and 
twenty karyotypically normal neonates at term vaginal birth delivery.  The fetal blood 
and cord blood samples were processed using Ficoll 1077 and Percoll 1083 density 
gradient centrifugation, respectively followed by anti-GPA selection on MACS to obtain 
glycophorin-A-(GPA)-positive fetal erythroblasts.  Morphology of primitive fetal 
nucleated erythroblasts was evaluated by Wright stain and presence of ε-globin within the 
cytoplasm was determined using immunocytochemical staining.  
 
To address hypothesis 2a, primitive fetal erythroblasts were isolated from products of 
conception obtained in the first trimester after surgical termination of pregnancy and were 
spiked into adult peripheral blood and processed through the three-step enrichment 
method comprising of first step Percoll 1118 density gradient, second-step enrichment 
method using anti-CD45/anti-GPA on MACS followed by treatment with ammonium 
chloride/1mM acetazolamide cocktail lysis buffer. FNRBCs recovered were calculated 
and identified by Wright’s staining and ε-globin immunocytochemistry and ICC-cFISH.   
 
To address hypothesis 2b, two maternal blood samples were collected from each patient: 
20 ml prior to surgical termination of pregnancy and another 20 ml within 5 minutes after 
the surgical procedure (n = 10). They were processed immediately using our three-step 
enrichment protocol. Cells enriched were cytospun for identification.  Fetal gender was 
confirmed by cFISH on FNRBCs and trophoblasts prepared from trophoblastic villi 
obtained from same patients. 
 
 xiii 
Cytospun slides were Wright’s stained for morphological identification of FNRBCs.  
Slides containing NRBCs as identified by Wright’s staining were de-stained and 
examined for the presence of fetal ε-globin positive primitive erythroblasts by 
immunocytochemistry. The locations of these cells were recorded. Slides were then 
destained in xylene, rinsed in distilled water, put through ICC-cFISH, to examine gender 
of ε-globin cells. 
 
Both total and cffDNA were quantified using real-time quantitative PCR.  TaqMan 
amplification reactions were set up in a reaction volume of 25 µl. Each reaction contained 
1x Taqman Universal-Master-Mix, 240 nM of each amplification primer, 100 nM of the 
corresponding TaqMan probe and 5 µl of the extracted plasma DNA. Thermal cycling for 
both SRY and β-globin was initiated with 2-min incubation at 50˚C, which followed the 
first denaturation step for 10 min at 95˚ C and then 55 cycles of 95˚C for 15s and 60˚C for 
1 min.     
 
Results 
Compared to normal controls, the proportion of fetal nucleated red blood cells was found 
to be 16- and 14-fold higher in a second trimester trisomy 18 fetus (n = 1) and in trisomy 
18 neonates at birth (n = 3), respectively.  Epsilon-globin-positive primitive fetal 
nucleated erythroblasts were found both during second trimester and at birth, indicating 
continued gene expression of epsilon-chain in trisomy 18 aneuploidy.   
 
The three-step enrichment protocol to be tested for its efficiency in in-vitro model 
consisted of Percoll 1118 density-gradient-centrifugation (first-step), anti-CD45 or anti-
GPA alone or as anti-CD45/anti-GPA combination (second-step) and selective 
erythrocyte lysis by combination of NH4Cl/acetazolamide buffer at the ratio of 1:2 (third-
 xiv 
step).  Using anti-CD45/anti-GPA combination gave a pure population of red blood cells 
compared to their use alone, making the former suitable as the second-step enrichment 
method.  Selective lysis during third step with the combination of NH4Cl/acetazolamide 
buffer showed 96% of adult erythrocytes to be lysed and 93% of fetal nucleated red blood 
cells intact.  Thus, a three-step protocol was adopted to test its efficiency in in-vitro 
model. 
 
The efficiency of the three-step enrichment system in in-vitro model was 37% (95% CI, 
28.5%-45.6%; n = 8).  Enriched primitive fetal erythroblasts were accurately identifiable 
by both ε-globin light microscopic immunocytochemistry and ICC-cFISH. 
 
Using surgical termination of pregnancy as an in-vivo model, significantly more FNRBCs 
and ε-globin positive primitive erythroblasts were recovered from post-termination of 
pregnancy maternal blood samples (3 and 2.8-fold, respectively).  A significant positive 
correlation was also observed between gestational age and increase in FNRBCs (r=0.66; 
p=0.03) and ε-globin positive cells (r=0.65; p=0.04).  
 
Increase in FNRBCs in maternal blood after surgical termination of pregnancy was 
associated with a concomitant increase in ε-globin positive fetal primitive erythroblasts 
(correlation co-efficient, r=0.82; p=0.004).  
 
In pregnancies with male fetuses (n=8), a significant increase in FNRBCs (3 fold) and ε-
globin positive primitive fetal erythroblasts (2.8 fold) was seen after the surgical 
termination of pregnancy. 
 
 xv 
There was no change in either the total DNA or the cell-free male fetal DNA levels in 
maternal plasma after, compared with before, surgical termination of pregnancy.   
 
Therefore, surgical post-termination of pregnancy enrichment of ε-globin positive 
primitive fetal erythroblasts can estimate the efficiency of that particular enrichment 
system in on-going pregnancies.  It shows that an enrichment protocol can expect three-
fold fewer fetal cells in an ongoing first trimester pregnancy than the number of cells 
enriched from first trimester maternal blood obtained after surgical termination of 
pregnancy.   
 
A mathematical relationship between the distribution of epsilon positive fetal 
erythroblasts in pre- and post-termination maternal blood was derived as follows:  
Observed number of pre-termination primitive FNRBCs = co-efficient between pre- and 
post-termination primitive FNRBCs x observed number of post-termination primitive 
FNRBCs.  The co-efficient of our model is 0.35 (95%CI, 0.26-0.44) and the regression 
coefficient, R2 is 0.89.   
 
Our observations suggest that an accurate in-vivo enrichment efficiency of any new 
enrichment protocol could be developed using maternal blood obtained within 5 minutes 
after first trimester surgical termination of pregnancy.    
 xvi 
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Without prenatal diagnosis, 1 in 50 babies are born with serious physical or mental 
handicap, and as many as 1 in 30 with some form of congenital malformation (Harper, 
1998).  These may be due to structural or chromosomal abnormalities, or single gene 
disorders.  The diagnosis of aneuploidy, monogenic disorders and fetal rhesus D status 
requires invasive testing by amniocentesis, chorionic villus biopsy or fetal blood 
sampling.  These tests carry a procedure-related risk of miscarriage of 1-4% (Tabor et al., 
1986; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group 1989; Rhoads et 
al., 1989; MRC Working Party 1991; Buscaglia et al., 1996; Wald et al., 1998). 
 
In contrast to monogenic conditions which are largely confined to certain ethnic groups 
or clustered within families, over 90% of the structural or chromosomal abnormalities 
arise in pregnancies with no specific risk factors.  Thus, while prenatal diagnosis for 
single gene disorders is concentrated on at-risk populations, low-risk populations are 
offered universal screening for structural anomalies and aneuploidy.  Whereas second 
trimester screening for structural malformations by ultrasonography may at the same time 
be diagnostic, current prenatal screening for chromosomal abnormalities using 
biochemical and sonographic markers for aneuploidy is more an antenatal risk-estimation 
exercise (Chitty, 1998).   
 
The diagnosis of aneuploidy and single gene disorders depends upon recovery of fetal 
cells and fetal DNA (deoxyribonucleic acid), but the hazard of fetal loss associated with 
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current invasive methods limits the uptake of these procedures by women identified at 
increased risk by screening tests (Chitty, 1998).   
 
Observations that cell-free fetal DNA and intact fetal cells can enter and circulate within 
maternal blood have raised the possibility of non-invasive access to fetal genetic material 
that would allow the prenatal diagnosis of chromosomal and monogenic disorders (Lo et 
al., 1990; Walknowska et al., 1969).  
 
Use of circulating fetal DNA has progressed from an idea to clinical application of 
prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma (Lo et 
al., 1998a) mainly because of the significant quantity of fetal DNA within maternal 
plasma and serum (Lo et al., 1998b) compared with the rarity of intact fetal cells within 
maternal blood (Bianchi et al., 1997).  However, the usefulness of fetal DNA in prenatal 
genetic diagnosis is limited to a few paternally-inherited monogenic conditions whereas 
recovery of intact fetal cells would allow accurate genetic diagnoses of all aneuploidies 
and single gene disorders. 
 
Among the fetal cells identified to-date, fetal nucleated red blood cells (FNRBCs) are the 
favoured target cells at present because they are the predominant nucleated cell type in 
the first and early second trimester of pregnancy, they are mononuclear and suitable for 
chromosomal fluorescence in-situ hybridisation (cFISH), their limited lifespan makes 
them unlikely to persist across pregnancies (Pearson, 1967) and unlike trophoblasts, 
which demonstrate confined placental mosaicism in 1% of cases (Hahnemann and 
Vejerslev, 1997), these cells reveal the representative fetal genotype.  Recent evidence 
suggests that ε-globin is the ideal fetal cell marker for non-invasive prenatal diagnosis 
using fetal cells derived from maternal blood (Choolani et al., 2001; Al-Mufti et al., 
 3 
2001; Choolani et al., 2003; Mavrou et al., 2003), and Choolani and colleagues (Choolani 
et al., 2001; Choolani et al., 2003) have addressed the issue of specific identification of 
fetal origin of first-trimester primitive nucleated erythroblasts using embryonic ε-globin 
and the simultaneous fluorescence labelling of this marker with cFISH for non-invasive 
prenatal diagnosis.     
 
Despite this breakthrough (Choolani et al., 2001; Choolani et al., 2003), enriching these 
rare cells from maternal blood still remain a challenge: there is only 1 fetal nucleated cell 
per 107 maternal nucleated cells (Bianchi et al., 1997) and five hundred-fold less if 
compared with maternal anucleate red blood cells.  As little can be done to alter the 
frequency of fetal erythroblasts in maternal blood, researchers have focussed on using 
various enrichment methods that could help them in enriching these cells from maternal 
blood for non-invasive prenatal diagnosis.  Current enrichment protocols incorporate a 
magnetically-activated cell sorting (MACS) or fluorescence activated cell sorting (FACS) 
step to deplete or select target cell groups.  In either case, density gradient centrifugation 
is used as the first-step to deplete maternal anucleate red blood cells.  However, the 
efficiency of enrichment protocols used to-date for this rare cell isolation remains to be 
established.  Few methods have been adopted to test the efficiency of enrichment systems 
for fetal nucleated erythroblast isolation from maternal blood for non-invasive prenatal 
diagnosis.  While some have attempted to determine the efficiency by applying the 
protocols directly on maternal blood, others used invasive procedures as in-vivo model 
system to determine the efficiency.  This may not be an ideal strategy as the numbers of 
cells obtained are too small to reflect the efficiency of the enrichment system.  In this 
thesis, I explored the possibility of using termination of pregnancy as an in-vitro as well 
as an in-vivo model system to study the efficiency of an enrichment system for first-
trimester non-invasive prenatal diagnosis.  I also explored the prospect of termination of 
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pregnancy as a model system to study first-trimester non-invasive prenatal diagnosis 
using cell-free fetal DNA as a biological marker. 
 
1.2 Current methods of prenatal diagnosis  
 
Current methods of prenatal diagnosis of chromosomal abnormalities and single gene 
disorders involve diagnostic tests.  Screening tests are designed to be non-invasive, safe, 
sensitive and applicable to a low-risk population.  Many prenatal screening tests however, 
have high false-positive rates.  At a detection rate of 60%, 70%, 80% and 90%, the false 
positive rate of double test is 5.5%, 9.2%, 15.9% and 29.9%, respectively.  The false 
positive rate of triple test is 2.7%, 5.5%, 11.1% and 24.1%, respectively.  The false 
positive rate of quadruple test is 1.6%, 3.3%, 7.0% and 16.5%, respectively (Wald and 
Hackshaw, 2000).  In contrast, diagnostic tests are accurate but may be invasive.   
 
Prenatal diagnosis of structural malformations which occur in 2.1% of pregnancies 
(Bricker et al., 2000) can be diagnosed non-invasively using ultrasonography.  Since 
most structural abnormalities occur in the low-risk population, routine screening scans 
are offered to all pregnant women in Singapore between 20-22 weeks.  The sensitivity of 
this technique, which ranges from 2.3-100%, depends on the gestational age, scanning 
policy, skill of the operator, type of machines being used and the type of anomalies 
included in the evaluation.   
 
Currently, the diagnosis of chromosomal, monogenic disorders and most fetal rhesus D 
status requires invasive testing by amniocentesis, chorionic villus sampling (CVS) or 
fetal blood sampling (FBS).  These tests carry a small but definite risk of procedure-
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related fetal loss.  As such, non-invasive screening tests have been devised to identify 
high-risk population for targeted diagnostic invasive testing. 
 
1.3 Screening for chromosomal disorders 
 
A screening test is not diagnostic. It distinguishes between those who are at high risk of 
being affected from those not being affected.  The more effective the screening test, the 
better the discrimination.  The three screening parameters relevant to the mother are 
detection rate which is the proportion of affected individuals with a screen positive result, 
false-positive rate, which is the proportion of unaffected individuals with a screen 
positive result and OAPR (the odds of being affected given a positive result). 
 
In Down syndrome screening, a woman is judged screen positive if her risk of having an 
affected pregnancy based on her age and marker levels exceeds a specified cut-off level.  
Usually the cut-off level is chosen to yield a 5% false-positive rate and the corresponding 
detection rate is determined.   
 
The expected rate of major chromosomal anomalies in live births of a given population is 
0.65% including trisomy 21 with a frequency of 0.12% (Hsu, 1992).  For this reason, 
invasive testing is confined to a selected population at high-risk for chromosomal 
anomalies in order to reduce the total number of chromosomally normal healthy fetuses 
lost due to the procedure. 
 
Trisomy 21 is the commonest chromosomal aneuploidy seen to reach viability and carries 
a significant risk of long-term morbidity and mental handicap.  It has an estimated birth 
prevalence of 1.3 per 1000 live births (Cuckle et al., 1991).  Trisomy 13 and 18, on the 
other hand are usually lethal in-utero or in the first few months of life, and have a birth 
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prevalence of 0.15 and 0.08 per 1000 live births, respectively (Robert, 2000).  Therefore 
most prenatal screening programmes have been designed to detect Down syndrome. 
 
Maternal Age:  Maternal age is being used to estimate the risk of chromosomal 
abnormalities based on the fact that the risk increases with maternal age and a cut-off 
level of 35 years (when the risk of Down syndrome is around 1 in 280) in United 
Kingdom has been placed, and all women at or above 35 years at the time of delivery are 
offered invasive testing (Surbek and Holzgreve, 2001).  Cut-off level of 35 was used 
initially in UK, as that equates to 5% of all deliveries in UK and it happen to correspond 
to 1 in 280 risk of down syndrome, a decision made by department of health.  
Considering the fact that 36,900 deliveries took place in Singapore in 2004 (Ministry of 
Health, Singapore, 2004), and 20% of all pregnancies were above 35 years of age, and 
the Down syndrome prevalence being 1.17/1000 live births (Lai et al., 2002), the 
expected number of cases of Down syndrome occurring in 2004, are 43.   As 30% of 
cases of Down syndrome occur in women above 35 years of age (in U.K) (Chitty, 1998; 
Wald et al., 1998), 7380 women may have undergone amniocentesis to identify 11 cases 
of Down syndrome.  Therefore, to identify 1 case of Down syndrome 671 women needed 
to undergo amniocentesis and 7 of them may have had procedure-related miscarriage.  
Further, 70% of affected neonates are born to mothers under 35 years of age, whom will 
be classified as low low-risk using maternal age alone. 
 
Strategies which have been developed to estimate the risk for chromosomal anomalies in 
individual pregnancies includes serum biochemical markers and ultrasound measured 
nuchal translucency (NT) so as to improve the sensitivity and specificity of detection of 
Down syndrome.  Information from these tests are analysed together with the maternal 
age to determine the woman’s individual risk of having a baby with Down syndrome.  It 
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is known that, about 80% of pregnant women would choose to have a screening test for 
Down syndrome if available and 90% of those with affected fetuses would terminate the 
pregnancy (Wald et al., 1998).   
 
Biochemical markers:  Biochemical screening in the second trimester include hormonal 
markers such as alpha-fetoprotein (AFP), unconjugated oestriol (uE3), free β-subunit of 
human chorionic gonadotrophin (β-hCG) and dimeric inhibin-A.  In 1984, low maternal 
serum AFP levels were found to be associated with Down syndrome (Merkatz et al., 
1984; Cuckle et al., 1984).  Later, free β-hCG level was found to be raised (Bogart et al., 
1987) and the uE3 reduced in Down syndrome fetuses (Canick et al., 1988; Wald et al., 
1988a).  In 1988, the three were combined with maternal age and were coined a name of 
triple test (Wald et al., 1988b).  In 90’s, a new second trimester marker dimeric inhibin-A 
was described (Van Lith et al., 1992; Wald et al., 1996; Wald et al., 1997a), the levels of 
which was found to be twice as great as those in unaffected pregnancies of the same 
gestational age (1.91 multiples of the median) (Wald and Hackshaw, 2000).  Multiple of 
the median is a measure of how far an individual test result deviates from the median.  
MoM is used where the median is highly variable.  The test is usually performed between 
14-21 weeks as the double test (AFP, β-hCG), triple test (AFP, β-hCG, uE3) or quadruple 
test (AFP, β-hCG, uE3, inhibin-A).  At a false positive rate of 5%, the detection rates are 
58%, 69% and 75% respectively, for the double, triple and quadruple test and an OAPR 
of 1:65-50, depending on whether two, three or four biochemical parameters are used 
(Wald et al., 1998). 
 
Nuchal Translucency screening:  Measurement of fetal nuchal translucency (NT) 
thickness provides an effective screening for Down syndrome in the first-trimester 
(Szabo and Gellen, 1990).  The mechanism of this increased NT (an echolucent space) is 
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not understood but seems to be related to minor cardiac anomalies in chromosomally 
abnormal fetuses (Hyett et al., 1999).  NT measurements increase with gestational age.  
Five percent of normal fetuses have NT measurements greater than 2.2mm to 2.8mm at 
crown-rump lengths (CRLs) of 38 and 84mm, respectively (Pandya et al., 1995). 
Subsequently, 14 studies were published from different research groups over a period of 
4 years.  Snijders et al. (1998) looked at a sufficient number of patients to allow 
assessment of the sensitivity of the method (96,127 patients between 10-14 weeks).  They 
took maternal age and NT into account in the calculation of risks.  They demonstrated 
that at a false-positive rate of 8.3%, NT screening detected 82% of fetuses with Down 
syndrome.  For a false positive rate of 5%, the detection rate was 77%. 
 
Combined test:  Wald and Hackshaw (1997b) reported a combination of four parameters 
for use in the first trimester (10-14 weeks) screening for Down sydnrome:  maternal age, 
first-trimester maternal screening marker Pregnancy Associated Plasma Protein A 
(PAPP-A) which was found to be 60% lower (0.38 multiples of the median in 
pregnancies with Down syndrome), free β-hCG which was 80% higher in affected 
pregnancies (1.83 multiples of the median) and NT.  They demonstrated a detection rate 
of 85% using the combined test at 5% false-positive rate.  A recent prospective study 
(Bindra et al., 2002; Spencer et al., 2003) have demonstrated that screening for trisomy 
21 in a one-stop clinics for early assessment of fetal risk (OSCAR) setting by the 
combination of four parameters at 11-14 weeks gestation is associated with a detection 
rate of 90% for a false-positive rate of 5%. 
 
Recently, Cicero and colleagues (2001) reported that in about 70% of fetuses with 
trisomy 21, the nasal bone is absent at the 11th to 14th week ultrasound scan.  When this 
marker was incorporated together with NT, maternal age, free-βhCG and PAPP-A in the 
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first-trimester screening, a 90% detection rate could be retained with a simultaneous ten-
fold reduction in the false-positive rate from 5% to 0.5%.  For a 5% false-positive rate, 
the detection rate could increase to 97% (Cicero et al., 2003). 
 
Integrated test:  Since first- and second-trimester serum screening and NT assessment are 
independent measures of the risk of a Down syndrome pregnancy, adjusting the a priori 
risk of maternal age, recent efforts have attempted to combine first - and second-trimester 
serum screening into the integrated test.  This involves both the first- and second-
trimester tests and holds the information, finally providing the patient with a single 
screening risk estimate result.  The integrated test involves first-trimester PAPP-A and 
NT and second-trimester free-βhCG, AFP, uE3 and inhibin-A to derive a single risk 
figure for the test (Wald et al., 1999).  Recently, a prospective Serum, Urine and 
Ultrasound Screening Study (SURUSS) were carried out on 47,053 singleton pregnancies 
(including 101 pregnancies with Down syndrome).  NT measurements were also taken.  
Serum and urine samples were collected between 9 and 13 weeks, and again between 14 
and 20 weeks of pregnancy.  For an 85% Down syndrome detection rate, the false-
positive rate for the integrated test (NT and PAPP-A) at 11 completed weeks of 
pregnancy, and uE3, AFP, free β-hCG and inhibin-A in the early second trimester, serum 
integrated test (without NT), combined test (NT with free β-hCG and PAPP-A at 11 
weeks), quadruple test (AFP, uE3, free β-hCG and inhibin-A) and NT alone at 11 weeks 
were 0.9%, 2.7%, 4.3%, 6.2%, and 15.2% respectively. All tests included maternal age. 
Using the integrated test at an 85% detection rate, there would be six diagnostic 
procedure-related unaffected fetal losses following amniocentesis per 100,000 women 
screened compared with 35 using the combined test or 45 with the quadruple test.  It was 
concluded that integrated test offers the most effective and safe method of screening for 
women who attend in the first trimester followed by serum-integrated test. While the 
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quadruple test is most effective for women who first attend in the second trimester, the 
authors were not in the favour for retaining the double or triple tests, or NT alone (with or 
without maternal age) in antenatal screening for Down syndrome (Wald et al., 2003).  
 
Recently, a US National Institute of Child Health and Human Development (NICHD) 
funded large trial named the FASTER (First and Second Trimester Evaluation of Risk for 
Aneuploidy) trial conducted at 15 centres in United States (Dolan, 2004).  The trial 
involved 33,557 pregnant women at 15 centers who underwent combined first-trimester 
screening with NT measurement and serum testing for the biochemical markers PAPP-A 
and free β-hCG between 10+3 to 13+6 week gestation.  The women also underwent 
second-trimester quadruple screening between 15 and 18 weeks gestation.  The trial 
revealed that integrated screening yields 90% sensitivity in screening for Down 
syndrome, with a 5.4% false-positive rate.  
 
Integrated screening strategy however has remained controversial.  This is because the 
first-trimester results need to be withheld from women until the second-trimester markers 
have been measured.  Further, clinical staff may find non-disclosure of high-risk first-
trimester results unacceptable, believing that the interests of individual patients may be 
better served by immediate counselling for invasive prenatal diagnosis (Herman et al., 
2002).  Similarly, the patients may put considerable pressure on the clinicians to reveal 
intermediate findings since for social and personal reasons they would prefer to terminate 
an abnormal fetus as early as possible (Copel and Bahado-Singh, 1999).  Also there is a 
possibility of loss of follow up of the patients and finally if they fall in high-risk category 
at around 16 weeks, they may have to undergo termination of pregnancy using intra-
amniotic prostaglandin instillation or prostaglandins or dilatation and evacuation, which 
is more complicated then termination of pregnancy in the first trimester.  These concerns 
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have provoked others to recommend a policy of routine disclosure (Herman et al., 2002) 
despite the concomitant considerable increase in false-positive rate for any given 
detection rate (Wald et al., 2003; Cuckle and Arbuzova, 2004). 
 
Recently, Wright and co-workers (2004) have reported contingent screening for Down 
syndrome.  To present the first and second-trimester Down syndrome screening strategy, 
the second-trimester marker determination is contingent on the first-trimester results.  
Unlike the integrated test, which requires all women to have markers in both trimesters, 
this allows large proportion of the women to complete screening in the first trimester.  
The authors developed contingent sequential screening by using statistical modelling to 
define optimal first-trimester upper and lower risk cut-offs which describes three types of 
results, namely the positive for early diagnosis, negative with screening complete and 
intermediate needing second-trimester markers.  Multivariate Gaussian modelling with 
Monte Carlo simulation was used to estimate the false-positive rate for a fixed 85% 
detection rate.  Simulation refers to any analytical method meant to imitate a real-life 
system, especially when other analyses are too mathematically complex or too difficult to 
reproduce.  Without the aid of simulation, a spreadsheet model will only reveal a single 
outcome, generally the most likely or average scenario.  Spreadsheet risk analysis uses 
both a spreadsheet model and simulation to automatically analyze the effect of varying 
inputs on outputs of the modeled system.  One type of spreadsheet simulation is Monte 
Carlo simulation, which randomly generates values for uncertain variables over and over 
to simulate a model.  Model parameters were taken from the SURUSS trial.  It was 
concluded that contingent screening can achieve results comparable with the integrated 
test with second-trimester screening being avoided in up to 80% of the unaffected 
pregnancies.  However, both the strategies need to be evaluated in large-scale prospective 
studies particularly in relation to psychological impact and practicability.   
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The optimal screening method for Down syndrome has yet to be decided.  Compared 
with screening by maternal age alone, detection rates have improved significantly to 95% 
with the introduction of the additional screeing modalities from 30%.  Unfortunately, the 
invasive testing rate remains high at 5%.  As 36,900 deliveries took place in Singapore 
the previous year (2004), 1845 women may have undergone invasive procedure to 
identify 37 cases of Down syndrome with consequent 18 miscarriages associated with the 
procedure.   
 
1.4 Screening for Genetic Disorders 
 
 
Missed or late diagnoses make estimations of the incidence of genetic disease at birth less 
accurate, but it has been estimated that it may be as high as 1.7% (Polani, 1973).  Of the 
many genetic diseases described to-date, only a few warrant more than a family history as 
a method of prenatal screening and most of these conditions are autosomal recessive 
disorders These include cystic fibrosis amongst Caucasians, Tay-Sachs diseases within 
the Ashkenazi, Sickle cell disease in individuals of African descent and the thalassaemias 
in Mediterranean, Middle East and Asian people.  Within these at-risk populations, the 
parents-to-be may be screened using biochemical or genetic analysis to determine their 
carrier status.  The tests may investigate mutations on the gene, altered protein production 
or altered protein function.  Invasive prenatal testing is offered to couples at increased 
risk (>/= 25%) of having an affected fetus. 
 
1.5 Diagnosis of Chromosomal and Genetic Disorders 
 
In contrast to screening test, definitive diagnostic test for these conditions require 
invasive testing by amniocentesis, chorionic villus sampling (CVS) or fetal blood 
sampling (FBS).  The method used depends upon the gestational age, the condition being 
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investigated, tests already performed, the expertise available, the risks of the procedure 
and parental preference.   
 





Amniocentesis is usually performed at 15 to 17 weeks of gestation when the uterus is an 
abdominal organ that can be sampled with minimal risk of injury to the maternal bowel.  
Before the development of real-time ultrasound, amniocentesis was performed blindly 
and was responsible for anecdotal cases of exsanguinations, intestinal atresia, gangrene, 
fistulae, brain damage and blindness in the fetus.  Real-time ultrasound enabled greater 
precision and its use is now a standard care.  Prior to amniocentesis, ultrasound 
examination is performed to evaluate fetal number and viability to confirm gestational 
age by fetal biometric measurements, to estimate amniotic fluid volume and to establish 
placental localisation.  While avoidance of the placenta during the ultrasound-guided 
procedure reduces the likelihood of maternal rhesus (Rh) alloimmunisation in Rh-
negative women, in 2-3% of second trimester amniocentesis, a fetal-to-maternal 
haemorrhage of at least 0.1ml still occurs and this haemorrhage leads to Rh- 
isoimmunisation in 2.1-5.4% of the at-risk pregnancies (Bowman and Pollock, 1985).  
This complication is preventable by prophylactic administration of anti-D immunoglobin 
to Rh-negative women before amniocentesis (Bradbenberg et al., 1989).  Following the 
scan, a needle insertion site is selected and a 22-guage spinal needle is introduced into the 
amniotic cavity through an aseptically prepared area on the maternal abdomen and 
amniotic fluid is aspirated.   
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In the mid 70s it was suggested that amniocentesis before 15 weeks is associated with an 
unacceptable procedural and culture failure rate (Golbus et al., 1979).  The advent of 
high-resolution ultrasound and direct needle guidance made the amniotic sac accessible 
as early as 7 weeks (Barbara and Wapner, 2002).  This, together with the development of 
improved tissue culture methods, improved laboratory capability requiring less fluid and 
fewer cells for cytogenetic analysis, led numerous investigators to a reconsideration of 
amniocentesis earlier in gestation (Hanson and Tennant, 1990; Nevin et al., 1990; Penso 
et al., 1990; Stripparo et al., 1990; Thayer et al., 1990; Hanson et al., 1992; Jorgensen et 
al., 1992).  However, recent randomised trials have demonstrated a number of concerns 
related to early amniocentesis performed prior to 14 weeks, the most important being a 
10-fold increase in the risk of severe talipes equinovarus (The Canadian Early and Mid-
Trimester Amniocentesis Trial Group, 1998).  The CEMAT group comparison of early 
amniocentesis and mid-trimester sampling demonstrated a twofold-increased risk of fluid 
leakage with the earlier procedure.  When this occurred, there was a 15% incidence of 
talipes equinovarus.  Without fluid leakage, the incidence of talipes was still 
approximately 10-fold higher than had been expected.  Also, early amniocentesis 
demonstrated a 1.7% increased risk of pregnancy loss compared with the mid-trimester 
amniocentesis. 
 
The primary concern for patients undergoing prenatal testing is the chance that the 
procedure will lead to the loss of the desired pregnancy.  The first major prospective 
study of genetic amniocentesis, which included 1040 subjects and 992 matched controls, 
was conducted by the US National Institute of Child Health and Human Development 
(NICHD) (National Registry for Amniocentesis Study Group, 1976).  Of all women who 
underwent amniocentesis, 3.5% experienced fetal loss between the time of the procedure 
and delivery compared with 3.2% of controls.  The small difference was not statistically 
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significant and disappeared completely when corrected for maternal age.  In Canada, a 
collaborative group conducted a cohort study but did not include a concurrent control 
group (Simpson et al., 1976; Medical Research Council, Canada, 1977).  The pregnancy 
loss rate was 3.2%, a frequency similar to that reported in the US collaborative study.   
 
A British collaborative study (United Kingdom Medical Research Council Working Party 
on Amniocentesis, 1978) found that the rate of fetal loss following amniocentesis was 
significantly higher than in controls (2.6% versus 1%).  In this study, however, a common 
indication for amniocentesis was elevated maternal serum alpha-fetoprotein (MSAFP) 
now recognised on its own as a factor associated with increased fetal loss and adverse 
perinatal outcome.  After excluding subjects undergoing amniocentesis for that 
indication, the loss rates between subject and control groups narrowed to less than 1%, 
although still a statistically significant difference (NICHD Consensus Conference on 
Antenatal Diagnosis, 1979). 
 
The relevance of the collaborative studies cited above has been questioned because they 
were not conducted with high quality ultrasonography as defined by today’s standards, 
nor was concurrent ultrasonography even universally applied.  The Danish group, the 
only study, which is based on large prospective, randomised controlled trial, addressed 
this criticism in the 1980s and found even in the hands of experienced operators the 
excess risk of miscarriage due to amniocentesis, was as high as 1% (Tabor et al., 1986).  
Recently, Seeds (2004) reviewed reports of more than 1000 amniocentesis to establish an 
estimate of procedure-related pregnancy loss after mid-trimester amniocentesis.  They 
found amniocentesis with concurrent ultrasound guidance in controlled studies was 
associated with the procedure-related pregnancy loss of 0.6% above the baseline risk of 
1.08% due to natural loss without amniocentesis among control patients.   
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Chorionic Villus Sampling 
 
CVS is usually performed in one of two approaches between 10-13 weeks.  In the 
original, transcervical approach, the procedure is performed with the patient in the 
lithotomy position.  A catheter or biopsy forceps is inserted through the cervix 
(aseptically prepared) into the placental substance.  Transabdominal CVS, as now widely 
performed, is similar to amniocentesis in that a needle is inserted through the maternal 
abdomen into the long axis of the placenta.  In both procedures, a tissue sample is drawn 
by negative pressure into a heparinised syringe containing nutrient medium. 
 
Fresh sample of fetal chorionic villi are contaminated by maternal decidua and blood.  
Thus, in order to prevent culturing maternal decidual cells, the tissues need to be 
separated by microdissection (Roberts et al., 1988).  The incidence of confined placental 
mosaicism, a discrepancy between the chromosomal complement of the fetus and its 
placenta that occurs due to post-zygotic mitotic errors during embryonic development in 
CVS specimens is 1% (Hahnemann and Vejerslev, 1997).  In these cases, fetal 
aneuploidy needs to be confirmed by a second invasive procedure (amniocentesis or fetal 
blood sampling) before termination of pregnancy can be considered. 
 
It is generally accepted that CVS is a slightly more risky procedure than mid-trimester 
amniocentesis, with a procedure related miscarriage rate around 2%.  Three large 
prospective collaborative studies compared the risks of these two procedures.  In the 
Canadian (Canadian Collaborative CVS/Amniocentesis Clinical Trial Group, 1989) and 
US (Rhoads et al., 1989) trials, an excess risk of fetal loss of 0.6% and 0.8% respectively 
for CVS, was found not to be statistically significant.  Both these trials were conducted in 
only a few centres: the Canadian trial in 11 and the US trial in seven.  In contrast, 31 
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centres participated in the European randomised trial (MRC Working Party, 1991) with 
an average of 52 cases recruited in each.  In this more widespread study by (possibly) less 
experienced operators, the risk of fetal loss due to CVS was 4.6% higher than 
amniocentesis (95% CI, 1.6% - 7.5%). 
 
Transcervical CVS is associated with a greater risk of fetal loss than transabdominal 
CVS.  Meta-analysis of randomised trials suggests that transcervical CVS has a 3.7% 
excess fetal loss rate compared with mid-trimester amniocentesis (Wald et al., 1998).  
There was also a non-significant trend for the transabdominal approach to be associated 
with a lower risk of miscarriage compared with transcervical CVS, making its safety 
comparable to mid-trimester amniocentesis (Smidt-Jensen et al., 1992; Wald et al., 1998).  
The transabdominal approach is now preferred and there is a case for CVS to be 
performed in tertiary referral centres where there is considerable expertise.  Thus fetal 
loss from CVS is at least as high as that of amniocentesis, and at least on a global scale, 
probably higher.   
 
With CVS, as with amniocentesis, severe complications such as septicaemia in the 
mother or limb reduction defects in the fetus are rare but subchorionic haematomata and 
vaginal spotting occur in up to 4% of cases after transcervical CVS (Brambati et al., 
1987).  Since the first report of limb reduction abnormalities, such as the oromandibular-
limb hypogenesis syndrome, occurring after CVS (Firth et al., 1991) several large studies 
have failed to confirm this association (Hsieh et al., 1995; Froster and Jackson, 1996).  In 
the largest of these studies published from the World Health Organisation International 
Registry and based on data from 63 centres, 77 (0.06%) of the 138,996 children born 
after CVS, had limb-defects.  This suggested there was no increase in risk compared with 
the general population.  The latest WHO report continued to show the same results 
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(WHO/PAHO consultation on CVS, 1999).  Early cases of CVS however were not 
included in these studies and it has been suggested that procedures performed prior to 10 
weeks may carry a risk of severe limb defects as high as 2% (Jenkins and Wapner, 1999). 
 
Fetal Blood Sampling   
 
Fetal whole blood is used for the extraction of fetal DNA while fetal white blood cells 
(lymphocytes) can be cultured rapidly to obtain metaphase spreads for karyotyping.  
However, the need to use fetal blood for prenatal diagnosis is declining as (i) 
abnormalities are increasingly identified by screening and diagnostic methods earlier in 
pregnancy, and (ii) as molecular testing replaces biochemical and haematological assays, 
and (iii) as rapid exclusion aneuploidy can now be achieved in more accessible and 
earlier samples by molecular methods. 
 
Fetal blood sampling procedure is associated with a risk of miscarriage of about 2% 
(Buscaglia et al., 1996).  The risk increases if the procedure is performed before 18 
weeeks (Orlandi et al., 1990) or in growth restricted or hydropic fetuses (Maxwell et al., 
1991).  It is thought that the procedure-related loss rate is about 1% (Weiner and 
Okamura, 1996; Tongsong et al., 2000) and that the main causes of fetal loss are rupture 
of membranes (pre-term, pre-labour), chorioamnionitis, puncture of the umbilical artery, 
bleeding from the puncture site and prolonged bradycardia. 
 
1.5.2 Laboratory analysis of fetal material after invasive testing 
 
Amniocentesis:  Amniotic fluid contains cells, enzymes, metabolites and cell-free deoxy-
ribonucleic acid (DNA).  Amniotic fluid cells can be cultured to contain metaphase 
spreads for karyotyping or analysed directly by chromosomal fluorescence in-situ 
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hybridisation (cFISH) (Klinger et al., 1992; American College of Medical Genetics, 
1999).  Enzymes and some metabolites from cultured and uncultured cell and from the 
supernatant can be used to detect inborn errors of metabolism but has largely been 
replaced by molecular testing.  The DNA extracted from cultured and uncultured cell can 
be used for analyses by polymerase chain reaction (PCR).  Amnio-PCR, the amplification 
and quantification of specific regions within the DNA of uncultured amniocytes using 
PCR, is being considered as an alternative to conventional karyotyping because the 
results are available within two days of the amniocentesis (Levette et al., 2001; Leung et 
al., 2003).  The amniotic fluid also contains fetal DNA suitable for PCR-based diagnosis.  
Recently, the cell-free fetal DNA extracted from amniotic fluid can be analysed using 
comparative genomic hybridisation (CGH) micro-array to identify fetal sex and 
aneuploidy (Larrabee et al., 2004). 
 
CVS:  The chorionic villi represent a source of fetal DNA that can be obtained in the first 
trimester without the need for cell culture.  The average sample contains 15-30 mg of 
villous tissue.  Uncultured mononuclear cytotrophoblast cells from such samples, when 
exposed to colchicine, generally contain a sufficient number of cells in mitotic metaphase 
to allow rapid karyotyping and banding studies (Simoni et al., 1983).  The mesenchymal 
core of the villi can be cultured and accurately karyotyped in the conventional fashion.  
Since enzymes are present in sufficient quantity to allow direct measurement or bioassay, 
biochemical testing for metabolic disease is possible in fresh uncultured villi; again this 
has largely been replaced by molecular testing.   
 
Fetal Blood Sampling:   Fetal whole blood is used for the extraction of fetal DNA while 
fetal white blood cells can be cultured readily to obtain metaphase spreads for 
karyotyping.  However, the need of FBS for prenatal diagnosis has now been replaced by 
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methods which can be carried out earlier in pregnancy such as CVS and amniocentesis.  
Further, rapid prenatal diagnosis using molecular methods such as FISH can now be 
applied to these more accessible and earlier samples (Lapidot et al., 1996; Pierlugi et al., 
1996). 
 
With the availability of new biochemical and ultrasound screening markers for 
identifying women at high-risk of carrying an aneuploid fetus, detection rates have 
improved significantly.  However, the number of women undergoing unnecessary 
invasive procedures and the subsequent loss of a healthy fetus remain a cause of concern.  
On the other hand, definitive diagnosis of fetal chromosomal and monogenic disease 
requires access to fetal cells and/or fetal DNA which can be currently obtained by 
invasive methods.  These procedures carry the risk of miscarriage and therefore limit the 
uptake of prenatal diagnosis for these conditions.  Hence, there is a need for a risk-free 
non-invasive method for prenatal diagnosis.   
 
1.6 Developments on non-invasive prenatal diagnosis of 
chromosomal and single gene disorders 
 
The demonstration that fetal cells (Walknowska et al., 1969) and fetal DNA (Lo et al., 
1990) can be obtained from maternal blood, and that chorionic cells that shed into the 
maternal cervix can also be retrieved (Shettles, 1971), raised the possibility of obtaining 
fetal genetic material for prenatal diagnosis without the need for invasive testing.  The 
debate as to which fetal material (cells or DNA) and which source (blood or trans-
cervical aspirate) to use continues, most investigators in this field currently analyse 
maternal blood because it contains both fetal DNA and fetal cells and is less likely to be 
contaminated by foreign cells or DNA (e.g. spermatozoa).  There is relatively much more 
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cell-free fetal DNA in maternal blood than intact fetal cells (Lo et al., 1998b), but the 
usefulness of cell-free fetal DNA is limited to paternally-inherited fetal conditions for 
which the mother is not a carrier.  Analysis of intact fetal cells would allow a wider range 
of diagnoses to be made, including the detection of fetal aneuploidy.  However, their 
rarity in maternal blood has hindered the development for non-invasive prenatal 
diagnosis.  It is likely that any clinical test ultimately developed that analyses fetal 
material within maternal blood will use both cell-free fetal DNA and intact fetal cells to 
determine the chromosomal and genetic status of the fetus.    
 
1.6.1 Cell-free fetal DNA in maternal plasma 
 
The demonstration of relatively large amounts of circulating cell-free fetal DNA in 
maternal blood (Lo et al., 1997) revealed yet another source of fetal genetic material that 
could be used for non-invasive prenatal diagnosis (Bianchi, 1998).  Fetal DNA can be 
extracted from maternal plasma and serum (Lo et al., 1997; Houfflin Debarge et al., 
2000; Honda et al., 2001).  It is detectable as early as 7 weeks and increases as pregnancy 
advances (Lo et al., 1997).  This sharp increase in fetal DNA in maternal plasma and 
serum in the late pregnancy stage could be related to gradual breakdown of the maternal 
fetal interface/placental barrier (Bianchi, 2000a; Bianchi, 2000b). Chan et al. (2003) 
performed serial analysis of fetal DNA concentrations in late pregnancy and observed a 
mean increase of 29.3% of fetal DNA each week during the late third-trimester.   
 
The mean half-life of fetal DNA in maternal blood has been estimated by real-time 
quantitative PCR (Taqman system, Applied Biosystems, Foster City CA) in postnatal 
samples to be 16.3 min (range 4-30 min) suggesting that the level of fetal DNA in 
maternal blood reflects a real-time balance between production and clearance (Lo et al., 
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1999a) and that the placenta is the likely source of cell-free nucleic acids circulating in 
the maternal blood.  Fetal DNA was reliably detected in up to 80% of cases in as little as 
10 μl of maternal plasma (Lo et al., 1997) and comprised 3.4% and 6.2% of total DNA in 
maternal plasma, in early and late pregnancy respectively (Lo et al., 1998b).  The 
concentration of fetal DNA in the plasma fraction of maternal blood is 21-fold greater 
than in the cellular fraction (Lo et al., 1998b).  Together, these findings suggest that the 
source of the fetal DNA in maternal blood is more likely to be the continous cellular 
remodelling at the maternal-placental-fetal interface rather than immune destruction or 
apoptotic disintegration of the fetal cells that enter and circulate within maternal blood 
(Sekizawa et al., 2000; Van Wijk et al., 2000; Kolialexi et al., 2001).  In their recent 
finding (Zhong et al., 2002), the group were not able to observe any relationship between 
fetal nucleated erythroblast numbers and cell-free fetal DNA levels in the first- and 
second-trimester normal pregnancies by a combination of XY FISH on enriched fetal 
cells and real-time PCR on the plasma DNA.  Similarly, no change in fetal DNA levels in 
maternal plasma were observed for up to 24 hours in the collection tube following 
drawing of blood (Angert et al., 2003).  These results indicate that cell-free fetal DNA 
could most likely be coming from the placenta and may not be the result of fetal cell 
trafficking.  Evidence also comes from strong correlation noted between fetal DNA and 
hCG concentration when measured from the same maternal sample (Sekizawa et al., 
2001; Ohashi et al., 2002).   
 
It has been suggested that the amount of fetal DNA in maternal plasma is increased in 
cases of Down syndrome (Lo et al., 1999b; Zhong et al., 2000).  These studies aimed to 
expand on an earlier observation of a six-fold increase in fetal-cell DNA equivalents in 
maternal blood when the fetus was trisomic for chromosome 21 (Bianchi et al., 1997).  In 
two of these studies (Bianchi et al., 1997; Lo et al., 1999b) the results were confounded 
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by the fact that in most pregnancies complicated with Down syndrome, maternal blood 
was obtained after amniocentesis.  In all three studies, although the amount of total fetal 
DNA between aneuploid and euploid fetuses was significantly different, the number of 
valid comparisons was small and there was considerable overlap.  Recently, a 1.7 (Lee et 
al., 2002) and a 1.8 fold (Wataganara et al., 2003) increase in fetal DNA in maternal 
serum was observed in trisomic pregnancies as compared to controls.  In contrast, no 
difference was observed in the fetal:maternal DNA ratio in maternal plasma of patients 
with affected trisomy 21 fetuses compared to normal controls (Hromadnikova et al. 
(2002a).  Similarly, no difference was found in the fetal DNA concentrations in 
pregnancies carrying euploid (n=55) and aneuploid (n=9) fetuses (Ohashi et al., 2002).  
This could be because they found a large variation in the normal range (18-fold 
difference between the maximum and minimum values).  There is also a daily variation 
in the amount of free fetal DNA present in the plasma of the same mother (Hahn et al., 
2001).  Recently, a scientific group (Farina et al., 2003) evaluated the use of circulating 
serum fetal DNA as a second-trimester maternal serum marker of Down syndrome.  They 
found the median fetal DNA concentration to be 1.7-fold greater in Down syndrome 
cases than in controls.  When incorporated with the quadruple marker screen, non-
invasive aneuploidy detection improved to 86% at a fixed 5% false-positive rate.   
 
Before circulating fetal DNA can be evaluated as a method of first-trimester screening for 
fetal trisomies, consistent and reproducible results are first required for increased 
concentration of fetal DNA in aneuploid pregnancies detected from maternal plasma and 
serum.  The above studies are limited by fetal gender, and widespread implementation of 
fetal DNA quantitation awaits development of accurate gender-independent markers. 
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The relatively high fetal DNA in maternal plasma and serum has permitted the non-
invasive prenatal diagnosis of fetal rhesus (Rh) D status (Lo et al., 1998b).  It has now 
shown to be highly accurate by several groups and has been introduced as a routine 
service by the British National Blood Service since 2001 (Finning et al., 2004).  This is 
the first routine use of non-invasive DNA-based prenatal diagnosis.  Other genetic 
applications of fetal DNA in maternal plasma include the detection of myotonic 
dystrophy (Amicucci et al., 2000) achondroplasia (Saito et al., 2000), cystic fibrosis 
(Gonzalez-Gonzalez et al., 2002), Huntington disease (Gonzalez-Gonzalez et al., 2003), 
congenital adrenal hyperplasia (Rijnders et al., 2001; Chiu et al., 2002) and β-
thalassaemia (Chiu et al., 2004; Li et al., 2005).  The main limitation in all these 
examples is that the fetal genes or mutations detected are paternally-inherited and 
genetically different from corresponding sequences in the mother.  Novel strategies such 
as the use of short tandem repeats (Pertl et al., 2000) and differentially methylated 
sequences (Poon et al., 2002) have been explored but as yet seem unlikely to be 
applicable to non-invasive prenatal diagnosis of the common aneuploidies or monogenic 
disorders.    
 
1.6.2 Transcervical sampling of fetal cells 
 
 
Shedding of the trophoblastic cells from the placenta into the cervical canal and its 
subsequent retrieval for non-invasive prenatal sex determination was observed more than 
three decades ago (Shettles et al., 1971).  This pioneering observation was confirmed by a 
scientific group four years later (Rhine et al., 1975) who correctly predicted the fetal sex 
in 31 out of 36 cases examined. 
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The advent of PCR and cFISH revolutionised molecular diagnostics a decade ago.  
Utilising this technology, the first prenatal diagnosis of a fetus with trisomy 18 by the use 
of FISH probes on 26% of the trophoblast cells were reported (Adinolfi et al., 1993).  The 
cells were obtained by transcervical flushing.  Since then, transcervical fetal cells have 
been actively investigated as a source of genetic material for non-invasive prenatal 
diagnosis (Adinolfi, 1995; Adinolfi and Sherlock, 1997, Adinolfi and Sherlock, 2001).  
Mucus sampling is considered as the best option because unlike transcervical cell 
sampling technique that involves the flushing of the endocervical or the uterine cavity, it 
seems to be deprived of any invasiveness.  Use of cytobrush for mucus collection makes 
this sampling method similar to a Pap smear, which is not considered harmful in 
pregnancy (Rodeck et al. 1995; Fejgin et al. 2001).  However, transcervical sampling has 
been found to be more effective in fetal cell recovery (Chang et al., 1997; Cioni et al., 
2002) than the less invasive cervical mucus aspiration (Daryani et al., 2000) but has also 
been implicated in fetal limb reduction defects (Chou et al., 1997).  Recently, Ian Findlay 
and his group were able to demonstrate the efficiency of serially enriching fetal cells 
from pap smears and identifying such cells as fetal using single cell DNA fingerprinting 
(International Genetics Congress, Melbourne 2003).  Although efforts to use 
transcervically derived fetal cells for non-invasive prenatal diagnosis continue (Cirigliano 
et al., 1999; Ergln et al., 2001), poor recovery of fetal cells (Overton et al., 1996; Cioni et 
al., 2003), contamination by foreign genetic material (Daryani et al., 1997) and 
considerable variation in the composition and quality of recovered material (Miller et al., 






1.6.3 Fetal cells in maternal blood 
 
In 1893, Schmorl first documented the presence of fetal-derived trophoblast sprouts in 
the lungs of women who died from complications of eclampsia.  Although, similar 
observations were reported by Douglas and co-workers (1959) and Attwood and Park 
(1960), the definitive proof that fetal cells circulate in maternal blood came in 1969 when 
lymphocytes carrying an X and a Y chromosome were detected in the peripheral blood of 
pregnant women (Walknowska, 1960).  Convincing evidence of the existence of fetal 
cells in maternal blood came in 1990 with the advent of sophisticated molecular genetic 
techniques such as cFISH and PCR (Simpson and Elias, 1993).  Currently, the research in 
this area not only focuses on the understanding of their biological role and effect in the 
mother but also how to isolate and use these for non-invasive prenatal diagnosis. 
 
1.6.3.1 Candidate target cells for non-invasive prenatal diagnosis 
 
Trophoblasts:  Trophoblast cells are formed very early in gestation, have a short 
replication time and circulate in the maternal blood as a consequence of their invasive 
and proliferative nature.  These cells have a unique morphology, which permits definitive 
microscopic identification (Pertl and Bianchi, 1999) and secondly, they do not have to 
cross the placenta in order to reach the maternal blood.  In fact, specific placental cells 
actively breach the maternal vessels and enter into maternal circulation extensively 
during the first trimester (Oudejans et al., 2003).  In contrast to cells of the erythroid and 
lymphoid lineage which originate from pregnancies and can persists in maternal 
circulation several years after delivery (Bianchi et al., 1993), trophoblast cells are not 
programmed for long-term circulation in the blood and are unlikely to persist after 
delivery including subsequent pregnancies (Van Wijk et al., 1996).  
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The use of trophoblast cells for non-invasive prenatal diagnosis has met with several 
difficulties.  Trophoblast deportation into maternal circulation does not appear to be a 
phenomenon common to all pregnancies (Sargent et al., 1994).  When it does occur, the 
cells are cleared rapidly by the pulmonary circulation (Attwood and Park, 1960; 
Benirschke, 1994).  Their extraembryonic origin as part of the placenta implies that 
trophoblast cells are likely to exhibit confined placental mosaicism in 1% of cases 
sampled (Hahnemann and Vejerslev, 1997) and any prenatal diagnostic screening test 
relying exclusively on these cells may not reflect the true fetal karyotype.  Similarly, 
syncytiotrophoblast cells which are multi-nucleate, do not give accurate results when 
chromosomes are analysed by FISH.   
 
Perhaps the greatest obstacle in using trophoblast cells for non-invasive prenatal 
diagnosis has been the development of specific monoclonal antibodies against trophoblast 
cell surface antigens.  In the early 80s, Trophoblast Like Cells were identified in the 
peripheral maternal blood through immunocytology in the antecubital veins of six of ten 
women between 8 weeks gestation and full term (Goodfellow & Taylor, 1982).  Two 
years later, identification of syncytiotrophoblast cells from maternal blood was reported 
using H315 antigen through flow cytometry (Covone et al., 1984).  Later, the same group 
(Covone et al., 1988) and others (Bertero et al., 1988; Pool et al., 1989) were not able to 
detect any nucleated elements that were clearly reminiscent of the free inter-villous 
trophoblast cells.  They observed H315 antigen can be absorbed onto maternal 
lymphocytes and most of the Trophoblast Like Cells were leukocytes of maternal origin, 
which had absorbed trophoblast membrane antigens.  A similar finding was observed 
(Adinolfi et al., 1988) when most H315+ cellular elements did not react with Y-
chromosome specific probes regardless of whether the fetus was male.  They affirmed 
that maternal blood cells adsorbed H315 as they circulated through placenta.   
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In an attempt to find monoclonal antibodies (MAbs) that are truly specific for trophoblast 
antigens, 6800 antibodies were generated and screened (Mueller et al., 1990).  They 
found five MAbs FDO161G, FDO66Q, FDO338P, FDO78P and FDO93P appeared to 
react specifically with a surface membrane protein antigen residing on both villous 
syncytiotrophoblast and non-villous cytotrophoblast cells, but not with any other cells or 
serum components in maternal blood.  Two of the former, defined a single trophoblast 
membrane surface protein.  The labelled cells were gathered using magnetic beads and 
proved their fetal origin by PCR amplification of a Y-chromosome-specific DNA 
sequence.  Of 13 women carrying male fetuses, 12 had accurate prediction of fetal sex by 
this method.  Later, the same group demonstrated not only the morphology of the 
syncytiotrophoblast cells enriched from maternal blood but also identified paternally-
inherited mutations for β-thalassaemia (Hawes et al., 1994a; Hawes et al., 1994b).  
However, because of the lack of general availability of these MAbs, other research 
groups had never reproduced this work.   
 
The problems resulting from the adsorption of trophoblast antigens onto the cell surface 
of maternal leukocytes were overcome with the newer marker such as HASH2 (Van Wijk 
et al., 1998), HLA-G233 (Van Wijk et al., 1996; Loke et al., 1997; Van Wijk et al., 
2001), and MAb 340 (Durrant et al., 1996; Lim et al., 1999; Lim et al., 2001).  The proof 
of principle has however been demonstrated solely on the male fetuses using XY cFISH 
(Lim et al., 1999, Lim et al., 2001; Van Wijk et al., 2001) or by amplification of the Y-
chromosome-specific DNA sequence after initial density gradient centrifugation and 
purification with or without magnetic-activated cell sorting (MACS) (Durrant et al., 
1996; Van Wijk et al., 1996; Van Wijk et al., 2001).  It is yet to be seen how the 
trophoblast cells enriched from a female fetus would be differentiated from maternal 
nucleated cells using cFISH as an identification marker if a gender-independent non-
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invasive prenatal diagnosis has to be achieved.  Not all groups have been successful in 
detecting circulating trophoblast from maternal blood.  Using newer markers such as 
HASH-2, HLA-G, human placental lactogen and other known trophoblast antigens, one 
scientific group was unable to isolate and identify any trophoblast cells within maternal 
blood (Schueler et al., 2001).  Recent demonstration of the novel method of enrichment 
of trophoblast cells by the isolation by size of epithelial tumor cells method 
complemented by micro-dissection (Vona et al., 2002) is yet to be verified by 
independent investigators.  On the other hand, trophoblast-derived cells enriched from 
maternal blood using anti-HLA-G antibody were able to proliferate under in-vitro culture 
condition (Guetta et al., 2005).  However, a male fetal cell was observed in a woman 
carrying a female pregnancy.   
 
Therefore, it is essential that the fetal nucleated cell type selected as the target for non-
invasive prenatal diagnosis is a terminally differentiated species with a limited lifespan 
and no capacity to proliferate. Such a cell type would reflect the genetic status of only the 
current pregnancy. 
 
Leukocytes:  The landmark study that conclusively described that fetal cells do circulate 
in maternal blood was published by Walknowska et al. (1969).  The group demonstrated 
the presence of a Y chromosome in mitogen-stimulated lymphocytes obtained from 
pregnant women who were carrying male fetuses.  The presence of Human Leukocyte 
Antigen (HLA) on lymphocytes provided another means of successfully isolating fetal 
lymphocytes from maternal blood (Herzenberg et al., 1979; Iverson et al., 1981).  In 
contrast other group could locate only maternal cells after metaphase had been induced 
(Tharapel et al., 1993).  Most investigators focussed on fetal lymphocytes but others 
(Zillacus et al., 1975; Wessman et al., 1992) raised the possibility of using fetal 
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granulocytes as targets for non-invasive prenatal diagnosis, and suggested that fetal 
granulocytes transfer into the maternal compartment from as early as seven weeks and on 
a regular basis.  They found fetal granulocytes comprised on average 0.13%, and 
occassionally as much as 0.26%, of all mononuclear cells in maternal blood.  These 
results suggest a surprisingly high frequency of these cells, especially since they are 
uncommon in pure fetal blood before 20 weeks, but alternatively they might be 
artefactual, reflecting non-specific hybridisation of the Y-chromosome probe.  Available 
data therefore do not support the use of granulocytes as suitable targets for non-invasive 
prenatal diagnosis. 
 
One of the earlier attractions of fetal leukocytes was their ability to proliferate in-vitro.  It 
is interesting that this propensity for fetal white blood cells to proliferate is now regarded 
as a disadvantage (since it is thought that they can proliferate in-vivo in maternal organs) 
and has limited the development of this cell type for use in non-invasive prenatal 
diagnosis.  Numerous groups have described the persistence of fetal leukocytes in the 
maternal circulation after delivery.  While some found the persistence of fetal 
lymphocytes until one year after delivery (Schroder et al., 1974), others observed it in the 
samples from women 5-7 years (Ciaranfi et al., 1977) and 27 years post-partum (Bianchi 
et al., 1996).    Thus, there is concern that enriched leukocytes may be the remnants of 
previous pregnancies and does not represent the true fetal genetic status in the current 
pregnancy.   
 
Studies of fetal white cells in the maternal circulation for non-invasive prenatal diagnosis 
are limited by the abundance of contaminating maternal white cells, which excludes the 
application of white-cell-specific-markers but requires the application of individual 
specific antibodies for isolation such as HLA antibodies.  This may be impractical for 
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routine prenatal diagnosis because relying on HLA antigens requires not only known 
paternity, but also an informative polymorphic couple (Pertl and Bianchi, 1999).   
 
Thus, the cell type chosen for non-invasive prenatal diagnosis should be short lived 
within the mother, have no or limited capacity to proliferate, and have unique cell surface 
markers to facilitate enrichment in all pregnancies.   
 
Haemopoietic progenitors and stem cells:  One way to overcome the relative scarcity of 
fetal cells enriched from maternal circulation is by in-vitro cultivation.  This would allow 
selective amplification of the target cells and would provide a larger number of cells for 
prenatal genetic diagnosis.  Two cell types that fall under this category are the 
haemopoietic progenitors and stem cells. 
 
Erythroid progenitor cells of male fetal origin derived from fetal liver were co-cultured 
with a 100-fold excess of peripheral blood mononuclear cells from a non-pregnant 
woman in an erythropoietin-enriched medium (Lo et al., 1994).  A 26-fold increase in the 
number of male fetal cells was observed.  This was followed by culture of maternal 
peripheral blood samples containing male fetuses in the second trimester, which showed 
preferential expansion of fetal cells over maternal cells.  Subsequently, a successful 
enrichment and culture of early committed fetal erythroid progenitor cells CFU-E (colony 
forming unit-erythroid) and M-BFU-E (mature burst forming unit-erythroid) with 18% 
purity was observed (Valerio et al., 1996).  This was followed by successful culture of 
fetal hematopoietic cells in maternal blood of women carrying aneuploid fetuses (Valerio 
et al., 1997a; Valerio et al., 2000).  On the other hand, Chen et al. (1998) were not able to 
reproduce the results.  Two methods of fetal cell selection were tested on 27 samples 
from pregnant women between 9-17 weeks gestation and five non-pregnant controls.  
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One method was based on using different concentrations of erythropoietin ligand in 
culture and the other was based on the conditions similar to Valerio et al. (1996).  The 
erythroid colonies obtained under either culture conditions were from maternal 
progenitors, and not of fetal origin.   
 
A two-phase liquid culture system for fetal erythroid progenitor cells were developed 
(Han et al., 1999).  The liquid culture consisted of erythropoietin-independent and 
erythropoietin dependent phases followed by HbF staining.  One blood sample from a 
woman who was pregnant with a male fetus at 10 weeks gestation showed the presence 
of fetal cells by PCR, but no XY cells were observed by metaphase analysis.  A study of 
liquid-phase culture of fetal erythroid progenitor cells by the same group (Han et al., 
2001) led to similar results.  On the other hand, single clones of fetal erythroid progenitor 
cells from maternal blood were isolated and cultured (Tutschek et al., 2000).  PCR (locus: 
amelogenin Amg XY) showed the presence of male fetal cells.  Some of the colonies 
were mixed (fetal/maternal cells) and some contained pure fetal cells.  The presence of 
mixed clonal colonies and the use of PCR rather than FISH were subsequently questioned 
(Campagnoli et al., 2001a).  Others could not reproduce Tutschek’s work (2000) and 
culture of progenitor cells from all 16 male pregnancies did not show Y-bearing clones 
and all colonies were maternal in origin (Zimmermann et al., 2002).  They observed that 
Tutschek results could well be due to errors in their complex PCR assay, indicating that 
alleles might have been incorrectly amplified and presumed to be fetal.   
 
Optimisation of fetal cell selection methods and culture conditions were made using 
model mixture experiments whereby adult non-pregnant blood was spiked with a known 
number of fetal cells (Bohmer et al., 1999).  They reported the standardisation of serum 
content conditions for culture of FNRBCs in a co-culture model.  When applied to 
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maternal blood samples, fetal cells were not detected by FISH, PCR and sorting for HbF 
in 24 samples including known male pregnancies and trisomies (Bohmer et al., 2002).   
 
Fetal cells that express the CD34 antigen remain a target as they proliferate more rapidly 
in culture than similar cells of adult origin (Eridani et al., 1998).  FACS-sorted CD34+ 
haemopoietic progenitor cells were expanded from maternal blood samples (Little et al., 
1997).  They obtained a 2-5 fold expansion of CD34+ fetal cells after 5 days of culture.  
Recently, first trimester CD34+ fetal haematopoietic progenitors were selectively 
expanded in-vitro in model cultures (Campagnoli et al., 2002).  On the contrary, no XY 
cells were identified in culture of CD34+ enriched and non-enriched progenitor cells 
from 17 first-trimester maternal blood samples, of which 10 were confirmed male 
pregnancies (Manotaya et al., 2002).  Others identified fetal CD34+ cells in all samples 
from women carrying a male fetus by the presence of Y-chromosome-sequences detected 
by FISH and nested-PCR (Guetta et al., 2003).  Culturing of CD34+ cells resulted in a 
significant increase in fetal cell numbers and the CD34+ cells were more primitive in the 
maternal circulation than cells that had already committed to the erythroid differentiation 
pathway.  However, they also observed male CD34+ fetal cells from previous 
pregnancies in both non-pregnant women and those pregnant with a female fetus and the 
number of these cells persisting from previous pregnancies increased after culture over 
maternal CD34+ cells.   
 
A spiking model in which 3, 10, 36 or 71 male cord blood CD34+ cells were diluted in 
400,000 female CD34+ peripheral blood cells were used and showed a 1500-fold 
expansion of fetal cells in culture (Jansen et al., 2000).  When the same culture conditions 
and cytokine combination were applied to 100 maternal samples with gestational age 
ranging between 7-16 weeks, 65 of which were from women carrying male fetuses, there 
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was no preferential growth of fetal haemopoietic progenitor cells.  In a similar study, a 
spiking model was used of fetal erythroid cells, which were cultured and subjected to 
high-performance liquid chromatography (HPLC) and FISH analysis.  Although the 
results were promising in model mixture experiment, application of the same method to 
26 pregnant samples of maternal blood including 13 confirmed male fetuses did not show 
any Y-positive cells (Huber et al., 2000). 
 
The culture of fetal haematopoietic cells from maternal blood samples has not been 
achieved in a reproducible manner.  This could be due to the fact that the occurrence of 
expandable fetal haematopoietic progenitor cells in maternal blood is an extremely rare 
event.  Another reason could be that they require some as yet unidentified culture 
conditions.  Further, the finding that fetal haematopoietic progenitor cells can persist in 
the maternal circulation after delivery constitutes a potentially serious caveate for 
targeting such cells for non-invasive prenatal diagnosis.  This observation also represents 
a long-term low-grade chimeric state in women. 
 
Mesenchymal stem cells:  Fetal mesenchymal stem cells (MSCs) have been identified in 
the fetal blood, liver and bone marrow as early as the seventh week of gestation 
Campagnoli et al., 2001b). Their mesenchymal phenotype is demonstrated by the 
expression of specific markers such as SH2 – CD105 and SH3 and 4 – CD73 and 
expression of vimentin, fibronectin and vascular cell adhesion molecule (VCAM-1).  The 
multi-lineage potential of MSCs can be demonstrated under appropriate culture 
conditions by their differentiation into osteocytes, adipocytes, and chondrocytes.  The 
group (Campagnoli et al., 2001b) subsequently developed optimal protocols for fetal 
MSC enrichment in model mixture experiment.  When applied to the peripheral blood of 
pregnant women obtained after termination of pregnancy, they could detect MSC in only 
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one of 20 samples (O’Donoghue et al., 2003).  This therefore, precludes their clinical use 
for non-invasive prenatal diagnosis.  Further, their unique property to differentiate and 
proliferate makes us believe that like other stem cells, there is a possibility that they too 
may sequester in the organs of the mothers and persist in the circulation from previous 
pregnancies and continue to circulate in maternal blood in the current pregnancy.  
 
Endothelial cells:  Recently, few groups have looked into the possibility of culturing 
endothelial cell progenitors presumably of fetal origin from maternal blood.  Endothelial 
cell progenitors from maternal blood were tried to be cultured, but no XY cells were 
detected in women carrying male fetuses based on FISH analysis and the endothelial cell 
progenitors appeared to be of maternal origin (Rafii 2000).  Others hypothesised 
endothelial precursor cells might enter the maternal circulation (Gussin et al., 2002).  
FISH analysis revealed nuclei with XX signals where the women were carrying male 
fetus indicating that the primitive endothelial cells were maternal in origin.  In their 
subsequent report (Gussin et al., 2004), the authors enriched cells from maternal blood on 
the basis of their expression of CD133 and CD105, and placed both the positive fraction 
and the depleted fraction in culture in conditions favouring endothelial for 7 and 30 days, 
respectively.  No PCR products consistent with the presence of male cells were detected 
in women carrying male fetuses.  This indicates that CD133+ and CD105+ cells appear to 
be of maternal rather than fetal in origin.  Recently, they tried to determine optimal 
concentrations of colony stimulating factor-1 (CSF-1), placental growth factor (PlGF) 
and transforming growth factor-beta 1 (TGF-beta1) for preferential expansion of fetal 
endothelial cells in model culture.  These conditions when applied to maternal blood 
samples, did not demonstrate any fetal cells based on PCR for SRY in women carrying 
male fetuses (Gussin et al., 2005).  Therefore, fetal endothelial cell progenitors have not 
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been successfully enriched to-date from maternal blood for non-invasive prenatal 
diagnosis. 
 
Erythroblasts:  First trimester fetal blood contains two types of nucleated erythocytes:  
primitive fetal nucleated erythroblasts and definitive NRBCs (Palis and Segel, 1998; 
Keller et al., 1999).  The primitive cells, derived from the yolk sac (Palis and Yoder, 
2001) are large and have a high cytoplasmic:nuclear ratio.  In contrast, definitive 
erythroblasts, produced in the fetal liver and bone marrow, are smaller with a lower 
cytoplasmic:nuclear ratio and extrude their nuclei on maturation (Keller et al., 1999).   
 
The search for a fetal cell target that has a limited life span (Pearson, 1967) and can be 
distinguished morphologically from its counterparts in maternal blood (Bischoff et al., 
2002) led to the selection of the fetal nucleated erythrocyte.  Other advantages of this cell 
type that have made it the target cell of choice for most investigators include the 
following: (i) they are consistently present in maternal blood during pregnancy (Parano et 
al., 2001); (ii) they represent 10% of all the red blood corpuscles in a fetus of 11 weeks 
and 0.5% in a fetus of 19 weeks (Torricelli and Pescucci, 2001); (iii) are full 
complements of nuclear gene cells detectable early during pregnancy (Liou et al., 1993); 
(iv) are abundant in the first and second trimester fetal blood, (Thomas and Yoffey, 1962) 
as the erythrocyte line develops earlier in gestation than the white cell line (Pertl & 
Bianchi, 1999); (v) are mononucleated (Kelemen et al., 1979) and (vi) carry 
developmentally-specific markers such as fetal and embryonic haemoglobins.  In contrast 
to the leukocytes, they express several unique antigens such as CD71 receptor (Bianchi et 
al., 1990; Miltenyi et al., 1990; Ganshirt-Ahlert et al., 1992), erythropoietin receptor 
(Valerio et al., 1997b), thrombospondin receptor (CD36), glycophorin-A (Bianchi et al., 
1993), I/i blood group antigen, HAE9 (Savion et al., 1997) and FB3-2, 2-6B/6, H3-3 
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(Zheng et al., 1997) that allow their enrichment from maternal circulation, not just those 
in HLA-informative couple.   
 
An increase in NRBCs within maternal blood in the presence of Rh-incompatibility was 
observed after termination of pregnancy and amniocentesis (Clayton et al., 1966).  These 
cells were presumed to be fetal in origin based upon staining for fetal haemoglobin 
(Kleihauer et al., 1957) and that the frequency of NRBCs in the fetus in early gestation 
had been noted to be relatively high (Thomas and Yoffey, 1962).  Independent 
confirmation that NRBCs within maternal blood were of fetal origin was obtained much 
later.  In 1990, NRBCs were flow-sorted for transferrin receptor (CD71) expression and 
PCR was performed for a Y sequence from the peripheral blood of pregnant women prior 
to amniocentesis.  After enrichment, Y sequences were found in six of eight pregnancies 
in which women were carrying male fetuses (Bianchi et al., 1990).  A year later, the cells 
were sorted not only for CD71 but also for cell size, cell granularity, and glycophorin-A 
(GPA) positivity.  Using nested-PCR for a Y-specific sequence, 12 of 12 male fetuses 
and five of six female fetuses were correctly identified in flow-sorted samples (Wachtel 
et al., 1991). 
 
The first prenatally detected fetal aneuploidy of trisomy 18 by enrichment of fetal 
erythroblasts from maternal blood was demonstrated at 10+8 weeks of gestation before 
CVS sampling procedure (Price et al., 1991).  They analysed inter-phase cells by FISH 
with chromosome-specific-probes.  This was followed by proof of principle 
demonstration of aneuploidy by several other groups (Bianchi et al., 1992; Simpson and 
Elias, 1993; Ganshirt-Ahlert et al., 1993; Simpson and Elias, 1994).  The general 
availability of MAbs against red cell antigens, the relative ease of enrichment protocols 
and the demonstration of successful cytogenetic diagnosis in fetal nucleated red blood 
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cells (FNRBCs) isolated from maternal blood make erythroblasts arguably the target cell 
type of choice for non-invasive prenatal diagnosis. 
 
To-date, fetal material that has been targeted for non-invasive prenatal diagnosis includes 
fetal DNA or fetal cells.  The usefulness of the former is limited to paternally-inherited 
fetal conditions for which the mother is not a carrier.  On the other hand, the latter could 
allow a wider range of diagnoses to be made, including the detection of fetal aneuploidy.  
The source through which fetal cells can be obtained is transcervical or from maternal 
blood.  The risk of miscarriage associated with the transcervical route and contamination 
by foreign genetic material makes maternal blood the ideal source of enriching the cells.  
Of all the fetal cells enriched so far from maternal blood, fetal nucleated erythroblasts are 
the most suitable target for non-invasive prenatal diagnosis.  Although, fetal anucelated 
red blood cells also cross over into maternal circulation but they do not contain any 
nucleus and therefore cannot be used for non-invasive prenatal diagnosis.   
 
1.6.4 Non-invasive prenatal diagnosis using fetal nucleated 
erythroblasts in maternal blood 
 
The accuracy of prenatal diagnosis using fetal nucleated erythroblasts enriched from 
maternal blood depends upon the specificity of their identification.  The presence of a cell 
surface antigen that is highly specific for fetal erythroblasts would be ideal since it could 
be used both to isolate these cells from maternal blood and to identify their fetal origin.  
Such a fetal cell marker is not yet available (Huie et al., 2001).  It was thought that 
NRBCs are rare in maternal blood (Pembrey et al., 1973).  Recent enrichment systems 
have demonstrated that a much larger population of NRBCs that originate in the maternal 
bone marrow circulate in pregnancy (Slunga-Tallberg et al., 1995).  This implied that the 
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earlier assumption that morphology could be used to identify fetal NRBCs was incorrect.  
It also meant that a marker for fetal, as opposed to maternal, NRBCs needed to be 
identified (Zheng et al., 1999).  Fetal haemoglobin has been used to differentiate maternal 
from fetal NRBCs, but 20% of all HbF-positive NRBCs in maternal blood are maternal in 
origin (de Graaf et al., 1999) and are found in all pregnancies (Lim et al., 2001).  Thus, if 
fetal nucleated erythroblasts are to be used as target cells for accurate non-invasive 
prenatal diagnosis, a more specific identification system needs to be developed.   
 





The three NRBCs identifier studied so far are the fetal and embryonic haemoglobins γ-, 
ζ- and ε-globins.  In 1993, Zheng and co-workers confirmed the origin of FNRBCs by 
labelling intracytoplasmic, developmental-specific fetal haemoglobin.  Since then, most 
groups identify fetal erythroblasts by using MAb labeling of γ-globin (DeMaria et al., 
1996; Mavrou et al., 1997; Oosterwijk et al 1998a; de Graaf et al., 1999; Samura et al., 
2000; Lim et al., 2001), or confirming the presence of HbF by the Kleihauer test 
(Rodriguez et al., 1999; Wang et al., 2000; Rodriguez et al., 2001; Parano et al., 2001; 
Martel-Petit et al., 2001).  Even if a suitable enrichment technique was established which 
enriches NRBCs, using γ-globin as a fetal cell identification marker will not promote a 
gender independent non-invasive prenatal diagnosis.  This is because production of γ-
globin (HbF) is increased during acute erythroid expansion such as in pregnancy 
(Pembrey et al., 1973; Popat et al., 1977), during recovery from iron deficiency anaemia 
(Dover et al., 1979) and in patients with β-thalassaemia (Olivieri, 1999, Weatherall, 
2000).   
 
 40 
Anti-γ globin antibody (DeMaria et al. 1996) and Kleihauer test (Martel Petit et al. 2001) 
directed against fetal haemoglobin, is highly fetal specific.  These findings were based on 
enrichment of male cord blood NRBCs from artificial mixtures in non-pregnant adult 
female blood.  This is true in a model mixture experiment where HbF positive NRBCs 
are unlikely to be found in non-pregnant adult blood.  In contrast, nucleated erythroblasts 
were enriched from maternal blood obtained within 30 minutes after transcervical CVS 
and fetal gender was predicted within γ-globin positive cells by XY cFISH (Oosterwijk et 
al., 1998a).  Of the 10 cases in which the fetuses were confirmed to be XY by 
karyotyping, in one the γ-globin positive cells were XX.  Similarly, using HbF as a fetal 
cell identification marker, 22 percent of all HbF positive NRBCs enriched from maternal 
blood of male pregnancies were found to be of XX karyotype on cFISH, indicating that 
these cells were maternal in origin (de Graff et al., 1999).  FNRBCs were enriched from 
CVS supernatant and the gender was correctly identifed by cFISH.  HbF positive NRBCs 
with two XX signals however, were also detected in the CVS supernatant (Mavrou et al., 
1997).  In 21 percent of pregnant women carrying male pregnancies, all of the HbF 
positive NRBCs on Kleihauer test had two X chromosome signals present on cFISH 
analysis suggesting maternal origin of NRBCs (Rodriguez et al., 1999).  All γ-positive 
cells enriched in 46 percent of pregnant women between 6-23 weeks contained two X 
chromosome signals consistent with females (Samura et al., 2000).  In one case report, it 
was observed that 54 percent of γ-positive cells enriched from a pregnant woman 
carrying a male fetus were maternal in origin with 2 XX signals (Zheng et al., 1995).  In 
another study, 433 nucleated γ-globin positive candidate fetal cells in 13 maternal blood 
samples obtained after termination of pregnancy were recovered.  Of these, 42 XX cells 
(9.7%) were found in 11 of the 13 samples (84.6%) (Wang et al., 2000).  HbF positive 
XX NRBCs were found in the maternal blood of 100% of the 23 subjects carrying male 
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fetuses (Lim et al., 2001).  In the only publication that demonstrated 100% specificity 
while staining for HbF (Parano et al., 2001), a judegment call was required by the 
observer/operator as to the pinkness of candidate cells (intensity of HbF staining in fetal 
vs. maternal NRBCs) and only the brightest staining cells were transferred by 
micromanipulation onto fresh glass slides for cFISH.  A system, which is operator 
dependent as this, is prone to error if applied in routine clinical practice.   
 
Based on the leaky expression of γ-globin in adults, the use of the embryonic ζ-globin 
was instead suggested (Cheung et al., 1996).  They established the principles by the non-
invasive prenatal diagnosis of one case each of sickle cell anaemia and β-thalassaemia in 
micromanipulated, ζ-globin positive NRBCs enriched from maternal blood between 10-
12 weeks.  While ζ-globin is definitely less likely to be present in adult blood cells, its 
expression is not completely switched off after the embryonic period.  It was shown that 
ζ-gene transcription continues in the definitive erythropoiesis by detecting ζ-mRNA in 
fetal liver (Yagi et al., 1986).  Synthesis of ζ-chains could be detected in fetal definitive 
erythrocytes between 15-22 weeks gestation and in definitive erythrocytes of normal 
newborn cord blood (Kutlar et al., 1987; Chui et al., 1989).  ζ-globin was present in 53% 
of definitive erythrocytes between 15-22 weeks and in 34% at term (Luo et al.,1999).  ζ- 
globin transcript was also demonstrated within the peripheral blood of healthy individuals 
(Albitar et al., 1989).  Others found ζ-globin chains in adults with the α-thalassaemia trait 
(Chung et al., 1984; Chui et al., 1986; Tang et al., 1992).  The consistency of this finding 
suggested that ζ-globin could be used as a marker applicable to the general population for 
the α-thalassemia-1 haplotype with a cis-deletion of both α-globin genes on chromosome 
16 (Chui et al., 1986).  These findings suggest that the expression of ζ-globin is not 
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strictly restricted to the fetus and may not be useful as a fetal cell specific identification 
marker.   
 
After the initial idea of using embryonic instead of fetal globins (Cheung et al., 1996), the 
presence of ε-globin positive male fetal erythroblasts was demonstrated in two post-CVS 
maternal blood samples (Mesker et al., 1998).  This publication emphasised the 
possibility of first trimester non-invasive diagnoses of fetal aneuploidy and single gene 
disorders using ε-globin as a fetal cell specific marker.  Later, the specificity of ε- and ζ-
globin was compared in CVS supernatant and it was found that embryonic ε-globin was 
more reliable and specific for the detection of embryonic NRBCs than anti-ζ (Mavrou et 
al., 1999).  Subsequently, an indirect evidence was provided that ε-globin expression is 
more tightly regulated than ζ-globin (Luo et al., 1999).  They found an 18-fold greater 
expression of ζ- compared with ε-globin when fetal erythroblasts were cultured in-vitro.  
Using a sensitive reverse transcriptase-PCR (RT-PCR) method, ζ-globin transcripts was 
observed in the CD71 positive mononuclear cell fraction of the peripheral blood of 3 out 
of 20 non-pregnant women while ε-globin transcripts were found in none (Hogh et al., 
2001).  A similar result was obtained (Boye et al., 2001) whereby differential display RT-
PCR method was used to compare transcription differences between the mononuclear cell 
fraction of adult female blood and trophoblast tissue, which included fetal nucleated 
erythroblasts but not in adult blood cells.  No differential expression of ζ-globin was 
noted by this method, confirming the presence of ζ-globin mRNA within adult blood 
cells.  In their study on CVS washings (Voullaire et al., 2001) ε-globin nucleated red 
blood cells was found to be increased at 10 weeks and a rapid decline was observed by 13 
weeks of gestation.  On the other hand, study on pure fetal blood samples in the first 
trimester demonstrated that 50% of the fetal primitive nucleated erythroblast still 
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contained ε-globin as late as 12 weeks gestation and reached negligible levels by 14th 
week of gestation (Choolani et al., 2001).  The group also investigated the presence of ε-
globin positive fetal nucleated erythroblasts in the bone marrow aspirate from healthy 
adult donor and found no ε-globin positive erythroblasts.  In their study on 
chromosomally normal fetal blood samples (Al-Mufti et al., 2000) 97% of cells were 
reported to contain ε-globin chain at 10 weeks and 45% of cells still exhibited ε-globin 
chain at 12 weeks.  It was suggested that rare adult NRBCs might also contain ε-globin 
(Lau et al., 2001), but their findings could have been confounded by autoflourescence 
artefact (Choolani et al., 2002).  Recently, it was reported that primitive fetal nucleated 
erythroblasts is a suitable FNRBCs to be targeted in the first trimester of pregnancy as the 
ε-globin intracytoplasmic protein is present in 100% of primitive fetal erythroblasts and 
rarely in definitive NRBCs (Choolani et al., 2003).    
 
These data suggest no definitive evidence that ε-globin is produced in adult blood cells or 
in definitive erythroblast indicating ε-globin to be more tightly regulated than γ-globin.  It 
also indicates that ε-globin is a highly specific marker for fetal nucleated erythroblast 
identification and could be used for first-trimester non-invasive prenatal diagnosis.   
 
1.6.4.2 Diagnosis of chromosomal and monogenic disorders using fetal 
nucleated erythroblasts enriched from maternal blood 
 
The three most important molecular techniques that have allowed genetic analysis of 
enriched fetal cells are PCR (Saiki et al., 1985), RT-PCR (Rappolee et al., 1988) and 
cFISH (Pinkel et al., 1988).  The ability of PCR to amplify minute quantities of DNA 
(even single copy) over a billion-fold has been exploited by several investigators to 
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demonstrate the possibility of prenatal diagnosis of monogenic disorders using fetal cells 
enriched from maternal blood (Camschella et al., 1990; Suzumori et al., 1992; Lo et al., 
1993; Takabayashi et al., 1995; Sekizawa et al., 1996; Cheung et al., 1996; Watanabe et 
al., 1998; Samura et al., 2001).  In cells expressing a particular gene, there are many more 
copies of the RNA (ribonucleic acid) message compared with only one or two alleles 
within the genome.  Thus, RT-PCR for fetal mRNA (messenger RNA) is more sensitive 
than PCR amplification of genomic DNA (Al-Mufti et al., 1998).  cFISH allows the 
detection of anueploidy and chromosomal rearrangements in inter-phase nuclei.  It has 
been used to detect most of the major fetal aneuploidies within fetal cells isolated from 
maternal blood (Price et al., 1991; Elias et al., 1992; Bianchi et al., 1992; Ganshirt-Ahlert 
et al., 1993; Simpson and Elias, 1993; Simpson and Elias, 1994; Elias et al., 1996; 
Pezello et al., 1997; Oosterwijk et al., 1998c; Al-Mufti et al., 1999; Rodriguez de Alba et 
al., 1999; Hromadnikova et al., 2002a; Mavrou et al., 2003).    
 
PCR:  Camschella et al. (1990) first demonstrated fetal inheritance in fetal cells, by 
showing Hb Leporn-Boston by PCR amplification of putative sequences in the buffy coat 
of maternal peripheral blood.  The Lepore-Boston gene is a hybrid δ-β gene arising from 
a 7 kb deletion between codon 87 of exon 2 of the δ-gene and the 5′ end of intron 2 of the 
β-gene (Flavell et al., 1978).  The gene confers a thalassaemia phenotype.  The 
investigators designed primers that flanked the δ-β junction to amplify a 356 bp product 
if the mutant gene were present.  They diagnosed the inheritance of the mutant gene in 
two fetuses and confirmed this by CVS.  This was the first time a clinical condition in the 
fetus was demonstrated by PCR amplification of maternal blood. 
 
Subsequently, the feasibility of fetal sex determination by Y-sequence amplification 
(Suzumori et al., 1992) and fetal RhD genotyping by nested amplification of a 262 bp 
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segment of the RhD gene in rhesus-negative mothers (Lo et al., 1993) respectively, was 
demonstrated.  It was initially thought that determination of the fetal RhD status would be 
one of the more important applications of fetal cells enriched from maternal blood 
(Geifman-Holtzman et al., 1996; Geifman-Holtzman et al., 1998; Geifman-Holtzman et 
al., 2000).  However, it is now known that this can be successfully and more easily 
performed by analysing cell-free DNA in maternal plasma (Lo et al., 1998a). 
 
Whether cells or cell-free DNA are used, the detection of fetal RhD status by analysis of 
maternal blood has confirmed the importance of PCR.  It allowed the first clinical 
application of non-invasive prenatal diagnosis.  Non-invasive confirmation that the fetus 
is RhD negative would reassure parents that the fetus is not at risk and would avoid any 
unnecessary use of RhD immune globulin and avoid the risks of invasive diagnosis in 
alloimmunised women whose partner is heterozygous for RhD. 
 
RT-PCR:  It was hypothesised that since there are many more copies of mRNA of an 
expressed gene than there are the genomic sequences, RT-PCR amplification of message 
should be more sensitive than PCR amplification of genomic DNA (Al-Mufti et al., 
1998).  They observed a doubling in sensitivity for the non-invasive prenatal diagnosis of 
fetal RhD status using RT-PCR.  In contrast, PCR detection of fetal DNA in maternal 
plasma was found to be more sensitive than RT-PCR detection of fetal RNA (Poon et al., 
2000).  They suggested that this was because fetal RNA is more susceptible to enzymatic 
degradation in maternal blood than fetal DNA.  Thus the value of RT-PCR in non-
invasive prenatal diagnosis remains controversial. 
 
cFISH:  The place of cFISH in non-invasive prenatal diagnosis has been firmly 
established.  The use of this technique was successfully demonstrated in the prenatal 
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diagnosis of autosomal trisomies 18 and 21 (Price et al., 1991).  These observations were 
extended by diagnosing fetal trisomy 21 in the maternal blood of a 42-year old woman 
taken before CVS (Elias et al., 1992).  Subsequently, trisomy 21 fetus was identified from 
maternal blood before termination of pregnancy (Bianchi et al., 1992).  Following this 
report, five cases of trisomy 18 and ten cases of trisomy 21 were confirmed in NRBCs 
enriched from maternal blood (Ganshirt-Ahlert et al., 1993).  Sex chromosome 
mosaicism was detected by cFISH in fetal cells enriched from maternal blood (Bischoff 
et al., 1995).  Further, it was shown that, sex chromosome aneuploidy could also be 
detected reliably (Cacheux et al., 1992; Al-Mufti et al., 1999).  The latter group was also 
successful in identifying aneuploidy cases between 10-14 weeks of gestation, including 
36 cases of trisomy 21, 24 cases of triosmy 18 and 10 cases of trisomy 13.  Similarly, one 
(Pezzello et al., 1997) and three cases (Al-Mufti et al., 1999) of fetal triploidy was 
diagnosed by cFISH on enriched fetal cells and confirmed by CVS.  On the other hand, 4 
cases of trisomies on FNRBCs enriched from maternal blood (Rodriguez et al., 1999) and 
18 cases of trisomy 21 between 12-25 weeks of gestation was demonstrated 
(Hromadnikova et al., 2002a).  Also, 4 cases of trisomy 21 after amniocentesis and before 
termination of pregnancy in the second trimester was successfully demonstrated (Mavrou 
et al., 2003).  Some investigators have attempted to increase the number of chromosomes 
that could be analysed by inter-phase FISH by performing simultaneous multicolour 
cFISH (Bischoff et al., 1998) or by sequential hybridisation of chromosome pairs (Zhen 
et al., 1998). 
 
Simultaneous immunophenotyping and cFISH:  Several groups (Zheng et al., 1993; 
Oosterwijk et al., 1998b) suggested the simultaneous visualisation of fetal cell identifier 
and cFISH, after enrichment of NRBCs using either cell sorting with MACS (Zheng et 
al., 1993) or triple density gradient (Oosterwijk et al., 1998b).  The authors showed that 
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the combination of immunophenotyping with mouse monoclonal anti-HbF antibody 
using Vector red (Zheng et al., 1993) or blue substrate, (Oosterwijk et al., 1998b) and 
fluorophores for FISH analysis allowed the identification of FNRBCs within the excess 
of maternal cells.  Using this combined immunoenzymatic labeling of fetal antigens and 
cFISH have however, proved problematic as it is necessary to register the location of γ-
globin-positive cells with a graticule and relocate each cell for analysis after cFISH 
(Zheng et al., 1993), cumbersome switching between transmission and fluorescence 
modes on a fluorescence microscope (Pazouki et al., 1996), and performing a 
simultaneous in-situ detection technique that allows co-visualisation of the fetal cell 
identifier and any genetic signals (Price et al., 1992; Kibbelaar et al., 1992; Oosterwijk et 
al., 1998b).  Furthermore, if the globin were labeled using a light microscopy dye and the 
hybridisation probes with fluorophores, exposure of the latter to the bright light of a 
transmission microscope bulb would bleach the cFISH signals quickly, which could lead 
to inaccurate diagnosis.  Since most genomic probes are fluorescently labeled, some 
investigators used fluorescent dyes to label the fetal cell marker and cFISH signals but 
found that when anti-γ-globin antibody was conjugated to fluorescein isothiocyanate 
(FITC), the intense green cytoplasmic staining precluded the use of FITC-labelled cFISH 
probes because the two labels could not be satisfactorily distinguished from each other 
and also limited the detection sensitivity by FACS due to haem auto-fluorescence 
(DeMaria et al., 1996).  The above studies were also limited by the fact that some of the 
HbF positive cells enriched from maternal blood showed two copies of X chromosome, 
which suggested that the cells were maternal in origin.  Therefore, even if the above 
shortcomings are overcome, correct identification of fetal cells is still the linchpin of a 
non-invasive prenatal diagnostic technique.  The identification system should be fetally 
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specific, gender-independent and reliant on developmental differences between mother 
and fetus.   
 
Based on the above information of ε-globin being a fetal cell identifier, successful 
enrichment of ε-globin positive primitive fetal nucleated erythroblasts was demonstrated 
from maternal blood using immunoenzymatic staining followed by FISH for gender 
identification and chromosomal aneuploidy (Mavrou et al., 2003).  The hybridisation 
efficiency using X- and Y-chromosome specific probes was only 64%, while the 
efficiency with chromosome-21-specific probe was 54.7%.  In 2001, Choolani and 
colleagues demonstrated that labelling the ε-globin intracellular fetal cell antigen with the 
blue fluorescent dye AMCA (7-amino-4-methylcoumarin-3-acetic acid) not only 
circumvents the problems of haem auto-fluorescence, which thus far had been the 
limiting factor preventing simultaneous visualisation of the fetal cell identifier and 
molecular genetic signals (DeMaria et al., 1996; Oosterwijk et al., 1998b) but also 
enhances cFISH efficiency and limits further fetal cell loss.  Previous attempts at 
reducing or correcting auto-fluorescence, which involved mathematical manipulations of 
pixel intensity (Szollosi et al., 1995) or concomitant use of dyes absorbing certain emitted 
wavelengths (Mosiman et al., 1997) met with little success.  The group (Choolani et al., 
2001) has been successful in developing a novel technique which consists of 
immunolabelling of the highly specific ε-globin positive first-trimester primitive fetal 
nucleated erythroblasts followed by cFISH. 
 
This recent breakthrough (Choolani et al., 2001; Choolani et al., 2003) has addressed the 
issue of specific identification of fetal primitive nucleated erythroblasts of first trimester 
origin using embryonic ε-globin and the simultaneous fluorescence labelling of this 
marker with cFISH for non-invasive prenatal diagnosis.  However, the first phase that is, 
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enrichment of target cells from the mother's blood remains a challenge.   Due to the 
scarcity of fetal nucleated erythroblasts in the maternal blood (1 in 107 to 1 in 109 
maternal nucleated cells) (Smits et al., 2000), several strategies to exploit the differences 
in physical, chemical and biological properties of individual cells have been used to 
enrich fetal erythroblasts from maternal blood.   
 
1.6.4.3 Various approaches for the enrichment of fetal nucleated 
erythroblasts from maternal blood   
 
Charge flow separation:  The charge flow separation instrument has been utilised by 
some investigators to enrich FNRBCs (Wachtel et al., 1996; Wachtel et al., 1998; 
Shulman et al., 1998).  In their technique, the investigators employed a horizontal cross-
flow fluid gradient opposing an electric field in a separation chamber.  Cells flow 
vertically, perpendicular to the gradient and the electric field.  According to their 
characteristic surface charge densities, the different cell types are separated from each 
other and are focused in different compartments, where they are directed into waiting 
collection tubes.  Though the initial results reported by the authors were encouraging 
(Wachtel et al., 1996), when carried out on a large sample size of 225 patients between 
10-18 weeks of gestation, no NRBCs could be recovered from one-third of patients and 
from the remaining cases the authors inferred that 30% of NRBCs in maternal blood were 
fetal in origin (Wachtel et al., 1998).  On the contrary, it is likely that most of the cells 
recovered by this technique were not fetal, as only 17 samples were evaluated by FISH 
with chromosome-specific probes.  This view was affirmed in their recent review article 
(Wachtel et al., 2001) where the authors indicated from their unpublished data that their 
earlier figure was an overestimate for the number of fetal cells that can be recovered by 
charge flow separation. 
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Density Gradient Centrifugation:  The trend to use density gradient centrifugation as the 
first-step to eliminate/reduce the overwhelming abundance of maternal red blood cells 
followed a publication in 1990 (Bhat et al., 1990).  They demonstrated using cord blood 
samples that if Histopaque-1077 were used alone, 82.6% of NRBCs would pellet, 
indicating that 1077 density gradient though eliminates most of the erythrocytes and 
polynuclear leukocytes, also depletes NRBCs as well.  They showed that if a 
discontinous double density gradient of Histopaque 1077 and 1119 were prepared, less 
than 0.5% of NRBCs would collect at the top of the interface and 78.6% would settle at 
1119.  They found that Histopaque-1077 when used alone or in combination with 1119 
could also deplete FNRBCs.  Subsequently, the authors developed discontinuous triple 
density gradient protocol (Bhat et al., 1993) by layering Histopaque 1119 at the bottom, 
Histopaque 1107 in the middle, and Histopaque 1077 on the top in a model mixture 
experiment where the adult blood was spiked with cord blood.  The enriched cells were 
sorted by flow-cytometry using anti-CD71 antibody followed by anti-CD13 anti-CD45 
antibody.  They reported a 25-fold enrichment of NRBCs with triple density gradient as 
compared to single density gradient.  In fact, this result represents the efficacy of the 
entire protocol rather than of the first step.  It would have been more appropriate to 
identify the number of NRBCs enriched at the first step so as to know the exact efficacy 
of the first-step enrichment method.  Since then, the choice of density gradients used in 
the fetal cell enrichment protocols has been guided by model mixtures using cord blood 
NRBCs. 
 
Following the above findings (Bhat et al., 1993) numerous researchers have been using 
triple density ficoll gradient as part of their enrichment protocol to isolate fetal 
erythroblasts from maternal blood (Ganshirt-Ahlert et al., 1993; Ganshirt-Ahlert et al., 
1998; Pezello et al., 1997; Oosterwijk et al., 1998a; 1998c; Kuo et al., 1998; Al-Mufti et 
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al., 1999; Al-Mufti et al., 2003).  Recently, the efficacy of triple density gradient was 
compared with that of single density gradient Ficoll 1077 in the same group of patients 
and it was observed that triple density gradient had better efficacy then single density 
gradient (Al-Mufti et al., 2004).  The study is limited by the samples being processed 
across the entire protocol starting from the first-step enrichment method to second-step 
enrichment rather than determining the efficiency of the gradient centrifugation at the 
first step alone.  Other groups used either single density gradient Ficoll 1077 (Price et al., 
1991; Bianchi et al., 1992; Cheung et al., 1996; Hromadnikova et al., 2002a; 
Hromadnikova et al., 2002b) or Ficoll 1119 (Martel-Petit et al., 2001) or Ficoll 1090 
(Kitagawa et al., 2002) or Ficoll 1083 (Mavrou et al., 2003) for FNRBCs enrichment 
from maternal blood for gender and aneuploidy analysis.  Several others preferred to use 
double density gradient comprising of Ficoll 1077 and 1109 (Rodriguez de Alba et al., 
2001) or 1077 and 1083 (Parano et al., 2001) for enrichment of fetal nucleated 
erythroblasts from maternal blood. 
 
The efficiency of single density gradient Ficoll 1077, 1098, 1110 and 1119 were studied 
by spiking cord blood with non-pregnant female adult peripheral blood in the model 
mixture experiment (Troeger et al., 1999).  It was found that the yield of erythroblast was 
higher with Ficoll 1119 and was preferred to be used as the first-step enrichment method.  
Subsequently, the efficacy of single Histopaque-1090 was compared with 1119 for 
maximum recovery of FNRBCs directly on maternal blood instead of testing the protocol 
in the model mixture experiment (Samura et al., 2000).  They reported the median 
number of FNRBCs separated by the 1119 density gradient was significantly higher than 
that by 1090.  The result of the study was however confounded by the fact that all the 
samples were collected immediately after termination of pregnancy and by inclusion of 
aneuploidy pregnancies.  Such a finding do not reflect the efficiency of the enrichment 
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protocol used because firstly, invasive procedures itself cause fetal blood to pass into the 
maternal circulation (Brambati et al., 1986).  Secondly, in aneuploidy fetuses, the 
placental feto-maternal barrier is disturbed due to impaired development and function of 
placental villi leading to an increased feto-maternal transfusion (Genest et al., 1995).  An 
altered haematopoiesis is also indicated in the early trisomic embryos (Thilaganathan et 
al., 1995) leading to an increased NRBCs content in fetomaternal transfusion.  Therefore, 
it is not clear whether the significant recovery of FNRBCs was due to the Histopaque 
gradient 1119 or due to the fetomaternal haemorrhage secondary to the procedure or 
whether it was the biology of the aneuploidies which worked in favour of the test.  Also, 
the post-procedure results are of limited clinical significance if the enrichment technique 
needs to be brought into actual clinical practice.   
 
Other groups looked into the possibility of using Percoll as a suitable gradient for fetal 
nucleated erythroblast enrichment from maternal blood.  The efficacy of single Percoll 
density gradient 1090 and 1083 was assessed for fetal cell enrichment on maternal blood 
(Sekizawa et al., 1999).  It was observed that 1.4 times more MNCs were being separated 
at the first-step 1090 density.  The results were confounded by all the samples being 
obtained after termination of pregnancy.  Unlike this study, other group (Smits et al., 
2000) assessed the efficacy of different Percoll gradients as the first-step for enrichment 
of FNRBCs in model mixture experiment whereby cord blood was mixed with adult 
peripheral blood.  They observed an increase in the recovery of fetal nucleated 
erythroblast from 3.23% to 68.56% with an increase in single density Percoll gradient 
from 1075 to 1098 respectively.  Use of double Percoll gradient (Percoll 1075 and Percoll 
1085) did not lead to any significant erythroblast enrichment.  Despite this finding, others 
considered double density gradient as successful for FNRBCs enrichment from maternal 
blood (Takbayashi et al., 1995; Sekizawa et al., 1996, Watanabe et al., 1998). 
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Recently, Choolani and his group (2003) exclusively studied the buoyant densities of 
first-trimester primitive fetal nucleated erythroblasts enriched from fetal blood samples. 
They observed even with the most commonly used Ficoll such as 1077 and 1119  being 
used on patient samples for fetal cell enrichment, 91.4% and 68.3% of NRBCs 
respectively, settle down in the erythrocyte pellet at the first-step density gradient 
centrifugation process.  They also observed the median recovery of fetal nucleated 
erythroblast from mixtures in maternal blood was superior with Percoll 1118 with 64.1% 
recovery as compared to 35.3% using Ficoll 1119.  They therefore, recommended the use 
of Percoll 1118 as the first-step method for primitive fetal nucleated erythroblasts 
enrichment from maternal blood.    
 
Cell Sorting by targeting surface antigen:  FACS and MACS are the two most commonly 
employed systems in the field of non-invasive prenatal diagnosis.  Both FACS and 
MACS exploit antigenic differences between cells and are capable of providing either 
positive selection (selection for those cells desired for analysis) or negative selection 
(selection against cells not desired for analysis).  FACS first used over two decades ago 
for this purpose (Herzenberg et al., 1979), is able to enrich cells with high purity so that 
slides with sorted cells can be readily scanned manually.  It also allows multi-parameter 
sorting:  simultaneous analysis of several criteria on a single cell and can be adapted for 
use with intracytoplasmic antigens.  The disadvantages of the technology are its cost, 
expensive maintenance, requirement for specially trained laboratory personnel, limitation 
in the number of cells that can be put through the system in a reasonable amount of time 
and fading of the fluorochrome if exposed to cFISH after sorting and cell loss. 
 
MACS has gained popularity because of its speed of operation and ease, and is faster and 
less expensive bench-top technique better suited to process larger cell numbers.  It can 
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also be performed in most laboratories without trained staff and high maintenance costs.  
The antibodies conjugated to magnetic beads can be directed against the cells sought for 
enrichment.  These beads attaching the desired cell type are retained under a magnetic 
field when cells in solution pass through (positive selection).  Cells that lack the antigen 
in question fail to attach to beads, are not retained in the magnetic field and pass through 
unimpeded to be discarded.  After releasing the magnetic field, cells attached to the beads 
can then be collected for subsequent analysis.  In addition the converse can be performed:  
desired cells are allowed to pass through and non-desired cells are retained under the 
magnetic field.  Although both negative and positive selections can be performed on the 
same population of cells in the same experiment, enrichments must be performed in 
series because cell selection can be based on only one antigen at a time.  When studying 
the absolute numbers of fetal cells recovered, it has been shown that MACS is at least as 
effective as and more specific than FACS (Wang et al., 2000).  Recently, National 
Institute of Child Health and human Development Fetal Cell Isolation Study (NIFTY) I 
data suggests that feal cell recovery and detection were better using MACS than with 
FACS (Bianchi et al., 2002). 
 
No surface antigens specific for fetal erythroblasts have been identified to-date (Huie et 
al., 2001).  FNRBCs were first enriched from peripheral blood of pregnant women using 
anti-CD71 antibody against transferrin receptor (Bianchi et al., 1990).  The transferrin 
receptor (CD71) is present on all cells that incorporate iron including monocytes, 
activated lymphocytes and trophoblast.  It is also known to be expressed on erythroid 
cells from the burst forming unit–erythoid stage up to and including the reticulocyte stage 
(Loken et al., 1987a).  This signifies that CD71 antigen is not specific to FNRBCs but is 
also found on maternal NRBCs as well (Bianchi et al., 1994; Slunga-Tallberg et al., 1996; 
Zheng et al., 1997).  Poor specificity of CD71 antibody was reported (Ganshirt-Ahlert et 
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al. 1992), indicating that alone it is insufficient for the isolation of FNRBCs.  Similarly, 
about 1 in 1000 nucleated cells was identified to be fetal after density gradient 
centrifugation and MACS with anti-CD71, indicative of a considerable contamination by 
maternal CD71+ cells (Troeger et al., 1999).  Despite these limitations, numerous groups 
to-date have still been using CD71 to enrich FNRBCs from maternal blood, 
compromising the purity of the enriched fraction (Price et al., 1991; Bianchi et al., 1992; 
Ganshirt-Ahlert et al., 1993; Ganshirt-Ahlert et al., 1998; Elias et al., 1992; Chueng et al., 
1996; Al-Mufti et al., 1999; Al-Mufti et al., 2003; Rodriguez de Alba et al., 2001; 
Mavrou et al., 2003).   
 
A study was conducted to demonstrate whether using anti-CD36, anti-CD71 or GPA in 
combination or alone would be effective in enriching FNRBCs from maternal blood in 
the first and second trimester (8-19 weeks) (Bianchi et al., 1993).  CD36 was selected 
because it recognises a 90 kD glycoprotein corresponding to the thrombospondin receptor 
(Edelman et al., 1986) which is expressed during the colony-forming unit erythroid 
(CFU-E) stage of erythroid differentiation.  GPA was selected as it is the major 
sialoglycoprotein of the erythroid membrane (Loken et al., 1987b) and is expressed on all 
erythrocytes.  Blood samples from 47 women were flow sorted using FACS for three 
different antibodies to fetal erythrocyte antigens.  They observed that using anti-CD71, 
gender prediction was 57% correct while it was 88% correct with anti-CD36.  Anti-GPA 
when used alone or in combination with anti-CD71 or anti-CD36 improved gender 
prediction to 100%.  This indicates anti-GPA alone or in combination with anti-CD36 or 
anti-CD71 improves the yield rather than using anti-CD36 or anti-CD71 alone.  Several 
groups tried to verify the results of Bianchi and co-workers (1993) by using combination 
antibodies for enrichment of fetal cells from maternal blood.  A combination of anti-
CD36/anti-GPA and anti-CD71/anti-GPA was used to flow-sort FNRBCs from maternal 
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blood across all the three trimesters (Sohda et al., 1997).  More than 90% of NRBCs by 
were found by either combination.  MACS with the combination of anti-CD36/anti-GPA 
and anti-CD71/anti-GPA were used to enrich fetal nucleated erythroblasts from maternal 
blood in the second trimester (15-19 weeks) (Campagnoli et al., 1997).  They observed 
no difference in either method in terms of percentage of fetal cells recovered.  The 
efficacy of anti-GPA, anti-CD71 and anti-CD36 were assessed in the model mixture 
experiment using MACS (Troeger et al., 1999).  This was followed by testing the 
efficiency of these antibodies on maternal clinical samples.  They observed the recovery 
of NRBCs was significantly higher with anti-GPA than with anti-CD71 and using anti-
CD36 was not as successful as anti-GPA.  
 
Although fetal nucleated erythroblasts have been enriched from maternal blood using 
anti-CD36 (Bianchi et al., 1993; Bianchi et al., 1994; Campagnoli et al., 1997; Sohda et 
al., 1997; Troeger et al., 1999), it is likely that the NRBCs exhibiting this surface antigen 
were definitive erythroblasts in origin.  This is because, although the targeted samples 
were between 8-19 weeks gestation (Bianchi et al., 1993), the authors have not mentioned 
how many of them belonged to the first trimester and it is possible that the CD36 positive 
cells may have been enriched from the patient samples obtained in the second trimester.  
In another study (Sohda et al., 1997) patients were enrolled across all the three trimesters 
while Campagnoli et al. (1997) recruited the patients only from the second trimester. In 
contrast, Troeger et al. (1999) have not documented the gestational age of the patients.  
Thus it remains plausible that the difference in sensitivity they observed was a result of 
different cell populations being selected.   
 
As fetal erythroblasts are negative for CD45 antigen, Zheng and co-workers (1993) 
investigated the utilisation of using anti-CD45 so as to deplete maternal leukocytes in the 
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MACS after first-step enrichment process.  CD45 is present on the cell surface of all 
mature human leukocytes and is not expressed on immature and mature erythrocytes.  A 
method of enriching NRBCs by negative MACS using anti-CD45 alone was deployed by 
only a few research groups (Zheng et al., 1995; Slunga-Tallberg et al., 1995; Samura et 
al., 2000).  On the other hand, Hromadnikova et al. (2002a) and Mavrou et al. (2003) 
used a combination of depleting antibodies CD45 and CD14, as CD14 recognises 
antigens on monocytes (Bianchi et al., 1998) and anti-CD45, respectively.  This was 
followed by positive selection of FNRBCs by using non-specific CD71 antibody.   
 
The cell surface antigen properties of exclusively first-trimester primitive fetal nucleated 
erythroblast in pure fetal blood were recently studied (Choolani et al., 2003).  They 
observed the antigenic profile of these cells were similar to adult erythrocytes, being 
100% positive for GPA and 100% CD36 and CD45 negative.  In contrast to adult NRBCs 
96% of which express CD71 (Loken et al., 1987a), they reported only 68% of primitive 
fetal erythroblasts were weakly positive for CD71 as compared with 100% of definitive 
erythroblasts.  On MACS sorting for pure fetal blood, the mean recovery of primitive 
fetal erythroblasts was greatest using anti-GPA and poorest with anti-CD71, the most 
frequently used antibody for enriching fetal erythroblasts from maternal blood.  This was 
subsequently confirmed in the model mixture experiment where the yield and the purity 
were higher with anti-GPA then with anti-CD71.  This finding was in line with other 
study (Troeger et al., 1999) that anti-GPA was indeed superior and indicate that its 
utilisation would eventually enrich both primitive and definitive fetal erythroblasts.  The 
authors (Choolani et al., 2003) also observed anti-GPA when used with anti-CD45 
depletion gave a yield similar to that of using anti-CD45 alone (76%) albeit with 24% 
loss of target cells and 100% purity.  The group suggested the use of anti-CD45/anti-GPA 
as a second-step enrichment method.    
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Enzymes:  Though, several enzymes such as 2,3-biphosphoglycerate (Von Koskull and 
Gahmberg, 1995) and thymidine kinase (Hengstschlager and Bernaschek, 1997) have 
been used to differentiate fetal from maternal red cells after enrichment, the most 
extensively studied has been carbonic anhydrase enzyme (Saunders et al., 1997).  The 
selective lyses of adult anucleated red blood cells are based on enzyme difference 
between maternal and fetal red blood cells.  Maternal cells contain carbonic anhydrase I 
and II whereas fetal cells only contain carbonic anhydrase II.  By adding substrate 
(ammonium chloride and potassium bicarbonate), ammonium bicarbonate is formed 
within the maternal cells, which will lyse due to the uptake of water (de Graaf et al., 
1999) and are therefore more susceptible to ammonium chloride lysis than fetal 
erythroblasts (Alter et al., 1979) as carbonic anhydrase activity is at least five-fold greater 
and acetazolamide permeability about ten-fold less in adult compared with fetal red blood 
cells (Boyer et al., 1976).   
 
Selective lysis of maternal red blood cells was first used for the diagnosis of 
haemoglobinopathies where globin chains extracted from a highly purified population of 
fetal red blood cells were analysed by electrophoresis, a technique in which significant 
fetal cell loss could be tolerated.  Ammonium chloride lysis of erythrocytes is known to 
effect functional studies in white cells (Webster and Pockley, 1993; Ridings et al., 1996).  
It was believed that the effect on erythroblast remains unchanged and they are intact 
during this process. Subsequently, several research groups tried to study the affect of 
ammonium chloride on FNRBCs and adult anucleated red blood cells and to find out 
whether it could be introduced as the first-step enrichment process. An enrichment 
protocol was developed from the model mixture experiment where first-trimester fetal 
erythroblasts isolated from CVS washings were spiked with adult peripheral blood 
Voullaire et al., 2001).  Ammonium chloride for selective lysis of adult erythrocytes was 
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used as the first-step enrichment process.  This was followed by double-density Percoll 
and MACS MS column using anti-CD71 antibody.  They were able to recover 70% of 
FNRBCs in their model system.  When applied to the actual clinical samples in the first 
trimester they found no FNRBCs in all the 15 patient samples taken before CVS inclusive 
of two aneuploid cases (Voullaire et al., 2003).  Similarly, differential lysis was carried 
out by another group (Huber et al., 2000).  However, none of the primitive erythroid cells 
were found to be fetal.  Despite methods that were able to detect presumably 1 to 2 fetal 
cells from among 750,000 maternal cells and surveying 100 cases for a minimum of 
750,000 cells each, no actual fetal cells were found (Huber et al., 2000).  On the other 
hand three-step enrichment procedure comprising bulk separation method, lysis buffer 
technique as a second-step enrichment method followed by triple percoll gradient was 
used directly on patient samples (de Graaf et al., 1999).  They were not able to enrich 
FNRBCs from 30% of cases.  Selective lysis of adult erythrocytes using ammonium 
chloride in their model mixture experiment was attempted as the first-step enrichment 
method (Choolani et al., 2003).  They observed a lysis of 88% adult erythrocytes with no 
lysis of first-trimester FNRBCs when cell mixtures were exposed to 10:1 v/v ammonium 
chloride/1mM acetazolamide for 30 minutes.  Despite this promising result, a significant 
clumping between unlysed erythrocytes and enriched primitive NRBCs rendered a poor 
morphology of the target cells and made it impossible to be recognised during fetal cell 
identification assay technique.  Their findings indicate that ammonium chloride lysis 
technique may not be an ideal method to be used as a first-step enrichment method as 
FNRBCs in some way are altered by the lysis procedure and there might be an alteration 
in the erythroblast membrane properties.  It may however be useful if incorporated after 
the initial density gradient and MACS step, when maximum number of adult erythrocytes 
is already depleted.   
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Till to-date, no fetal cell enrichment protocol has demonstrated superiority over the other.  
This is because, the choice of protocols have been guided by (i) testing the efficiency 
directly on patient blood samples in the first and second trimester where the initial 
number of target cells remain unknown (ii) using invasive procedures as in-vivo model 
system where, the numbers obtained before and after the procedure is too small to reflect 
the efficiency of a system and (iii) model mixtures using cord blood NRBCs (Bhat et al., 
1990; Troeger et al., 1999; Smits et al., 2000) rather than the cells actually to be targeted 
for non-invasive prenatal diagnosis: first-trimester erythroblasts.   
 
1.6.4.4. Testing enrichment protocols in maternal blood 
 
In any fetal cell enrichment protocol, two efficiencies need to be defined:  in-vitro 
enrichment efficiency and in-vivo enrichment efficiency.  The in-vitro enrichment 
efficiency can be readily obtained from experiments on model mixture of the target cells 
in maternal blood.  The in-vivo enrichment efficiency is harder to define since these 
would vary with different protocols, and the exact number of fetal cells circulating in 
maternal blood can never be known with certainity.  Using various combinations of the 
above-mentioned enrichment methodologies, numerous groups applied their protocols on 
maternal blood samples to enrich fetal nucleated erythroblasts (Table 1), without testing 
its efficiency in in-vitro model system.   In their in-vitro model mixture experiment using 
CVS (Voulliare et al., 2001) they observed the efficiency of their protocol to be 
approximately 70%.  However, in an in-vivo model, no FNRBCs could be enriched in the 
pre-CVS maternal blood samples (Voulliare et al., 2003).  Others used pre- and post 
procedure maternal blood samples to test the efficiency of enrichment protocols (Table 
2).  CVS was the most commonly used procedure.  This could help them identify the 
number of fold increase in the FNRBCs in the maternal blood and therefore, the number 
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of target cells to be expected to circulate in an ongoing pregnancy in the first and second 
trimester.  Triple density gradient (Ficoll 1077, 1110, 1119) and MACS of anti-CD71 
MAb was used (Ganshirt-Ahlert et al., 1993) to determine the total number of enriched 
erythroblasts before and after invasive procedures.  They observed no significant 
differences.  The authors did not document the kind of invasive procedures used.  In their 
subsequent study (Ganshirt-Ahlert et al., 1998) they again reported no difference and the 
invasive procedures included in this study were CVS, amniocentesis and fetal blood 
sampling.  These studies were limited by the fact that the pre and the post procedure 
blood samples were obtained from two different groups of women.  The range of 
gestational age of the pregnancies examined had not been documented as there is a 
biological variation in the number of FNRBCs present in maternal blood at different 
gestations (Bianchi et al., 1991; Ganshirt-Ahlert et al., 1994; Sohda et al., 1997; Lim et 
al., 2001).  Further, the distribution of normal and abnormal karyotype in the pregnancies 
examined before and after the invasive procedures was not given and it is known that in 
trisomic pregnancies the number of fetal cells in maternal blood is increased (Genest et 
al., 1995).   
 
Other group (Jansen et al., 1997) isolated fetal cells by Ficoll 1077 single density gradient 
centrifugation and maternal white cells depletion with anti-CD14/anti-CD45 followed by 
anti-CD71 MACS enrichment.  They then applied FISH for the Y chromosome from 
blood samples obtained immediately before and after CVS in women carrying 
karyotypically normal male fetuses at 11-14 weeks gestation.  In only 8 cases, CVS was 
associated with an increase in the number of fetal cells (1-175).  Before CVS, the cell 
numbers ranged from 0-2.  In 9 cases no fetal cells were isolated before and after CVS.  
This inconsistency in FNRBC recovery before and after CVS could most likely be due to  
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the use of inefficient enrichment protocol as 91.4% of FNRBCs are lost in the pellet with 
the use of Ficoll 1077 single gradient centrifugation (Choolani et al., 2003).    
 
Quantifification of NRBCs were carried out in blood samples taken both before and after 
CVS from the same group of 20 patients carrying male euploid pregnancy between 10+3 
and 13+4 weeks of gestation (Oosterwijk et al., 1998a).  The authors used triple density 
gradient as the first-step enrichment protocol.  They found a 12-fold increase in the 
number of NRBCs with a mean number of 1.8 NRBCs in the Pre-CVS and 21.7 NRBCs 
in the post-CVS group.  However, the study had numerous limitations.  Firstly, the data 
in the pre-CVS group was skewed towards zero with 70% of cases demonstrating no 
cells.  Under the non-gaussian distribution, median is a better statistical marker for 
reporting (Pre-CVS: median = 0; range = 0-8; Post CVS: median = 10; range = 4-100).  
Secondly, the number of NRBCs was detectable on the basis of HbF staining, which is a 
non-specific fetal cell marker, as 20% of all HbF positive NRBCs in maternal blood are 
of maternal origin in the first trimester (de Graaf et al., 1999).  No subsequent analysis 
with FISH was carried out to prove the fetal origin of NRBCs and hence the numbers, 
before and after CVS.  In their subsequent case report, (Oosterwijk et al., 1998c) the 
authors reported 52 HbF positive NRBCs before and 80 after the CVS procedure with a 
1.5-fold increase in the number post-CVS.  When cFISH was carried out to determine the 
fetal origin, only 58% of pre-CVS and 42% of post-CVS cells showed one X and one Y 
signal, suggesting that a fraction of HbF positive NRBCs could be of maternal origin.   
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Table 1.1: Enrichment of fetal nucleated erythroblasts from maternal blood 
 
 
Authors    Year   GA         Density          Deplete    Select       Detection 
   
Price et al       1991      1st & 2nd trimester     Ficoll 1077                  CD71/GPA       cFISH /PCR         
                                     
Bianchi et al     1992                19          Ficoll 1077              CD71     
cFISH   
Elias S et al     1992        10+                           CD71/GPA             cFISH    
  
Chueng et al     1996               10-12             Ficoll 1077          CD71 Immunfluorescence  
staining   
                                                                                                                                                                     for  zeta/gamma- 
             globin/PCR 
 
Pezello et al     1997               15+6      Triple density Ficoll gradient                      CD71               cFISH  
 
Kuo et al     1998                5-32     Triple density Ficoll gradient              KB 
           
 
Al-Mufti et al    1999               12        Triple density Ficoll gradient       CD71           KB/cFISH 
 
Rodriguez et al  2001            10-20      Double density Ficoll 1077 and 1109                     CD71          KB/cFISH 
 
Parano et al      2001            16-18      Double density Ficoll 1077 and 1083                                        KB/cFISH 
 
Martel et al        2001            14-29      Ficoll 1119        CD71/GPA    KB/cFISH 
 
Hromadnikova et al     
                          2002            19-21      Ficoll 1077  CD14/45       CD71    cFISH 
 
Kitigawa et al   2002            11-16      Ficoll 1090                                Lectin/cFISH 
 
Mavrou et al     2003             11-14      Ficoll 1083                            CD45        CD71      IHC for epsilon- 
                  globin/cFISH 
 
Choolani et al   2003           8-10+6     Percoll 1118  CD45         GPA       Simultaneous                                                                                                                                                                                                                                
                                                                                                                                                               immunofluorescence  
                   staining  for epsilon- 
                               globin and cFISH 
                                                          
 
GA: Gestational age; Density: Type and density of solution used in density gradient centrifugation; 
CD: Types of cell development antibodies used; GPA: Glycophorin A; cFISH: Chromosomal 
fluorescence in-situ hybridisation; PCR: Polymerase chain reaction; KB: Kleihauer-Betke staining for 
fetal haemoglobin; IHC:Immunohistochemistry
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Table 1.2: Testing efficiency of enrichment protocols by using invasive 




Authors         Year        GA             Density                  Deplete   Select          Detection 
 
Ganshirt et al     1993     Not known       Triple density       CD71              cFISH                                 
                                        (before & after Ficoll gradient  
                                 invasive procedure)                       
                         
Ganshirt et al     1998     Not known  Triple density                                       CD71                   H & E staining                                 
                                 (before & after  Ficoll gradient 
                            Amnio, CVS, FBS)                              
                                      
Jansen et al     1997        11-14  Ficoll 1077                 CD14/45         CD71                       cFISH 
                               (before & after CVS)                    
 
Oosterwijk et al 1998     10+3-13+4                Triple density Ficoll gradient                      IHC for HbF  
                               (before & after CVS)           
 
Oosterwijk et al 1998           11  Triple density Ficoll gradient   IHC for HbF/cFISH  
                               (before & after CVS)           
 
Raghad et al     2003        11-14 Triple density Ficoll gradient     CD71           KB/ Immunoflouresecence  
                              (before & after CVS)       staining for epsilon- gobin/gamma- 
                    globin/cFISH                                                                                                                                                                                                                                 
                     
Christensen  
et al                  2003         9-14             BS /Lysis/Triple density    CD45          CD71    Immunoflouresecence staining        
                                (before & after CVS)   Percoll gradient                                              for epsilon-globin/gamma- 
                                                                                                                                      globin/cFISH                                                                                                                    




GA: Gestational age; Density: Type and density of solution used in density gradient 
centrifugation; CD: Types of cell development antibodies used; GPA: Glycophorin A; cFISH: 
Chromosomal fluorescence in-situ hybridisation; H & E:  Haematoxylin and Eosin staining; KB: 
Kleihauer-Betke staining for fetal haemoglobin; IHC: Immunohistochemistry; BS: Bulk 
separation by centrifugation using a specialised tube
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The study was confounded by the inclusion of trisomic pregnancy, which could have also 
influenced the number of FNRBCs in maternal circulation before the procedure.   
 
An increase in fetomaternal cellular trafficking of up to three-fold following CVS was 
reported (Al Mufti et al., 2003).  They followed the enrichment protocol as used by the 
above mentioned group (Ganshirt-Ahlert et al., 1993).  The authors included all 
karyotypically abnormal trisomy 18 cases in their study, which could have confounded 
the number of NRBCs enriched before the invasive procedure.  Further, the authors used 
Kleihauer-Betke method, immunocytochemistry staining using monoclonal fluorescein 
isothiocynate (FITC) conjugate fluorescent antibody against ε- and γ-gamma globin 
chains and Y-signal cFISH to calculate the enriched fetal erythroblast before and after the 
procedure.  Kleihauer-Betke staining against γ-globin chain is not specific for accurate 
fetal erythroblast identification and so as the immunohistochemistry, as both could stain 
HbF positive maternal NRBCs (section 1.6.4.1) and therefore can confound the number 
of FNRBCs enriched from maternal circulation before and after the CVS.   
 
Christensen et al. (2003) studied the efficiency of their enrichment protocol using CVS 
between 9-14 weeks on women carrying male fetus.  However, the study design was not 
appropriate.  Firstly, the samples were acquired from two different groups of women.  
Secondly, same enrichment protocols were not applied to all the patients.  Thirdly, the 
volume of blood samples analysed varied from patient to patient.  Fourthly, in post-CVS 
samples, antibody staining against γ and ε chains was used as compared to pre-CVS 
samples where antibody to ε-chain was used.  Only 72% of all NRBCs stained against γ-
chain were identified to be of fetal origin on cFISH.  Subsequently, in pre-CVS samples, 
only one cell was identified from among 18 cases.   
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 The above groups tried to assess the efficiency of enrichment protocols in the first and 
second trimester using the invasive procedure as an in-vivo model system.  This may not 
be an ideal strategy as the numbers of cells obtained are too small to reflect the efficiency 
of the enrichment system.  The studies also differed from each other in some way, 
making direct comparisons unreliable.  The results were further confounded by: 
 
1. Using enrichment protocols, the efficiency of which was tested by other group 
(Bhat et al., 1990) in model mixture experiments.  The cells of interest mostly 
came from cord blood samples.  Cord blood FNRBCs and definitive erythroblasts 
have identical morphology and similar biological and physical properties. 
However, they differ significantly from primitive fetal nucleated erythroblasts 
(Choolani et al., 2003) which are now considered the target for first trimester non-
invasive prenatal diagnosis (section 1.6.4.2).      
2. Non-uniformity of protocol for FNRBCs enrichment used among different groups 
3. Inclusion of aneuploid pregnancies in study design 
4. Usage of non-specific fetal cell markers during the enrichment and identification 
process 
5.  Application of enrichment protocols across varying gestational ages 
6. Pre and post procedure samples obtained from two different groups 
7. Targeting only male pregnancies. 
 
1.7 Experimental aims and hypotheses 
 
Development of non-invasive prenatal diagnosis has potential to reduce, or even 
eliminate, the risk of miscarriage from invasive diagnostic testing by CVS, amniocentesis 
and FBS.  Fetal DNA can be retrieved from maternal blood in the plasma or cellular 
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fraction.  Using DNA in the plasma fraction, only a few paternally inherited single gene 
differences can be diagnosed whereas the isolation of fetal nucleated erythroblasts 
permits the diagnosis of any fetal aneuploidy or monogenic disorder.  If such a 
technology is available in the first trimester, women having invasive diagnostic testing 
would increase the uptake of test (Zamerowski et al., 2001).   
 
Non-invasive prenatal diagnosis using a cell-based strategy can be divided into 3 phases: 
(i) enrichment of fetal cells from maternal blood (ii) identification of enriched cells as 
fetal and (iii) making the genetic diagnosis.  The latter two phases have been addressed 
by demonstrating ε-globin, a developmentally-specific embryonic globin, as a fetal 
nucleated erythroblast specific marker in normal and aneuploidy pregnancy in the first-
trimester for non-invasive prenatal diagnosis (section 1.6.4.2).  However, two problems 
need to be addressed:  
 
(a)  First, it remains to be identified whether ε-globin positive primitive fetal nucleated 
erythroblasts persist in the blood of chromosomally abnormal neonates at birth.  Since, 
45-50% of ε-globin positive erythroblasts are still found to be present in euploid fetal 
circulation as late as 12 weeks gestation (Al-Mufti et al., 2000; Choolani et al., 2001), it 
is likely to be enriched from pregnant women’s blood sample carrying euploid (Al-Mufti 
et al., 2001; Choolani et al., 2003) and aneuploidy fetuses in the first trimester such as 
trisomy 13 (Choolani et al., 2003) and trisomy 18 (Al-Mufti et al., 2003), respectively.  
Recently, it was observed that these cells persist in blood of chromosomally abnormal 
fetuses (Trisomy 13, 18, 21 and triploidy) up to 28 weeks gestation (Al-Mufti et al., 
2000).  Enrichment of ε-globin positive primitive fetal nucleated erythroblasts from 
women in the second trimester known to be carrying trisomy 21 fetus was demonstrated 
after the amniocentesis and before the termination of pregnancy (Mavrou et al., 2003).  
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These observations indicate that embryonic ε-globin gene is not switched off in 
chromosomally abnormal fetuses and such target cells could persist into the second 
trimester.  It was hypothesised that such cells could persist up to term in aneuploidy 
fetuses.  Trisomy 18 was selected as a model to prove this hypothesis.  The choice of T18 
as an aueploid model to base our investigations was based upon the assumption that the 
haemoglobin switch is similar in all aneuploidies, and that the placental interface is 
similar in its leakiness for both T18 and T21.  We acknowledge that T18 is rarer than T21 
and choosing T18 will limit our ability to gauge what happens in a T21 pregnancy which 
is more clinically relevant, it was due to the availability of T18 cases in our unit at that 
point in time and lack of any T21 cases, that we chose to undertake T18 to prove our 
hypothesis.  If proven, it could be of great clinical significance, as the existence of these 
cells could indicate not only the presence of a chromosomally abnormal fetus but also 
imply that the ε-globin primitive fetal nucleated erythroblasts are also ideal cell to be 
targeted in the second trimester for non-invasive prenatal diagnosis.  This thesis looks 
into, whether the ε-globin positive primitive fetal nucleated erythroblasts persists beyond 
the second trimester in the trisomy 18 fetus and in trisomy 18 neonates at birth. 
 
(b) Secondly, the first phase, i.e. enrichment of FNRBCs from maternal blood still 
remains a challenge, as to-date, efficiency of enrichment protocols which have been used 
for isolating fetal nucleated erythroblasts from maternal blood remains unknown.  This is 
because efficiency of FNRBCs enrichment methods have been tested using cord blood 
samples, aneupolid fetuses, post-procedure maternal blood samples and pre-procedure 
maternal blood samples.  Most of the protocols were developed on cord blood NRBCs 
(Ganshirt et al., 1992; 1998; Bhat et al., 1993; Troeger et al., 1999; Smits et al., 2000) in 
model mixture experiments.  Subsequently, they were applied directly on maternal blood 
samples in on-going prengnacies so as to test its in-vivo efficiency without actually 
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testing its efficiency in an appropriate in-vitro model system.  This method of testing the 
efficiency of enrichment protocols is not appropriate because (1) properties of cord blood 
FNRBCs are similar to that of maternal NRBCs and both contain γ-globin which is a 
non-specific fetal cell marker and (2) upto 50% of FNRBCs enriched by the protocols are 
maternal in origin (Troeger et al., 1999; Lim et al., 2001) and (3) the number of target 
cells obtained by applying enrichment protocols directly on maternal blood is too small to 
reflect the efficiency of an enrichment system for non-invasive prenatal diagnosis.   
 
Few groups tested the efficiency of the protocols directly on maternal blood samples 
complicated by aneuploidy (Price et al., 1991; Elias 1992; Bianchi et al., 1992; Pezello et 
al., 1997; Oosterwijk et al., 1998; Al-Mufti et al., 1999; Parano et al., 2001; 
Hromadnikova et al., 2002).  This is also not appropriate, as the placental feto-maternal 
barrier is disturbed due to impaired development and function of placental villi leading to 
an increased fetomaternal transfusion (Genest et al., 1995).   
 
Others used post-procedure maternal blood samples to study the efficiency of their fetal 
cell enrichment methods (Samura et al., 2000; Wang et al., 2000; Cha et al., 2003; 
Purwosunu et al., 2006).  It is possible to determine the in-vivo enrichment efficiency of 
novel fetal cell enrichment protocols following an invasive procedure since greater 
number of target cells circulate within maternal maternal blood.  It is impossible however 
to extrapolate how this enrichment protocol would behave in ongoing pregnancies in the 
absence of any invasive procedure.  It is logical to test new fetal cell enrichment 
protocols after invasive procedures, but no mechanism exist to-date that could predict the 
behaviour of such a protocol in ongoing pregnancies.  Furthermore, if the invasive 
procedure were a surgical termination of pregnancy performed for non-medical 
indications in the first trimester, the development of a predictive model would indicate 
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how this new enrichment protocol would work in healthy, ongoing pregnancies in the 
first trimester of pregnancy. 
 
First trimester PFNRBCs contain embryonic epsilon-globin, an ideal fetal cell identifier 
(Choolani et al., 2001; Choolani et al., 2003), and are the promising candidate target cells 
for non-invasive prenatal diagnosis (Choolani et al., 2001; 2003; Voulliare et al., 2001; 
Christensen et al., 2003; Mavrou et al., 2003).  However, protocols to enrich these cells 
from maternal blood have been developed at CVS (Al-Mufti et al., 2003; Christensen et 
al., 2003; Mavrou et al., 2003; Voullaire et al., 2003) and at surgical termination of 
pregnancy (Choolani et al., 2003).  In these studies feal cells were enriched from 
maternal blood post-procedure, but there was no way to reliably pedict the performance 
of the enrichment protocol in pre-procedure samples.  First trimester surgical termination 
of pregnancy for non-medical indications is preferable to CVS as the index invasive 
procedure as the results are less likely to be biased by an overrepresentation of high-risk 
pregnancies.    
 
Therefore, currently there is no accurate assessment of the efficiency of any enrichment 
protocol and no standard method is available to evaluate the efficency of new fetal cell 
enrichment system.  There is a lack of any such validated in-vivo biological model that 
can be used to assess the efficiency of a new fetal cell enrichment system.  This thesis 
aims to develop an in-vivo model of biological feto-maternal haemorrhage that could be 
used to evaluate new fetal cell enrichment protocol in standardized fashion in the first 
trimester.  Termination of pregnancy was chosen as a biological model to study first 
trimester non-invasive prenatal diagnosis because fetal blood sampling and amniocentesis 
is performed in the second trimester and by this time PFRNBCs reach negligible levels in 
the fetal circulation.  Therefore, it does not give the target cells i.e. primitive fetal 
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nucleated erythroblasts to study the efficiency of enrichment system in the first trimester.  
CVS is also not an appropriate model to use because it is an invasive testing method with 
fetal loss associated with it and the number of FNRBCs extracted for in-vitro model is 
too small to test the efficiency of any enrichment system.  Furthermore, CVS is 
performed only in those pregnancies which are at high-risk of carrying aneuploidy fetus 
and therefore the results are likely to be biased by an overrepresentation of high-risk 
pregnancies.  On the other hand, surgical termination of pregnancy does not carry any 
risk to the fetus and the PFNRBCs can be enriched in sufficient numbers from 
termination of pregnancy tissue for in-vitro model mixture experiments to study the 
efficiency of a novel enrichment system for non-invasive prenatal diagnosis in the first 
trimester.  Though the use of fetal tissue to extract FNRBCs can be further improved 
using pure fetal blood via cardiocentesis, it depends on the availability of such samples 
and would be near impossible to gather in Singapore.   
 
Recently, a novel two-step protocol, Percoll 1118 density gradient followed by anti-
CD45/anti-GPA on MACS based on first-trimester primitive fetal nucleated erythroblasts 
was designed (Choolani et al., 2003).  The properties of these cells differ significantly 
from second-trimester definitive nucleated erythroblasts as it contains embryonic ε-globin 
as a fetal cell specific marker.  However, the efficiency of this protocol is not yet been 
established.  This thesis investigates the efficiency of a novel fetal cell enrichment 
protocol.     
 
Cell free fetal DNA has been investigated as a marker for feto-maternal haemorrhage at 
surgical termination of pregnancy (Bianchi et al., 2001; Watagnara et al., 2004; 2005) 
and we plan to use this fetal genetic material as corroborating evidence of the quantity of 
feto-maternal haemorrhage.     
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The study was planned in 4 stages: (a) to demonstrate if ε-globin positive primitive fetal 
nucleated erythroblasts circulate in trisomy 18 fetus beyond the first-trimester and in cord 
blood of trisomy 18 neonates at birth (b) to evaluate efficiency of a new fetal cell 
enrichment protocol in in-vitro model system (c) to develop an in-vivo model of 
biological feto-maternal haemorrhage that could be used to evaluate efficiency of new 
fetal cell enrichment protocol for non-invasive preantal diagnosis in the first trimester and  
(d) to demonstrate cell-free fetal DNA as a marker of feto-maternal haemorrhage using 
surgical termination of pregnancy in the first trimester.   
 
1.7.1 Hypotheses 
1.    Embryonic epsilon-globin positive nucleated red blood cells persists beyond the  
       second trimester using T18 as a model. 
2a.  Surgical termination of pregnancy can be used to evaluate efficiency of a new fetal   
       cell enrichment protocol in in-vitro model system. 
2b.  Surgical termination of pregnancy can be used as an in-vivo model to study   
       enrichment efficiency of a novel non-invasive prenatal diagnosis method in the first  
       trimester. 
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2.1.1 Human tissue and blood samples 
 
 
2.1.1.1 Ethical approval for use of human tissue and blood samples 
 
 
Blood and fetal tissue collection for this research was approved by the Institutional 
Research Board of National University Hospital, National University of Singapore in 
compliance with guidelines regarding the use of fetal tissue for research purposes.  All 
research participants gave written informed consent for the collection of their blood 
samples and fetal trophoblasts tissue and fetal blood samples. 
 
2.1.1.2 First trimester trophoblasts, second trimester fetal blood samples and cord 
blood  
 
First trimester fetal trophoblasts tissue was collected immediately after termination of 
pregnancy from within the products of conception.  Fetal blood sample was collected by 
ultrasound-guided trans-abdominal cardiocentesis immediately prior to clinically 
indicated termination of pregnancy due to chromosomal abnormality in the second 
trimester.  Fetal blood samples were also collected by trans-abdominal cordocentesis 
from pregnant women undergoing prenatal diagnosis in the second trimester.  Cord blood 
was obtained from chromosomally normal and abnormal newborns at birth. 
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2.1.1.3 Peripheral blood from pregnant women 
 
Peripheral blood samples (23 ml) were collected from women undergoing termination of 
pregnancy in the first trimester for non-medical indications.  Samples were collected 
either, before and after termination of pregnancy or immediately after termination of 
pregnancy. 
 
2.1.1.4 Peripheral blood from healthy male volunteers 
 
Peripheral blood samples (3 ml) were collected from healthy male volunteers. 
 
2.1.2 Antibodies, reagents, media, solutions and kits 
 
All antibodies, reagents, media and kits used in the experiments are listed below together 
with their source. 
 
2.1.2.1 Antibodies  
 
Antibodies directed against the surface antigens GPA and CD45 conjugated to magnetic 
beads (Miltenyi Biotech, Germany, GMBH); unconjugated anti ε-globin antibody 
(Europa Bioproducts, Cambridge, UK); biotinylated goat anti-mouse secondary antibody 
(Vector Laboratories, Burlingame, CA). 
 
2.1.2.2 Reagents and supplements 
 
Methanol, ethanol, acetone, tri-sodium citrate, sodium chloride (NaCl) and glacial acetic 
acid (AnalaR, BDH Merck, Poole, UK); Nonidet p40 (NP40) and dextran sulphate (BDH 
Merck, Poole, UK); Wright stain (Weskor, Utah, USA); ammonium chloride (NH4Cl) 
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(StemCell Technologies, London, UK);  Hank’s Balanced salt solution (HBSS) without 
calcium and magnesium, phosphate-buffered saline (PBS) and ethylenediaminetetraacetic 
acid (EDTA) GIBCO/BRL, Invitrogen Life Technologies, Paisley, UK); trypsin (Difco, 
BD diagnostic systems, Oxford, UK); Tween-20 (polyoxyethylene sorbitan monolaurate; 
DAKO Corporation, Carpinteria, CA); formamide (Promega, Madison, WI); bovine 
serum albumin (BSA), normal goat serum, acetazolamide and Ficoll (Histopaque) 1077 
(Sigma Chemical Co., Poole, UK); Hepes 1M, Percoll 1.030 g/ml (Amersham Pharmacia 
Biotech, Buckinghamshire, UK); streptavidin conjugated with AMCA (7-amino-4-
methylcoumarin-3-acetic acid), antifade mounting medium with DAPI (diamidino-2-
phenyl-indole) and without DAPI (Vectashield) (Vector Laboratories, Burlingame, CA); 
DPX mountant (RA Lamb, East Sussex, UK); 10% fetal calf serum (ICN 




Carnoy’s fixative (3:1 methanol:glacial acetic acid) was prepared fresh for each 
experiment.  Dilutions of salted sodium citrate (SSC) were prepared from a stock of 20X 
SSC (3M NaCl, 0.3 M tri-sodium citrate); cFISH denaturation and hybridisation buffer 
(50% formamide and 10% dextran sulphate in 2X SSC, pH 7.0); MACS cell sorting 




Alkaline phosphatase Vector Blue substrate labelling kit (Vector Laboratories, 
Burlingame, CA); chromosome-specific centromeric repeat probes DXZ1, labelled with 
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SpectrumOrangeTM, and DYZ1, labelled with SpectrumGreenTM (Vysis XY FISH probes, 
Vysis, Downer’s Grove, IL). 
 
2.1.3 Hardware  
 
All specialised hardware used in the experiments is listed below together with their 
source. 
 
2.1.3.1 Pipettes, centrifuge tubes, slide storage box and filters 
 
Positive-pressure pipettes (Gilson, Villiers-le-Bel, France); Pipette-Aid motorised (Wolf 
laboratories, York, UK); 1.5 ml conical-bottom polypropylene tubes (Eppendorf, 
Cambridge, UK); Falcon 70 μm filters, 15 and 50 ml conical-bottom polypropylene tubes 
(BD Biosciences, Oxford, UK); slides storage box (BDH Merck, Poole, UK). 
 
2.1.3.2 Immunomagnetic cell sorting equipment 
 
VarioMACS, MACS multistand, miniMACS and midiMACS separation units, MS and 
LD columns (Miltenyi Biotech, Germany, GMBH). 
 
2.1.3.3 Centrifuges for polypropylene tubes 
 
Bench top centrifuge for 15- and 50 ml polypropylene tubes (Beckman GS-6R); bench 





2.1.3.4 Cytocentrifuge and water bath 
 
Cytocentrifuge (Cytospin 3, Shandon, Manchester, UK); standard water bath (Grant 
Instruments, Herts, UK). 
 
2.1.3.5 Chromosomal fluorescence in-situ hybridisation block 
 
DNA EngineTM thermal cycling system with tower block adaptor for slides (MJ 
Research, Waltham, MA). 
 
2.1.3.6 Blood collection tubes, slides, coverslips, haemocytometer, coplin jars, 
immersion oil and ParafilmTM 
 
Vacutainer tubes and needles (BD Vacutainer systems, Oxford, UK); frosted end 
microscope slides, coverslips, Neubauer haemocytometer and coplin jars (BDH Merck, 
Poole, UK); low fluorescence immersion oil (Zeiss, Welwyn Garden City Herts, UK); 
ParafilmTM (American National Can Company, Chicago, IL). 
 
2.1.3.7 Microscopes and filters 
 
Inverted light microscope (Olympus, Hamburg, Germany); Fluorescence microscope 
(Olympus BX51, Hamburg, Germany); Photometrics cooled charge coupled device 
camera (CCD) (Roper Scientific, Ottobrunn, Germany); Filter sets: triple bandpass filter 
cube (DAPI/Green/Red); Orange, Aqua and DAPI single bandpass filter cubes (Vysis, 




2.1.3.8 Computers and software 
 
Dell computer connected to fluorescence microscope (Olympus BX51); SPSS Software 




2.2.1 Nucleated cell count 
 
Up to 10 μl of a nucleated cell sample was diluted 1 in 2 with 3% glacial acetic acid and 
10 μl were loaded onto the Neubauer haemocytometer.  Nucleated cells were counted 
under the inverted microscope.  At least 200 cells or four separate areas were examined 
and the average number of cells, N, per 1 mm2, (0.1 μl volume) determined and the 
concentration of nucleated cells in the original sample calculated (N x Dilution x 104 per 
ml). 
 
2.2.2 Cytospin preparation 
 
Up to 3 x 104 nucleated cells were re-suspended in 300 μl of 0.5% BSA/PBS (w/v), 
loaded into a cytospin chamber and centrifuged on to a slide at 500 rpm for 5 min inside 
the cytocentrifuge.  Slides were air dried and processed immediately or stored in foil and 
Parafilm at -20oC. 
 
2.2.3 Preparation of fetal trophoblast cells and primitive fetal 
erythroblasts from products of conception  
 
Trophoblast digestion buffer was prepared as follows: 0.182 g trypsin (Difco) and 3.75 
ml 1M Hepes (Amersham Pharmacia Biotech) were mixed into 146.3 ml HBSS 
(Invitrogen Life Technologies) and warmed to 37oC to dissolve trypsin.  Products of 
conception were obtained in the first trimester of pregnancy.  The trophoblast tissues 
were carefully dissected off adjacent deciduas and washed twice in PBS to remove 
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maternal blood contamination.  The cleaned specimen was incubated in 50 ml of 
trophoblast digestion buffer at 37oC for 30 minutes in a water bath.  The cell suspension 
was transferred into a fresh 50 ml polypropylene tube and the enzyme activity stopped 
with 5 ml fetal calf serum.  The cell suspension was then strained through a 70 μm filter 
to obtain single cell suspension and centrifuged at 3000 rpm (2060 g) (Beckman GS-6R) 
with brakes off at room temperature for 10 minutes.  The cell pellet was re-suspended in 
5 ml of PBS and layered over Percoll 1083 and centrifuged at 3000 rpm (2060 g) 
(Beckman GS-6R) with brakes off for 20 minutes.  A gradient interface layer was 
obtained and the red cells were pelleted at the bottom.  The cells in the interface layer 
containing the trophoblast cells were collected separately and suspended in 0.5% 
BSA/PBS.  Up to 3x104 cells were re-suspended into 300 μl 0.5% BSA/PBS (w/v) and 
loaded into cytospin chamber and centrifuged onto a slide at 500 rpm for 5 minutes inside 
the cytocentrifuge.  Slides were air dried and processed for standard XY cFISH (section 
2.2.12).  Red cells pelleted at the bottom contained primitive fetal nucleated erythroblasts 
and were suspended in 0.5% BSA/PBS and washed once at 3000 rpm (2060 g) (Beckman 
GS-6R) with brakes off for 10 minutes to be used for model mixture experiments.  The 
remaining cells were immediately cytocentrifuged on to glass slides (section 2.2.2) to 
serve as internal positive and negative controls for immunocytochemical staining (section 
2.2.10), immunofluoresence staining using AMCA and XY cFISH (section 2.2.13), and 
combined immunoenzymatic, immunofluoresence and cFISH (2.2.14). 
 
2.2.4 Preparation of adult mononuclear cells using Ficoll 1077 for 
external negative controls 
 
Blood was obtained from adult male volunteers after informed consent and the samples 
were diluted 1:1 in PBS and carefully layered over an equal volume of Ficoll 1077 in 15 
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ml propylene tube.  Samples were centrifuged at 1800 rpm (700 g) (Beckman GS-6R) for 
30 minutes keeping the brakes off at room temperature.  Compact nucleated cell layers at 
the gradient interface were collected using a 22-gauge needle attached to a 3 ml syringe.  
Cells collected were transferred separately into clean 15 ml polypropylene tubes, washed 
twice with 5-10 ml of 0.5% BSA/PBS at 3000 rpm (2060 g) (Beckman GS-6R) for 10 
minutes with brakes off at room temperature.  The supernatant was carefully transferred 
and the cell pellet re-suspended in an appropriate volume of 0.5% BSA/PBS for counting 
of nucleated cells.  Up to 10 μl of a nucleated cell sample was diluted 1 in 2 with 3% 
glacial acetic acid and 10 μl was loaded onto Neubauer haemocytometer.  Nucleated cells 
were counted under the inverted microscope (section 2.2.1).  Cells were then 
cytocentrifuged onto glass slides (section 2.2.2) to serve as external negative controls 
during immunocytochemical staining (section 2.2.10) and fluorescence AMCA and 
cFISH (section 2.2.13), and combined immunoenzymatic, immunofluoresence and cFISH 
(2.2.14).     
 
2.2.5 Wright’s stain 
 
Cells cytospun on to glass slides were Wright stained by manual method.  The slides 
were dipped in additive methanol for 90 seconds followed by 1 min each in eosin stain 
and polychrome methylene blue, respectively.  The slides were finally rinsed in distilled 




2.2.6 Preparation of Percoll gradients 
 
Percoll is available commercially as a density gradient of 1.130 g/ml.  Percoll 1083 and 
1118 were prepared from this stock by dilution with 1.5M NaCl (ρ = 1.058 g/ml) (Percoll 
Methodology and Applications 2nd Edition, Amersham Pharmacia Biotech, 
Buckinghamshire, UK).  Percoll has a very low osmolality (<25 mOs/kg H2O) and can 
therefore form density gradients with iso-osmotic solutions (1.5M NaCl) without 
significantly affecting the physiological conditions.  This is important for obtaining 
preparations of cells with intact morphology. 
 
Percoll gradients of the following density were prepared: 1083 and 1118.  Following 
formula was used to prepare Percoll 1083 g/ml and Percoll 1118 g/ml by mixing 
combination of 1.5M NaCl, Percoll (1.130 g/ml) and distilled water. 
 
To prepare 50 ml of Percoll at a specified density, the following were mixed together: 
 
5ml 1.5M NaCl solution 
Percoll (1.130 g/ml), the volume of which was calculated as follows: 
               
                  ρ – 0.1ρ’ – 0.9 
V0 = V _______________ , where 
       
                         ρ0 – 1 
 
V0   = volume of Percoll (1.130 g/ml) in ml 
V     = volume of the final working solution in ml (50 ml) 
 ρ     = desired density of the final working solution in g/ml 
 ρ0   = density of Percoll stock in g/ml (1.130 g/ml) 
 ρ’   = density of 1.5M NaCl (1.058 g/ml) in g/ml 
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Distilled water to make up to 50 ml. 
 
2.2.7 Layering the cells 
 
Adult blood samples and mixtures of fetal primitive nucleated erythroblasts in adult 
blood samples 
 
Adult blood samples were diluted 1:1 in PBS and carefully layered over an equal volume 
of Percoll 1118 in 15 ml propylene tube.  All the tubes were coated with 5% BSA so as to 
avoid the target cells getting adhered to the wall of the tubes.  Samples were centrifuged 
at 2750 rpm (1745 g) (Beckman GS-6R) keeping the brakes off for 30 minutes at 18oC.  
Two layers were obtained at the gradient interface: an upper and a lower cell layer 
(Figure 2.1).  The layers were collected using a 22-gauge needle attached to a 3 ml 
syringe.  Cells were transferred into clean 15 ml polypropylene tubes, washed twice with 
0.5% BSA/PBS at 3000 rpm (2060 g) (Beckman GS-6R) keeping the brakes off for 10 
minutes at room temperature.  The supernatant was carefully transferred and the cell 
pellet re-suspended in an appropriate volume of 0.5% BSA/PBS for subsequent 
processing.  This density gradient is applied in this thesis as the first-step enrichment 
strategy for isolation of primitive fetal nucleated erythroblasts in model mixture 
experiments and from clinical samples. 
 
Fetal blood samples and cord blood samples 
 
Fetal blood samples and cord blood samples were diluted 1:1 in PBS and carefully 
layered over an equal volume of Ficoll 1077 g/ml and Percoll 1083 g/ml, respectively, in 
15 ml propylene tubes.  Samples were centrifuged at 1800 rpm (700 g) and 3000 rpm 
(2060 g) (Beckman GS-6R) for 30 minutes at room temperature keeping the brakes off, 
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respectively.  Nucleated cell layers at the gradient interface were collected using a 22-
gauge needle attached to a 3 ml syringe.  Cells were transferred into clean 15 ml 
polypropylene tubes, washed twice with 5-10 ml of 0.5% BSA/PBS at 3000 rpm (2060 g) 
for 10 minutes.  The supernatant was transferred and the cell pellet re-suspended in an 
appropriate volume of 0.5% BSA/PBS for subsequent processing (Chapter 3). 
 
Figure 2.1 Two cell layers formed after density gradient centrifugation with  
Percoll 1118     
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The behaviour of Ficoll and Percoll gradients is influenced by the model of the 
centrifuge, the angle of the rotor used, the rotation speed and the size of the centrifuge 
tubes.  Thus, centrifuge tubes were standardised and the same bench top centrifuges were 
used in all experiments.  Two sizes of conical-bottom polypropylene tubes were used: 1.5 
ml (Eppendorf) and 15 ml (Falcon).  The centrifugation speeds for two centrifuges 
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(Eppendorf microcentrifuge and Beckman GS-6R centrifuge) were optimised before 
specific experiments began.  The optimal speed for the microcentrifuge was 3000-5000 
rpm (654-1817 g) while for the Beckman GS-6R centrifuge was 1800 rpm (700 g) for 
Ficoll 1077 g/ml, 2750 rpm for Percoll 1118 (1745 g) and 3000 rpm for Percoll 1083 
(2060 g).  Lower or higher speeds produced smears of cells rather than compact layers at 
the gradient interface whereas very high speeds altered cell morphology.  The following 
formula was used to convert rotation speeds into g value: 
 
   g       = 1118 x10-8 x R x N2, where 
 
g    = relative centrifugal field (multiple of acceleration due to gravity g = 9.80 m/s2) 
R   = radius of rotation in cm 
N  = speed of rotation in revolutions per min (rpm) 
 
2.2.9 Selective lysis of mature anucleate red blood cells 
 
Lysis with ammonium chloride  
 
Ice-cold ammonium chloride was mixed with pure populations, or mixtures, of fetal 
erythroblasts and adult mature anucleated erythrocytes at 1:2 ratios.  These were 
incubated in ice for a specified duration.  The durations selected depended upon the aim 
of the particular experiment.  If the activity of carbonic anhydrase within red cells needed 
to be blocked, this was done using acetazolamide diluted in PBS.  Proportions of cells 
lysed were determined by analysing a small aliquot (10 μl) of the sample in a 






Expression of intracellular ε-globin (Europa Bioproducts) on first trimester primitive fetal 
nucleated erythroblasts was determined using alkaline phosphatase 
immunocytochemistry.  Cytospun slides containing FNRBCs isolated from first trimester 
products of conception were fixed in 1:1 (v/v) methanol:acetone for 5 minutes at room 
temperature and rinsed in PBS for 2 minutes and air-dried.  After rehydration in PBST, 
the slides were incubated with goat serum (Sigma) diluted 1:10 with PBS for 2 hours.  
The slides were washed twice with PBST, incubated with anti-ε antibody diluted 1:100 
for 60 minutes and washed again twice.  Subsequent incubations were with a secondary 
antibody, biotinylated goat anti-mouse (Vector Laboratories) and with streptavidin 
conjugated with alkaline phosphatase (Vector Laboratories), both diluted 1:100 and 
incubated for 30 minutes each.  The colour reaction was developed with freshly prepared 
Vector Blue substrate (Vector Laboratories) for 10 minutes without light.  All incubations 
were in a humidifying chamber at room temperature.  All washes were in PBST for 5 
minutes each and slides were washed between incubations.  The slides were finally rinsed 
in tap water and dehydrated in 100% ethanol for 30 seconds each, air dried and mounted 
in Vectashield (Vector Laboratories).  Slides were analysed by light microscopy, which 
demonstrated ε-globin positive primitive fetal nucleated erythroblasts (Figure 2.2A).  
Subsequently, some of the slides were stained for nuclear fast red stain.  After rinsing the 
slides under tap water for 30 seconds, nuclear fast red stain was applied for 20 minutes 
followed by rinsing under tap water for 30 seconds and dehydration with 70%, 90% and 
100 ethanol for 2 minutes each.  Slides were then air-dried and mounted.  Slides were 
examined under light microscopy (Figure 2.3).   
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Figure 2.2 Immunocytochemistry on fetal primitive nucleated erythroblasts 
enriched from products of conception 
 




  (60 x magnifications) 
 
2.2.11 Magnetically-activated cell sorting (MACS) 
 
Positive and negative selection using the MACS immunomagnetic separation system was 
performed with only modifications to the manufacturer’s instructions (Miltenyi Biotech).  
A B 
 
A: ε-globin positive primitive fetal nucleated erythroblasts (40 x magnifications) 
B: Primitive fetal nucleated erythroblasts without primary antibody (40 x 
magnifications) 
  
Figure 2.3 Nuclear fast red stain on ε-globin positive primitive fetal 
nucleated erythroblasts enriched from products of conception  
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Cells to be enriched were suspended in sorting buffer (80 μl per 107 total cells) and 
incubated with the appropriate immunomagnetic bead-conjugated anti-human murine 
monoclonal antibody (20 μl per 107 total cells, Miltenyi Biotech) at 4oC for 30 min and 
the tubes were tapped at every 5 minutes interval so as to allow maximum binding of the 
cells to the antibody-coated beads.  After washing with buffer, the pellet was re-
suspended in sorting buffer and passed through the MS or LD columns attached to the 
MACS multi-stand via the miniMACS or midiMACS separation units, respectively.  
Unlabelled cells that passed through the columns were collected as the negative fraction.  
Cells of the positive fraction, retained within the columns, were collected by positive-
pressure elution.  After washing, cells were re-suspended in the buffer appropriate for the 
next stage of investigation such as 0.5% BSA/PBS for cytocentrifugation. 
 
2.2.12 Standard XY cFISH 
 
Cytospun slides, prepared as described in section 2.2.2, were fixed using 5 drops (10 µl 
each) of Carnoy’s fixative and air-dried.  Slides were then dehydrated through 70%, 90% 
and 100% ethanol for 2 minutes and air-dried.  Five micro litres of Vysis XY FISH probe 
diluted 2:3 in the hybridisation buffer were added to each cytospin under a coverglass 
sealed with Parafilm.  Target DNA was denatured on an in situ hybridisation block at 
71oC for 7 minutes followed by 4 hours hybridisation at 37oC.  Post hybridisation washes 
included once in 0.4XSSC at 72oC for 2 minutes and once in 2XSSC for 2 minutes at 
room temperature.  Slides were dehydrated through an ethanol series and protected by 
coverslips mounted over fluorescence antifade medium containing DAPI (Vector 
Laboratories) and sealed with clear nail varnish.  Throughout the procedure, the slides 
were shielded from direct light.  Slides were analysed by epifluorescence microscopy 
using single band pass filters for Aqua, Orange and DAPI and triple band pass filter set. 
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Images were captured using a cooled CCD camera (Roper Scientific).  Nuclei with two 
red or orange signals were classified as female (XX) (Figure 2.4A).  Those with one red 
or orange signal and one green signal were categorized as male (XY).  
 
2.2.13 Simultaneous immunofluorescence cytochemistry and cFISH 
 
Cytospun slides prepared (section 2.2.2) were fixed in 1:1 (v/v) methanol:acetone for 8 
minutes at room temperature permeabilised with 0.25% glacial acetic acid in methanol 
(v/v) and rinsed in PBST.  The slides were incubated with goat serum (Sigma) diluted 1:1 
with PBS for 2 hours.  The slides were washed twice with PBST, incubated with anti-ε 
monoclonal antibody diluted 1:100 for 60 minutes and washed again twice.  Subsequent 
incubations were with a secondary antibody, biotinylated goat anti-mouse (Vector 
Laboratories) and with streptavidin conjugated with AMCA (Vector Laboratories) both 
diluted 1:100 and incubated for 30 minutes each.  All incubations were in a humidifying 
chamber at room temperature.  All washes were in PBST for 5 minutes each and slides 
were washed between incubations.  Slides were dehydrated through 70%, 90% and 100% 
ethanol air dried and prepared for cFISH to the sex chromosomes.  Five micro litres of 
the probe diluted 2:3 in hybridisation buffer were added to the each cytospin under a 
coverglass sealed with Parafilm.  Target DNA was denatured on an in situ hybridisation 
block at 71oC for 7 minutes followed by 4 hours hybridisation at 37oC.  Post 
hybridisation washes included once in 0.4 X SSC at 72oC for 2 minutes and once in 2 X 
SSC at room temperature for 2 minutes.  Slides were dehydrated through an ethanol 
series and protected by coverslip mounted over fluorescence anti-fade mounting medium 
without DAPI and sealed with clear nail varnish.  Slides were analysed by 
epifluorescence microscopy using single band pass filters for Aqua, Orange and DAPI 
and triple band pass filter set.  Images were captured using a cooled CCD camera (Roper 
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Scientific), which demonstrated simultaneous fetal cell specific ε-globin positive 
primitive fetal erythroblasts stained with AMCA and the diagnosis of female gender by 
cFISH (Figure 2.4B). 
 
Figure 2.4 Standard cFISH (A) and simultaneous AMCA and cFISH on fetal 













A: DAPI staining of the nucleus of primitive fetal erythroblast (40 x magnifications) 
B: Accumulation of AMCA around the nucleus and staining of intracytoplasmic ε-globin 
positive primitive fetal nucleated erythroblast, depicting the morphology of the entire cell 
(40 x magnifications) 
 
 
2.2.14 Combined immunocytochemistry-Vector Blue Substrate,   
Immunofluorescence AMCA and cFISH 
 
Cytospun slides demonstrating ε-globin positive primitive fetal erythroblasts on 
immuncytochemical staining (section 2.2.10) were processed further for fluorescence 
staining with AMCA and cFISH analysis for fetal cell identification and gender 
determination.  Slides were destained in Xylene followed by rinse in distilled water for 2 
minutes and air-dried.  Slides were then washed in PBST twice for 5 minutes and air-
A B 
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dried.  Subsequent incubation was carried out with streptavidin conjugated with AMCA 
(Vector Laboratories) diluted 1:100 and incubated for 30 minutes.  Incubation was 
performed in a humidifying chamber at room temperature followed by washes in PBST 
for 5 minutes each.  Cells were permeabilised with 0.25% glacial acetic acid in methanol 
(v/v) and 5 drops (10 µl each) was placed on each slide.  Slides were then dehydrated 
through 70%, 90% and 100% ethanol, air dried and prepared for cFISH to the sex 
chromosomes as described (section 2.2.12).   
 
2.2.15 Quantitative analysis of cell-free fetal DNA 
 
DNA extraction from plasma samples and Real-Time Quantitative PCR 
 
Whole blood samples were centrifuged at 2800 rpm for 15 minutes and plasma was 
carefully removed and placed into clean 1.5 ml eppendorf tubes and re-centrifuged at 
13000 rpm for 15 minutes.  The supernatant was collected in a fresh 1.5 ml eppendorf 
tube.  800 μl of plasma sample was used for DNA extraction and the remaining was 
stored at -80oC.  DNA was extracted from plasma samples by use of a High Pure PCR 
Template Preparation Kit (Roche, GmH) using the protocol for peripheral blood.  The 
concentration of fetal DNA in maternal plasma was determined by real-time PCR 
amplification using a Perkin-Elmer Applied Biosystems 7700 Sequence Detector 
(Applied Biosystems, Foster City CA), which is essentially a combined thermal 
cycler/fluorescence detector with the ability to monitor, optically, the progress of 
individual PCR reactions.  The amplification and product-reporting system used was 
based on the 5΄ nuclease assay (the TaqMan assay, Perkin-Elmer).  In this system, in 
addition to the two amplification primers, as in conventional PCR a dual labelled 
fluorogenic hybridisation probe was also included.  One fluorescent dye (6 
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carboxyfluorescein [FAM] served as a reporter, and its emission spectrum was quenched 
by a second fluorescent dye (6 carboxy-tetramethylrodamine [TAMRA]).  During the 
extension phase of PCR, the 5΄ to 3΄ exonuclease activity of the Taq DNA polymerase 
cleaves the reporter from the probe, thus releasing it from the quencher, resulting in an 
increase in fluorescent emission at 518 nm.  The fluorescent emission of the 96 
amplification wells were continuously measured during the DNA amplification process 
and recorded by computer using Applied Biosystems Sequence Detection System 
software, version 1.7.  
 
The SRY Taqman system consisted of the amplification primers SRY-109F, 5΄-TGG 
CGA TTA AGT CAA ATT CGC-3 ;΄  SRY-245R, 5΄-TGG CGA TTA AGT CAA ATT 
CGC-3 ;΄  SRY-245R, 5΄-CCC CCTAGTACC CTG ACA ATG TAT T-3΄; and a dual 
labelled fluoresecent TaqMan probe SRY-142T, 5΄-(FAM) AGC AGT AGA GCA GTC 
AGG GAG GCA GA (TAMRA)-3΄.  The β-globin TaqMan system consisted of the 
amplification primers β-globin-354F, 5΄-GTG CAC CTG ACT CCT GAG GAG A-3΄;  β-
globin-455R, 5΄-CCT TGA TAC CAA CCT GCC CAG-3΄; and a dual-labelled 
fluorescent TaqMan probe β-globin-402T, 5΄-(FAM)AAG GTG AAC GTG GAT GAA 
GTT GGT GG(TAMRA)-3΄ The TaqMan probes contained a 3΄-blocking phosphate 
group, to prevent probe extension during PCR.  Primer/probe combinations were 
obtained from Lo et al. (1998).  Sequence data were obtained from the GeneBank 
Sequence Database (accession numbers L08063 [SRY gene] and U01317 [β-globin 
gene]). 
 
TaqMan amplification reactions were set up in a reaction volume of 25 µl by use of 
components (except TaqMan probes and amplification primers) supplied in a TaqMan 
Universal Master Mix (Perkin-Elmer).  TaqMan probes and PCR primers were custom-
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synthesized by PE Applied Biosystems.  Each reaction contained 1 x Taqman Universal 
Master Mix A; 240 nM of each amplification primer; 100 nM of the corresponding 
TaqMan probe; 4mM.  5 µl of the extracted plasma DNA was used for amplification.  
DNA amplifications were carried out in 96-well reaction plates that were frosted, by the 
manufacturer, to prevent light reflection and were closed by use of caps designed to 
prevent light scattering (Perkin Elmer).  Each sample was analysed in triplicate with the 
mean value used for further calculations.  A standard curve of titrated, commercial male 
DNA was run simultaneously in parallel with each analysis.  For all samples, the β-globin 
gene was amplified to estimate the total amount of DNA in the sample.  Identical thermal 
profiles were used for both the SRY and the β-globin TaqMan systems.  Thermal cycling 
was initiated with a 2-minute incubation at 50oC, to allow the uracil N-glycosylase to act, 
followed by a first denaturation step of 10 minutes at 95oC and then 55 cycles of 95oC for 
15 seconds and 60oC for 1 minute.  The conversion factor of 6.6 pg of DNA per cell was 
used, for expression of results as copy numbers.     
 
2.2.16 Enrichment of epsilon-globin positive primitive fetal nucleated 
erythroblasts from trisomy 18 syndrome fetus beyond first-trimester 
and from neonates at term 
 
A pure sample of fetal blood was obtained from a viable trisomy 18 fetus at 20 weeks 
gestation prior to termination of pregnancy.  Only one case was obtained during the 
course of research period.  Fetal blood samples were also obtained by ultrasound guided 
cordocentesis (n = 4) in patients undergoing prenatal diagnosis in the second trimester 
(gestational age range = 21+2–23+1 weeks) the results of which were karyotypically 
normal (controls).  Cord blood samples were obtained from three trisomy 18 and twenty 
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karyotypically normal neonates (controls) at term vaginal birth delivery.  Though the 
diagnoses of T18 were made in the second trimester through amniocentesis by sending 
the amniotic fluid for cFISH, because of religious reason, the couples declined for 
termination of pregnancy and continued till term.  Gestational age was calculated from 
the date of the last menstrual period and confirmed by ultrasound examination in the first 
trimester.  The fetal blood and cord blood samples were processed using Ficoll 1077 and 
Percoll 1083 density gradient centrifugation respectively (section 2.2.7) and MACS 
(2.2.11) to obtain glycophorin-A-(GPA)-positive fetal erythroblasts.  Morphology of 
these cells was evaluated by Wright stain (section 2.2.5) and presence of ε-globin within 
the cytoplasm was determined using immunocytochemical staining (section 2.2.10).  
FNRBCs isolated from first trimester surgical termination of pregnancies served as 
internal positive controls whereas cells incubated with the secondary antibody only were 
used as internal negative controls (section 2.2.3). Mononuclear cells enriched from 
healthy male volunteer using Ficoll 1077 were used as external negative controls (section 
2.2.4).  Chromosome aneuploidy was confirmed with fluorescence in-situ hybridisation 
(cFISH) (section 2.2.12).   
 
2.2.17 Effect of ammonium chloride lysis buffer on first-trimester 
primitive fetal nucleated erythroblasts and on adult anucleate 
erythrocytes  
 
Pure population of primitive fetal nucleated erythroblasts were extracted from products of 
conception in the first trimester (Figure 4.1).  Fetal nucleated erythroblasts and adult 
anucleate erythrocytes were then treated with ammonium chloride at the ratio of one 
volume of cell suspension to 2 volumes of lysis buffer so as to identify the time period at 
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which the adult erythrocytes start to lyse and the target cells remain intact.  All the 
incubations were carried out on ice.  In between observations, reaction mixtures were left 
on ice.   
 
10 ul of PBS containing 6 x 102 first trimester fetal erythroblasts were mixed with ice 
cold ammonium chloride lysis buffer.  The effect of the lysis buffer on FRNBCs was 
observed across 5 to 40 minutes time interval.  The experiment was repeated four times 
and average percentages of cells remaining intact were calculated. 
 
In the second experiment, pure population of 1.5 x 106 adult erythrocytes diluted in 10 ul 
of PBS were treated with ammonium chloride lysis buffer across 5-40 minutes time 
interval.  Percentage of lysed cells was calculated over an average of four repeat 
experiments.  The test for 95% CI was calculated by repeated measures ANOVA for 
binary outcome. 
 
2.2.18 Effect of ammonium chloride alone and ammonium 
chloride/1mM acetazolamide on a model mixture of primitive fetal 
nucleated erythroblasts and adult anucleated red blood cells  
 
Products of conception were obtained in the first trimester of pregnancy.  In the first 
experiment, 104 FNRBCs were spiked with 5 x 106 adult erythrocytes (1:500) and 
exposed to ammonium chloride alone for 5 minutes.  The experiments were repeated four 
times and average percentage of lysed cells was calculated for both cell types. 
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In the second experiment, the mixture of first trimester fetal erythroblasts and adult 
anucleated erythrocytes were exposed to ammonium chloride containing 1mM 
acetazolamide.  Average percentage of lysed cells was obtained for four similar 
experiments.  Paired t-test was applied for data analysis. 
 
2.2.19 Optimisation of second-step enrichment method on maternal 
blood samples  
 
Six maternal blood samples (20 ml each) obtained in the first trimester of pregnancy were 
processed through Percoll 1118 density gradient as the first-step enrichment protocol 
(section 2.2.7).  At the second-step, three samples were treated with anti-GPA and three 
with anti-CD45 on MACS, respectively (section 2.2.11).  Four maternal samples (20ml 
each) were processed through Percoll 1118 density gradient centrifugation followed by 
anti-CD45 and then anti-GPA on MACS and subsequent selective erythrocytes lysis 
using ammonium chloride/acetazolamide buffer.  Slides obtained from all the cases were 
Wright stained (section 2.2.5) to assess for purity.  Fischer exact test was applied for data 
analysis. 
  
2.2.20 Examination of the efficiency of a novel three-step enrichment 
protocol for first-trimester non-invasive prenatal diagnosis in in-vitro 
model system  
 
Primitive fetal erythroblasts were isolated from products of conception obtained in the 
first trimester after termination of pregnancy (section 2.2.3).  104 fetal nucleated 
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erythroblasts obtained from female fetus were spiked in 2 ml of adult male volunteer 
blood and processed through the first step Percoll 1118 density gradient method (section 
2.2.7).  The upper and lower layers obtained were processed separately.  The supernatant 
obtained from the two washings were centrifuged at 3000 rpm (2060 g) (Beckman GS-
6R) for 10 minutes and any cell pellet obtained was added to the cell suspension of their 
respective layers.  Figure 4.8 shows presence of fetal nucleated red blood cells in the 
supernatant after the initial density gradient centrifugation step.  The cell pellets from the 
upper and lower layer were processed separately for second-step enrichment method 
using anti-CD45/anti-GPA on MACS. The positive fraction comprising of pure 
population of red blood cells after anti-GPA sorting from the upper and lower layer were 
re-suspended separately in 100 µl of 0.5% BSA/PBS and treated with ammonium 
chloride/1mM acetazolamide cocktail lysis buffer at the ratio of 1:2 on ice for 5 minutes.  
The recovery of FNRBCs from upper and lower layer was determined separately by 
analysing the samples in a haemocytometer.  The experiments were repeated eight times 
so as to test the reproducibility of the results.  Distribution of FNRBCs between the upper 
and lower was analysed using wilcoxon signed-rank test due to the non-normal 





Chapter 3: Presence of ε-globin primitive fetal 
nucleated erythroblasts beyond the first-trimester and 
at birth in trisomy 18 syndrome neonates:  Implication 




The greatest likelihood of enriching embryonic ε-globin primitive fetal nucleated 
erythroblasts from maternal blood for non-invasive prenatal diagnosis is in the first 
trimester.  This is because ε-globin NRBCs are found to be increased at around 9-10 
weeks in euploid fetal blood and 45-50% is still circulating up to 12 weeks gestation (Al-
Mufti et al., 2000; Choolani et al., 2001).  However, their numbers become negligible by 
14 weeks of gestation (Choolani et al., 2001).  Following these reports, the same groups 
have demonstrated the enrichment of these cells from first trimester maternal blood 
carrying not only euploid fetuses (Al-Mufti et al., 2001; Choolani et al., 2003) but also 
aneuploidy fetuses such as trisomy 13 (Choolani et al., 2003) and trisomy 18, 
respectively (Al-Mufti et al., 2003).  Al-Mufti et al. (2000) observed the persistence of 
these cells in blood of chromosomally abnormal fetuses (T18, T21, T13, triploidy) up to 
28 weeks gestation.  Mavrou et al. (2003) were able to enrich these cells from women 
carrying trisomy 21 fetuses in the second trimester, after the invasive procedure and 
before the termination of pregnancy.  These findings indicate that embryonic ε-globin 
positive primitive fetal erythroblasts could persist into the second trimester in 
chromsomally abnormal fetuses and the ε-globin gene is not switched off.  It was 
hypothesised that such cells could persist not only in the second trimester of 
 99 
chromsomally abnormal fetus, but also at term.  Trisomy 18 was selected as a model to 
prove this hypothesis.  The choice of T18 as an aueploid model to base our investigations 
was based upon the assumption that the haemoglobin switch is similar in all aneuploidies, 
and that the placental interface is similar in its leakiness for both T18 and T21.  We 
acknowledge that T18 is rarer than T21 and choosing T18 will limit our ability to gauge 
what happens in a T21 pregnancy which is more clinically relevant, it was due to the 
availability of cases of T18 in our unit at that point in time and lack of any T21 cases, that 
we chose to undertake T18 to prove our hypothesis.  With the availability of newer 
screening protocols (section 1.3), a proportion of pregnant women at risk for aneuploidy 
pregnancy may test screen positive in the second trimester and enrichment of such cells 
from this cohort of women could indicate not only the presence of a chromosomally 
abnormal fetus but also imply that the ε-globin primitive fetal nucleated erythroblasts are 
ideal cells to be targeted in the second trimester for non-invasive prenatal diagnosis.   
 
3.2 Enrichment of epsilon-globin positive primitive fetal nucleated 
erythroblasts from trisomy 18 syndrome fetus beyond first- 
trimester and from neonates at term (section 2.2.16) 
Aim:  To demonstrate whether the ε-globin gene expression persists beyond the first 
trimester in trisomy 18 syndrome fetus and in trisomy 18 syndrome neonates at birth.   
 
Results:  The proportion of FNRBCs identified in trisomy 18 syndrome fetus at 20 weeks 
gestation was 16-fold higher (0.55%; n = 1) as compared to karyotypically normal fetuses 
(0.034%; n = 4). Figure 3.1 and 3.2 shows numerous FNRBCs on peripheral smear and 
on MACS sorting after positive selection with GPA in trisomy 18 fetus (Arrows).   
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Figure 3.1 Peripheral smear from fetal blood of karyotypically normal fetuses (n = 
4; GA = 21-23 weeks) and trisomy 18 fetus (n = 1; GA = 20 weeks)  
 
           Karyotpically normal  fetuses       Trisomy 18 fetus 
 
 
A: Absence of fetal nucleated red blood cells on Wright stain in normal fetuses (10 x       
     magnifications) 
B: Fetal nucleated red blood cells on Wright stain in trisomy 18 syndrome fetus  
     (10 x magnifications) 
 
 Figure 3.2 Red blood cells sorted on MACS using positive selection with 
Glycophorin A after first step density gradient centrifugation by Ficoll 1077 on fetal 
blood of normal fetuses (n = 4; GA = 21-23 weeks) and trisomy 18 fetus (n = 1; GA = 









    
A: Absence of fetal nucleated red blood cells on Wright stain in normal fetuses (20 x 
magnifications) 
B: Fetal nucleated red blood cells on Wright stain in trisomy 18 syndrome fetus (20 
x magnifications) 
   Trisomy 18 fetus 
 




Embryonic ε-globin primitive fetal nucleated erythroblast cells were observed in trisomy 
18 syndrome fetus (n = 1).  No ε-globin positive cells were noted in the blood samples of 
karyotypically normal fetuses (n = 4) (Figure 3.3).   
 
                                                                                                                   A: All anucleate  
                                                                                                                   red blood cells are 
                                                                                     eryt                       epsilon-globin negative.  
                                                                                                                   No staining with vector  
                                                                                                                   blue (20 x   
                                                                                                                   magnifications) 
                                                                                                                   B,C: Epsilon-globin            
                                                                                                                   (vector blue) staining of          
                                                                                                                   fetal nucleated    
                                                                                                                   erythroblasts (20 x  





The proportion of FNRBCs identified in cord blood of affected T18 newborns (n = 3) 
were found to be 14-fold higher and significantly increased (Mann Whitney U test; 
median % = 3; Range = 2 - 3.46) as compared with karyotypically normal neonates (n = 
20) (median % = 0.22; Range = 0.073 – 0.50; p = 0.001).  Quantification of FNRBCs was 
done over 3 x 104 cells.  Figure 3.4, 3.5 and 3.6 shows numerous FNRBCs on peripheral 
smear, density gradient centrifugation and on MACS sorting after GPA in cord blood of 
trisomy 18 and karyotypically normal newborns (Arrows). Embryonic ε-globin positive 
primitive nucleated erythroblasts were observed in all the three trisomy 18 neonates 
(Median = 9; Range = 6-23).  No such cells were noted in the cord blood of twenty 
karyotypically normal newborns at birth (Figure 3.7).  FNRBCs isolated from first 
 
Figure 3.3 ε-globin staining (vector blue) of primitive fetal nucleated erythroblasts by alkaline 
phosphatase immunocytochemistry in a T18 fetus after first step density gradient 
centrifugation using Ficoll 1077 followed by positive selection with Glycophorin A on MACS 




   Normal fetuses         T18 fetus 
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trimester surgical termination of pregnancies served as internal positive controls whereas 
cells incubated with the secondary antibody only were used as internal negative controls.   
Mononuclear cells enriched from healthy male volunteer using Ficoll 1077 were used as 
external negative controls and no adult white blood cells were found to be ε-globin 
positive.  Figure 3.8 demonstrates nucleated erythroblast with three signals for 
chromosome 18 on cFISH.  
 
A 
A: Absence of fetal nucleated red blood cells on Wright stain in normal newborns at birth 
     (10 x magnifications) 
B: Fetal nucleated red blood cells on Wright stain in trisomy 18 syndrome newborns at birth  




Figure 3.4 Peripheral smear from cord blood of karyotypically normal (n = 20) 
and trisomy 18 newborns (n = 3) at birth 
           
               
              Normal newborns                                                    Trisomy 18 newborns  
    







Normal Newborns Trisomy 18 Newborns 
A B 
A: Fetal nucleated red blood cell on Wright stain in normal newborns at birth 
     (20 x magnifications) 
B: Fetal nucleated red blood cells on Wright stain in trisomy 18 syndrome newborns at   
     birth (20 x magnifications) 
 
Figure 3.5 Distribution of fetal nucleated red blood cells after first step density 
gradient centrifugation using Ficoll 1077 on cord blood of karyotypically normal 
(n = 20) and trisomy 18 newborns (n = 3) at birth 
     
     
Figure 3.6 Red blood cells sorted by MACS using positive selection with Glycophorin A after 
first step density gradient centrifugation with Ficoll 1077 on cord blood of karyotypically 
normal (n = 20) and trisomy 18 newborns (n = 3) at birth 
 
                      Normal newborns   Trisomy 18 newborns 
A: Absence of fetal nucleated red blood cells on Wright stain in normal newborns at birth 
     (40 x magnifications) 
B: Fetal nucleated red blood cells on Wright stain in trisomy 18 syndrome newborns at birth 




    Blue colour depicts the DAPI staining of the nucleus (60 x magnifications) 
 
Figure 3.8  cFISH demonstrating three copies of chromosome 18 in fetal 
nucleated red blood cells 
 
Figure 3.7  ε-globin staining (vector blue) of primitive fetal nucleated erythroblasts 
by alkaline phosphatase immunocytochemistry after positive selection with 
Glycophorin A following first step density gradient centrifugation with Ficoll 1077 
on cord blood of trisomy 18 newborns at birth (n = 3) 
 
A B C 




A-H: Epsilon-globin positive primitive fetal nucleated erythroblasts in trisomy 18 
newborns at birth (20 x magnifications) (Range = 6 - 23) 
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Interpretation:  Haematopoiesis in an embryo and fetus occurs at the mesoblastic, hepatic 
and myeloid period which corresponds to the yolk sac, liver and spleen and bone marrow 
stage, respectively.  In a normal pregnancy, from the 16th week onward, there is a rapid 
decrease in extramedullary and a rapid increase in medullary erythropoiesis.  This 
declining contribution from the liver with an exponential decrease in fetal blood 
erythroblast count as gestation advances could be due to the consequence of the switch 
from hepatic to medullary erythropoiesis and maturation of the haematopoietic tissues 
(Nicolaides et al., 1989).  The data in this chapter demonstrates an increase in proportion 
of nucleated erythroblasts in trisomy 18 fetus and in neonates at birth compared to normal 
euploid fetuses.  This finding is consistent with that observed by Thilaganathan et al. 
(1995) who reported erythroblast count in aneuploidy fetuses to be significantly higher 
than the appropriate normal mean for gestation.   
 
Similarly, the proportion of fetal nucleated erythroblasts was observed to be decreased 
with increase in gestation in chromosomally normal fetuses as compared to abnormal 
fetuses (Al-Mufti et al., 2000).  What actually triggers the onset of increased 
erythropoiesis in aneuploidy fetuses is still unclear.  However, it could be due to a 
developmental delay in maturation of fetal haematopoietic system in such aneuploidy 
fetuses (Thilaganathan et al., 1993; Thilaganathan et al., 1994) and therefore, likely to 
result in persistence of yolk sac and hepatic haematopoiesis.  Further, it could be possible 
that when the bone marrow takes over the haematopoiesis, nucleated erythroblasts in 
such aneuploidy fetuses are deformed in their shape and subsequently are able to traverse 
the marrow sinusoids.  Such cells have already been demonstrated to have increased 
mean cell volume (Fisk et al., 1989; Sipes et al., 1991).  The data also shows the presence 
of embryonic ε-globin nucleated erythroblasts not only in the mid-trimester trisomy 18 
fetus (n = 1) but also in neonates (n = 20) at birth, indicating that the ε-embryonic globin 
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gene is not completely turned off during early development but instead continues to be 
expressed up to term.  Few groups have demonstrated that ε-globin positive nucleated 
erythroblasts persists in the fetal blood of aneuploidy fetuses up to 20 weeks (Christensen 
et al., 2003) and 28 weeks gestation (trisomy 21,18,13 and triploidy) (Al-Mufti et al., 
2000) respectively.  However, in the former (Christensen et al., 2003) the authors have 
not mentioned the type of aneupolidy present in the fetuses. 
 
On the other hand, Huehns et al (1964a) using starch gel electrophoresis on haemolysates 
of day 4 and day 5 old trisomy 13 infants, observed embryonic haemoglobin Gower II, 
the proportion of which was 0.7% of the total haemoglobin, while Jansen and Murken 
(1976) observed the likely presence of embryonic haemoglobin Gower I and II in blood 
sample haemolysate of trisomy 13 infant at day 8 of birth using isoelectric focussing gel.  
However, persistence of ε-embryonic globin at single cell level in trisomy 18 neonates 
has not been reported.  Such an observation cannot be explained by a gene dosage effect 
as proposed by Huehns et al. (1964b) because the genes for the hemoglobin chains are 
situated on chromosome 11 (Gusella et al., 1979) and 16 (Diesseroth et al., 1977).    On 
the contrary, no ε-globin positive nucleated erythroblast cells or anucleated erythrocytes 
could be observed in the cord blood of 20 normal neonates at birth.  This finding is 
similar to that observed by other groups (Al-Mufti et al., 2000; Christensen et al., 2003) 
who also could not demonstrate ε-globin positive nucleated erythroblast in cord blood of 




The data presented in this chapter imply that ε-embryonic globin positive primitive fetal 
erythroblasts are not only detectable in trisomy 18 fetus in the mid second trimester, but 
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are also found to be present in affected newborns at birth.  This information could be 
used for non-invasive prenatal diagnosis in group of women who are identified at 
particularly high-risk for chromosomal aneuploidy in the second trimester and beyond. 
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Chapter 4: Termination of pregnancy as an in-vitro 
model system to study first-trimester non-invasive 




To-date, enrichment of fetal nucleated erythroblasts from maternal blood remains a 
challenge.  This is because of their rarity in maternal circulation (there may be 1 fetal cell 
per millilitre of maternal blood; 10-7 nucleated cells) (Bianchi et al., 1997).  As little can 
be done to alter the frequency of fetal erythroblasts in maternal blood, researchers have 
focussed on using various methods that could help them in enriching these cells from 
maternal blood (section 1.6.4.3).  However, the enrichment protocols used by them for 
this rare cell isolation are limited by two issues:  
 
(i) The protocols have been used without their efficiency being tested in an appropriate 
in-vitro model system.   
(ii) The protocols have been designed on model mixture experiments comprising NRBCs 
obtained from cord blood (Ganshirt et al., 1992; 1998; Bhat et al., 1993; Troeger et al., 
1999; Smits et al., 2000).   
 
This chapter examines the hypothesis (2a) that surgical termination of pregnancy can be 




The new fetal cell enrichment protocol comprised of Percoll 1118/anti-CD45/anti-GPA 
and has been adopted from Choolani et al. (2003).  Before testing the protocol, it was 
considered whether a third-step enrichment process of selective lysis using ammonium 
chloride buffer could be incorporated.  Earlier study by Choolani et al. (2003) was not in 
favour of incorporating it as the first-step enrichment process (section 1.6.4.3, Enzymes).   
If proven successful as a third-step method, it could help in reducing the number of 
background anucleated erythrocytes after the initial two-step protocol. 
 
4.2 Effect of ammonium chloride lysis buffer on first-trimester 
primitive fetal nucleated erythroblasts and on adult anucleate 
erythrocytes (section 2.2.17) 
 
Adult erythrocytes are more susceptible to ammonium chloride lysis than fetal 
erythroblasts, as carbonic anhydrase activity is at least five-fold greater and 
acetazolamide permeability about ten-fold less in adult compared with FNRBCs.  When 
lysis procedure was used as the first-step enrichment method, no FNRBCs were 
recovered in the pre-CVS samples, though there was 70% recovery in the model system 
(Voullaire et al., 2003) (section 1.6.4.3 Enzymes).  Choolani et al. (2003) in their model 
mixture experiment were able to show that ammonium chloride/acetazolamide cocktail 
buffer could retrieve 100% of primitive FNRBCs.  The authors did not favour its use as 
the first-step method as significant clumping between the primitive fetal erythroblasts and 
the remaining adult erythrocytes made it difficult to recognise the morphology of the 
target cells.  However, it could be useful after the initial two-step enrichment when 
majority of adult anucleate red blood cells are already depleted at the first-step density 
gradient centrifugation method.  If successful, inclusion of this technique could help in 
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reducing the number of background adult erythrocytes and could minimise the number of 
slides processed for analysis by Wright stain. 
 
Aim: To identify the time period at which adult anucleate erythrocytes start to lyse and 
fetal primitive erythroblasts remain intact. 
 
Results:  The effect of the lysis buffer on FNRBCs and adult anucleated erythrocytes was 
observed across 5 to 40 minutes time interval.  The experiment was repeated four times 
and average percentages of cells lysed were calculated.  It was observed that 100% of 
fetal nucleated erythroblasts remained intact and no cells lysed on exposure to 
ammonium chloride up to 20 minutes time interval (95% CI, 0% - 3.5%). (Table 4.1) The 
cells started to lyse only after 20 minutes.  In contrast, 93% of adult anucleated red blood 
cells were lysed at 5 minutes exposure to ammonium chloride (95% CI, 88.8% - 97.2%) 
and increased to approximately 100% at 40 minutes of time interval (95% CI, 97.9% - 









Arrow depicts population of primitive fetal nucleated red blood cells on Wright 
stain (40 x magnifications) 
 
Figure 4.1 Enrichment of primitive fetal nucleated erythroblasts from trophoblast 





Table 4.1 Effect of ammonium chloride lysis buffer on fetal nucleated erythroblasts 





             PFNRBCs lysed (%)  95% Confidence Interval (%) 
5                           0              0 – 0.01 
10                           0              0 – 0.05 
15                           0              0 – 3.5 
20                           0              0 – 3.5    
25                           25.0              0 – 53.5 
30                           37.5              9.0 – 66.0 
35                           75             46.5 – 100  
40                           87.5             59.0 – 100  
 
 
Table 4.2 Effect of ammonium chloride lysis buffer on adult anucelated red blood 




Percentage of adult erythrocytes lysed 
                      
95% Confidence Interval 
5                       93.0  88.8 - 97.2 
10                       93.2  88.9 - 97.5 
15                       94.3  85.7 - 90.1 
20                       95.1  91.0 - 99.4 
25                       97.2  93.0 - 100 
30                       97.2  93.0 - 100 
35                       97.3  95.6 - 100 
40                       99.8  97.9 - 100 
 
 
Interpretation: The above data demonstrate 93% of selective adult erythrocyte lysis on 
exposure to ammonium chloride at 5 minutes time interval.  100% of adult anucleated 
erythrocytes are lysed only at 40 minutes.  Although, fetal primitive erythroblasts remain 
intact up to 20 minutes time interval, adult RBCs lysis increase only marginally by 2%.  
Therefore, 5 mins lysis interval would be optimal for adult cell lysis while preserving 
FNRBC integrity which was then chosen as the cut-off point for subsequent model 
mixture experiments.  The ratio of one volume of cell suspension to 2 volumes of lysis 
buffer was chosen so as to allow minimum volume exposure of the lysis buffer to the 
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target cells.  This is because the sensitivity of FNRBCs to ammonium chloride lysis in 
this in-vitro model system may differ from the in-vivo situations, which are actually 
enriched from the maternal blood. 
 
4.3 Effect of ammonium chloride alone and ammonium 
chloride/1mM acetazolamide on a model mixture of primitive 
fetal nucleated erythroblasts and adult anucleated red blood 
cells (section 2.2.18) 
 
Aim:  To study the effect of ammonium chloride lysis buffer alone and its combination 
with 1mM acetazolamide on the mixture of first trimester fetal erythroblasts and adult 
anucleated erythrocytes at a ratio of 1:2 at 5 minutes time interval.  Acetazolamide was 
added to determine whether its enzyme (carbonic anhydrase) inhibition activity protects 
the fetal erythroblasts from lysis by ammonium chloride. 
 
Result:  In the first experiment, FNRBCs were spiked with adult erythrocytes and treated 
with ammonium chloride alone.  In the second experiment, the mixture was treated with 
combination of ammonium chloride and acetazolamide.  Significant number of FNRBCs 
(35%; p = 0.01) and adult erythrocytes (94%; p = 0.001) were lysed when exposed to 
ammonium chloride alone at 5 minutes of time interval (Table 4.3).  When acetazolamide 
was added, significant number of adult erythrocytes were lysed (96%; p = 0.001), while 
there was no significant difference in the percentage of fetal cells remaining intact (93%) 
from the original number of cells introduced before the exposure (p = 0.60) (Table 4.4).   
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Table 4.3 Effect of ammonium chloride on cell lysis in a model mixture of PFNRBCs 
and adult erythrocytes (n = 4) 
 
        
         Cell type 
 
    Mean 
 
     Standard  
    deviation 
 
Cells lysed (%) 
    (95% CI) 
 
   p - value* 
 
      PFNRBCs 
(Test value = 104) 
 
    6500 
 
     1290.9 
 
        35 
   (22 - 48) 
 
     0.01 
 
Adult erythrocytes 
(Test value = 5 x 106) 
 
  275,000 
 
   134,783.7 
 
        94 
(91.8 – 97.2) 
 
     0.001 
 
* paired t-test 
 
Table 4.4 Effect of ammonium chloride/1mM acetazolamide on a model mixture of 
PFNRBCs and adult erythrocytes (n = 4) 
 
        
         Cell type 
 
    Mean 
 
     Standard  
    deviation 
 
Cells lysed (%) 
    (95% CI) 
 
   p - value* 
 
      PFNRBCs 
(Test value = 104) 
 
    9250 
 
      2629.9 
 
         7 
   (0 – 18.8) 
 
     0.60 
 
Adult erythrocytes 
(Test value = 5 x 106) 
 
  182,500 
 
    66,017.6 
 
        96 
(95.0 – 97.6) 
 
     0.001 
 
* paired t-test 
 
Choolani et al. (2003) had reported significant clumping between the primitive fetal 
nucleated erythroblasts and unlysed erythrocytes, which made it difficult to recognise the 
morphology of the target cells.  A combined ε-globin fluorescence immunocytochemistry 
and cFISH was performed after cytocentrifuging the cell mixture on the glass slides.  No 
significant clumping between unlysed erythrocytes and the target cells was observed.  
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The morphology of fetal nucleated erythroblasts were visualised clearly on fluorescence 












Interpretation:  In the model mixture experiment, 35% of fetal erythroblasts and 94.0% 
of adult anucleated erythrocytes were lysed with ammonium chloride alone at 5 minutes.  
This result is different than when fetal nucleated erythroblasts alone were treated with 
ammonium chloride, where at 5 minutes, 100% of cells remained intact (section 4.2).  
Unnexplained changes in the FNRBCs membrane morphology altered by adult red blood 
cells could have lead to its susceptibility to ammonium chloride lysis buffer. 
  
By exposing cell mixtures to ammonium chloride/1mM acetazolamide for 5 minutes, 
93% of primitive fetal nucleated erythroblasts were observed to be intact in the mixture.  
The addition of acetazolamide was found to have protective effect on primitive fetal 
nucleated erythroblasts.  Thus, this buffer combination was found to be suitable for the 
selective lysis of adult erythrocytes.  Hence, selective erythrocyte lysis with ammonium 
A B 
Figure 4.2 Immunofluorescence staining and cFISH on primitive fetal nucleated 
erythroblasts after selective erythrocyte lysis  
 
 
A,B: Epsilon-globin positive XX primitive fetal nucleated erythroblasts. The red  
signals are X-chromosome probes within the nucleus.  Blue colour staining of the 
intracytoplasmic epsilon-globin by accumulation of AMCA, depicting the 




chloride/acetazolamide can be incorporated as a third-step for fetal erythroblasts 
enrichment.   
 
4.4 Optimisation of second-step enrichment method on 
maternal blood samples (section 2.2.19) 
 
This section investigates whether the use of anti-GPA or anti-CD45 antibody as the 
second-step enrichment method after the first step density gradient centrifugation with 
Percoll 1118 produces pure population of red blood cells.  The choice for either antibody 
was made because CD45 is present on the cell surface of all mature human leukocytes 
and is not expressed on immature and mature erythrocytes (Zheng et al., 1993).  Anti-
GPA is an appropriate antibody to separate both anculeated red blood cells and NRBCs 
from nucleated white cell population after most of the maternal erythrocytes and white 
blood cells have been depleted by the first-step density gradient centrifugation method.  
At the end of the experiment, a pure population of red blood cells is expected.  If 
obtained, this could minimise extra steps of washing and the possible loss of these rare 
fetal cells.   
 
Aim:  To demonstrate if a pure population of red blood cells can be obtained after 
second-step enrichment with anti-GPA or anti-CD45 antibody on MACS as compared to 
using anti-CD45 followed by anti-GPA after first step density gradient centrifugation 
with Percoll 1118. 
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Flow chart of three different groups subjected to different regime of 
selection/purification on MACS after first step density gradient centrifugation  
with Percoll 1118 
 
                         First step density gradient centrifugation (n= 10) 
 
                         
   Anti-CD45                      Anti-GPA              Anti-CD45, then anti-GPA followed  
   alone (n = 3)                             alone (n = 3)          by selective erythrocyte lysis (n = 4) 
 
 
            
   
              
No pure population   No pure population  Pure population 
of red  blood cells                    of red blood cells                   of red blood cells  
    
Results: Contamination from maternal white cells was noted on all the slides that were 
made using either anti-GPA or anti-CD45 alone during the second step (Figure 4.3).  
Using anti-CD45 to deplete maternal white cells followed by positive selection with anti-
GPA as a second-step enrichment method gave pure population of red blood cells as 
compared to none on the samples where single antibody was applied (Fischer exact test; 
p-value = 0.02) (Figure 4.4).   
 
Interpretation:  Anti-CD45 or anti-GPA antibody alone on MACS after the first-step 
Percoll 1118 density gradient on maternal blood samples did not produce pure population 
of red blood cells.   
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On a spiked model mixture system, Choolani et al. (2003) obtained similar results while 
using anti-CD45 antibody alone.  However, they observed 100% purity with both anti-
GPA and combined antiCD45/anti-GPA.  The result from this experiment does not 
support the use of anti-CD45 or anti-GPA alone as a second-step enrichment method.  
We therefore decided to use Percoll 1118 followed by anti-CD45/anti-GPA and selective 
erythrocyte lysis as a three-step enrichment protocol to test its efficiency in in-vitro 
model for first-trimester non-invasive prenatal diagnosis. 
 
Figure 4.3 Contamination with maternal polymorphonuclear leukocytes in enriched 
fraction using anti-GPA or anti-CD45 alone on MACS after first step Percoll 1118 
















A-D: Wright staining of enriched fraction showing contamination of 
maternal red blood cells with maternal polymorphonuclear leukocytes from 
four different patient samples after first step Percoll 1118 density gradient 





Figure 4.4  Pure population of red blood cells in enriched fraction after first step 
density gradient centrifugation using Percoll 1118 followed by anti-CD45 then anti-













A-D: Wright staining of pure population of red blood cells after three step 
enrichment protocol.  Arrows indicate enriched NRBCs from maternal circulation 
from four different patient samples (40 x magnifications).  Figure B and C is likely 
to be primitive fetal nucleated eryhtoblasts as they are large and have a high 
cytoplasmic:nuclear ratio.  In contrast, figure A and D are likely to be definitive 




4.5 Development of combined immunocytochemical, 
immunoflourescence staining of ε-globin and cFISH for first-
trimester non-invasive prenatal diagnosis 
 
Aim:  Embryonic ε-globin has been identified as a fetal cell specific marker (section 
1.6.4.1).  Simultaneous immunofluorescence cytochemistry in which the specificity of 
cell of fetal origin is confirmed using ε-globin and cFISH technique for gender analysis 
was recently reported by Choolani et al. (2001).  In this section, we examine whether 
immunohistochemistry using vector blue substrate can be used to screen for cytospun 
slides which contain embryonic epsilon-globin before subjecting the slides directly for 
AMCA- ε-globin/cFISH after the two step enrichment protocol which is more expensive 
and labour intensive.  Such a technique, if proven could help in reducing the number of 
slides being processed.   
 
 Results:   Of the ten maternal peripheral blood samples processed (section 4.4), only four 
cases demonstrated 4, 24, 27 and 64 NRBCs across 4, 16, 2 and 21 slides, respectively.  
These 43 slides were processed for immunoenzymatic staining with anti-ε antibody for 
fetal primitive erythroblasts, using vector blue as a substrate (section 2.2.10).  FNRBCs 
isolated from surgical termination of pregnancies served as internal positive controls 
whereas FNRBCs stained with the secondary antibody only were used as internal 
negative controls (section 2.2.3).  Mononuclear cells enriched from adult peripheral blood 
were used as external negative controls (section 2.2.4).  The frequency of ε-globin 
positive NRBCs in our enriched sample before cytospin was assumed to be in the region 
of 1-2 per 100,000 mononuclear cells given that one-third of the slides were positive for 
ε-globin cells and that each cytospin included 50,000 cells.  There were 4, 5, 27 and 18 
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embryonic ε-globin positive primitive fetal nucleated erythroblasts identified (total = 54) 
across 4, 1, 2, and 7 slides (total = 14) respectively, under light microscopy.  The area 
where these cells were located on the glass slide was noted using the scale on the X- and 
the Y-axis on the microscope. Only 14 out of 43 slides were then processed for 
simultaneous fluorescence immunocytochemistry using streptavidin AMCA 
identification of ε-globin and cFISH for determination of gender (section 2.2.14).  All 
enriched fetal primitive nucleated erythroblasts could be clearly identified by their 
morphology and ε-globin status on immunofluorescence AMCA staining.    
 
The fetal origin could be simultaneously confirmed by XY cFISH analysis and all cells 
clearly depicted the gender signals (95% CI, 95%-100%).  Figure 4.5 shows nucleated 
red blood cells confirmed to be of male fetus in origin on combined 
immunocytochemical, immunofluorescence staining and cFISH (A-D).  Figure 4.6 
demonstrates primitive FNRBCs from a female fetus after combined 
immunocytochemical, immunofluorescence staining and cFISH.  These were concordant 
with gender identified on trophoblast tissues (two female and two male fetuses) (Figure 
4.7 a,b).  Primitive erythroblasts stained in the absence of primary antibody and adult 
lymphocytes stained negative for ε-globin.   
 
Interpretation: This data demonstrate that firstly the combined immunoenzymatic 
staining followed by subsequent fluorescence immunocytochemistry and cFISH 
technique is effective in proving NRBCs to be of fetal origin. The cell morphology was 
well preserved, which allowed visualisation of the fetal cell identifier and genetic signals 
at the same time.  Secondly, the low numbers of ε-globin positive NRBCs enriched meant 
that not all the slides contained these cells.  The method helped in reducing the number of 
slides being processed for AMCA and cFISH from 43 to 14.  Such a strategy to screen for 
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ε-globin positive NRBCs using colorimetric immunostaining technique after the two step 
enrichment protocol would be cheaper and faster and would be considerable cost savings 
in performing AMCA- ε-globin/cFISH in only slides which contain such cells. 
 
Figure 4.5 Combined immunocytochemical, immunofluorescence staining and 
































Figure A,C shows epsilon-globin positive primitive fetal nucleated erythoblasts on 
immunocytochemical staining.  The figures show intact cell membrane and intact 
nucleus with vector blue staining of the cytoplasm containing epsilon-globin.  Figure 
B,D shows immunofluorescence staining with cFISH (red signal X; green signal: Y; 
Male fetus) within the nucleus and accumulation of AMCA around the nucleus and 
staining of intracytoplasmic epsilon-globin positive primitive fetal nucleated 




Figure 4.6 Combined immunocytochemical, immunofluorescence staining and 
cFISH on primitive fetal nucleated erythroblasts enriched from maternal blood: XX 
fetus 
                                                     










Figure A,C,E shows epsilon-globin positive primitive fetal nucleated erythoblasts on 
immunocytochemical staining.  The figures show intact cell membrane and intact 
nucleus with vector blue staining of the cytoplasm containing epsilon-globin.  Figure 
B,D,F shows immunofluorescence staining with cFISH (red signal XX chromosome; 
Female fetus) within the nucleus and accumulation of AMCA around the nucleus 
and staining of intracytoplasmic epsilon-globin positive primitive fetal nucleated 























    
       
 
 
             (40 x magnifications) 
  
    Figure 4.7b   cFISH on fetal trophoblasts cells enriched from products of   
     conception:  Immunofluorescence staining of nucleus with DAPI (Blue colour).   
     Red signal shows X chromosome and green signal shows Y chromosome: Male  




              
                   
             (40 x magnifications) 
Figure 4.7a   cFISH on fetal trophoblasts cells enriched from products of 
conception:  Immunofluorescence staining of nucleus with DAPI (Blue colour).  
Red signal shows XX chromosome: Female fetus  
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4.6 Examination of the efficiency of a novel three-step  
 
enrichment protocol for first-trimester non-invasive  
 
prenatal diagnosis in in-vitro model system (2.2.20) 
 
This section examines the efficiency of a three-step enrichment protocol comprising of 
Percoll 1118, anti-CD45/anti-GPA and ammonium chloride/acetazolamide in an in-vitro 
model system using termination of pregnancy derived FNRBCs.  Following steps were 
integrated:  
 
1. Red cell bulk was depleted using Percoll 1118. 
2. Both the upper and the lower layer obtained after the first enrichment step were 
processed separately for subsequent MACS and erythrocytes lysis. 
3. The supernatant obtained from the washings of both the layers were centrifuged at 
3000 rpm (2060 g) for 10 minutes. Any cell pellet obtained was added to the cell 
suspension of their respective layers (Figure 4.8).   
4.  White cells were depleted using antibodies directed against lymphocytes,    
      monocytes and granulocytes using anti-CD45, and red blood cells were   
      positively-selected using anti-GPA 
5. Ammonium chloride/acetazolamide was used for selective erythrocyte lysis as the 
third-step enrichment process.   
 
Aim:  To evaluate the efficiency of a new fetal cell enrichment protocol in in-vitro model 
system.   
 
Results:  The mean recovery of primitive fetal erythroblasts in in-vitro model system after 
the three-step enrichment method was 37% (95% CI, 28.5% - 45.6%; n = 8).  There was 
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no statistically significant difference in the distribution of of FNRBCs between the upper 
and lower layer after the three step enrichment protocol (wilcoxon signed-rank test: p 
value = 0.063; two-sided test).  Figure 4.9 demonstrate enriched FNRBCs in in-vitro 
model system.  Figure 4.10 depicts a female fetus correctly identified on simultaneous ε-
globin AMCA staining and cFISH which matched to that identified on trophoblast tissue 
(Figure 4.11).  Figures 4.12, 4.13, and 4.14 shows the loss of primitive fetal erythroblasts 
in the Percoll 1118 cushion, within the depleted fraction of the LD column and the 
negative fraction of the MS column, respectively.   
A, B: Wright staining of nucleated red blood cells.  Arrows indicate fetal 
nucleated red blood cells in supernatant after the first-step density gradient 
centrifugation (20 x magnifications) 
Figure 4.8 Loss of fetal nucleated red blood cells in supernatant after first 




Figure 4.9 Enrichment of fetal nucleated red blood cells after three-step method in 

















A-D: Arrow indicates enrichment of fetal nucleated erythroblasts after three-step 




Figure 4.10 Immunofluorescence staining and cFISH on primitive fetal nucleated 





Figure A,B shows immunofluorescence staining with cFISH (red signal XX chromsome; 
Female fetus) within the nucleus and accumulation of AMCA around the nucleus and 




Figure 4.11   cFISH on fetal trophoblasts cells enriched from products of 
conception:  Immunofluorescence staining of nucleus with DAPI (Blue colour).  Red 












                     (20 x magnifications) 
 
 
    Wright stain of cells lost in the Percoll 1118 cushion.  Arrow indicates fetal  
    nucleated red blood cell lost in Percoll 1118 cushion.  The cell is likely to be fetal  
    primitive erythroblast as it is large in size and has a high cytoplasmic:nuclear   
    ratio.  Surrounding cells are maternal polymorphonuclear leukocytes (20 x  
    magnifications) 
 
Figure 4.12  Loss of fetal primitive erythroblast in Percoll 1118 cushion after the 




Figure 4.13 Loss of fetal primitive erythroblasts within LD column during the 










A,B shows wright stain of nucleated cells depleted in the LD column.  Arrow 
indicates fetal nucleated red blood cells lost.  Surrounding cells are maternal 
polymorphonuclear leukocytes (20 x magnifications) 
 
 
Figure 4.14 Loss of fetal primitive erythroblasts in negative fraction of MS column 
during the second-step enrichment process on MACS 
 
 
A,B shows wright stain of nucleated cells depleted in the MS column.  Arrow 
indicates fetal nucleated red blood cells lost in the negative fraction of MS column 
during the second step enrichment process.  Surrounding cells are maternal 




Interpretation:   The upper and lower layer obtained after the first step density gradient 
centrifugation and processed separately for anti-CD45/anti-GPA cell sorting on MACS 
and treated finally with ammonium chloride/1mM acetazolamide cocktail lysis buffer    
comprised of pure population of nucleated and anucelated red blood cells.  Using three-
step enrichment method, more than one-third of fetal primitive nucleated erythroblasts 
were recovered in in-vitro model.  Assuming that 36% of target cells are lost after the 
first step enrichment process (Choolani et al., 2003) and 7% of target cells are expected 
to be lost during the lysis step (section 4.2), 20% of primitive fetal erythroblasts are lost 
in the second step enrichment process.  This finding is similar to that reported by 
Choolani et al. (2003) who observed 24% loss of target cells after cell sorting with anti-
CD45/anti-GPA enrichment process in their model mixture experiments.   
 
4.7 Conclusion 
It is important to evaluate the intrinsic protocol efficiency in-vitro before studying its 
enrichment efficiency in an in-vivo model.  Choolani et al. (2003) had previously 
developed an enrichment protocol comprising percoll density gradient centrifugation and 
MACS.  Here, we tested, and added, the selective lysis of adult anucleate erythrocytes 
using ammonium chloride and 1mM acetazolamide, an inhibitor of carbonic anhydrase 
(Boyer et al., 1976; De Graaf et al., 1999; Volluaire et al., 2001). This strategy 
selectively lysed 96% of adult anucleate red blood cells while keeping 93% of fetal 
NRBCs intact. Our in-vitro experiments were designed to model the enrichment of first 
trimester FNRBCs. Fetal primitive NRBCs extracted from placental tissues were mixed 
with adult blood to mimic their enrichment from maternal blood; we could recover 37% 




Hence, the results in this chapter demonstrate that: 
(1) a combination of ammonium chloride/acetazolamide could be used as a third-step 
enrichment method; 
       (2)  a combined immunoenzymatic staining, immunofluorescence cytochemistry and   
            cFISH could be used to prove NRBCs of fetal origin; and immunohistochemistry   
            using vector blue substrate can be used to screen for cytospun slides which  
            contain PFNRBCs, that can subsequently be processed for AMCA- ε- 
            globin/cFISH. 
      (3) surgical termination of pregnancy can be used to evaluate efficiency of a new fetal   
           cell enrichment protocol in in-vitro model system. 
(4) approximately one-third of target cells are likely to be enriched using the three-   
            step enrichment system on maternal blood. 
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Chapter 5: Termination of pregnancy as an in-vivo 
model to study enrichment efficiency of a novel non-
invasive prenatal diagnosis method in the first- 




Two main strategies have emerged as a risk-free method for non-invasive prenatal 
diagnosis of genetic disorders:  the enrichment of fetal cells from the maternal blood and 
recently, the analysis of cell-free fetal DNA in maternal plasma or serum.  For cell-based 
strategy, the target cell that has been most sought for in the maternal blood for more than 
a decade is the fetal nucleated erythroblasts. Recently, primitive fetal nucleated 
erythroblast has been considered as an ideal target fetal cell type for first-trimester non-
invasive prenatal diagnosis in contrast to definitive fetal nucleated erythroblasts.  This is 
because (1) its characteristics differ significantly from that of definitive fetal nucleated 
erythroblasts and (2) it contains embryonic ε-globin as a fetal cell specific marker.  This 
chapter examines termination of pregnancy as an in-vivo model system to test the 
efficiency of the three-step enrichment method for first-trimester non-invasive prenatal 
diagnosis.  Target cells are likely to be obtained before and after the termination of 
pregnancy.  To be certain that the numbers obtained indeed reflect 37% efficiency of the 
three-step enrichment method identified earlier in in-vitro model system, a mathematical 
model would be constructed.  This would determine how accurate the efficiency of the 
three-step enrichment system in in-vivo model is to the one identified earlier in in-vitro 
model (section 4.6).  If termination of pregnancy is proven as a model system for the 
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study of first-trimester non-invasive prenatal diagnosis,  prediction mathematical model 
can then be postulated to the scientific community where the number of fetal cells present 
in the maternal blood in the first-trimester can be predicted based on the numbers 
enriched in the post-termination samples. 
 
Recently, it has been speculated that termination of pregnancy is a biological model for 
fetomaternal haemorrhage (Bianchi et al., 1997; Bianchi et al., 2001).  However, these 
studies suffered following limitations: (1) fetal cells instead of FNRBCs were targeted to 
prove the hypothesis.  Fetal cells include erythroid or lymphoid progenitor cells as well, 
which tend to persist post-partum from previous pregnancies and could confound the 
numbers in the current pregnancy (2) no enrichment protocol was used (3) pregnant 
women were enrolled in the study either after the invasive procedure or those known to 
be carrying aneuploid pregnancy, and therefore the number of fetal cells were influenced 
by the invasive nature of the procedure or aneuploidy status of the fetus, respectively and 
(4) pre- and post-procedure samples belonged to two different groups of women enrolled 
at two different time periods (1997; 2001).  This chapter also addresses whether first-
trimester termination of pregnancy is a biological model for fetomaternal haemorrhage.  
It was hypothesised that a three-fold increase in embryonic ε-globin positive fetal 
primitive erythroblasts could be achieved after first-trimester termination of pregnancy.   
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5.2 Enrichment of primitive fetal nucleated erythroblasts from 
first-trimester maternal blood before and after termination of 
pregnancy 
 
Aim:  (1) To develop an in-vivo model that could be used to evaluate efficiency of new 
fetal cell enrichment protocol for non-invasive prenatal diagnosis in the first trimester and 
(2) to determine the termination of pregnancy as a model for fetomaternal haemorrhage. 
  
Sample Size: A sample size of 10 subjects was calculated based on following  
assumptions: 
 
• 2 sided test of 5% 
 
• Power of 80% 
 
• Three-fold increase in FNRBCs following CVS procedure, based on study by Al-
Mufti et al. (2003). 
 
Investigation:  Paired blood samples (23 ml) were obtained 2 hours before and within 5 
minutes of elective first-trimester surgical termination of pregnancy from 10 patients.  
Gestational age was established by ultrasonography.  Those in whom cervical priming 
was to be carried out, blood was drawn prior to the insertion of pessary.  Products of 
conception were collected and placed in phosphate buffered saline (PBS) for subsequent 
fetal gender confirmation only after cell sorting, staining for ε-globin and cFISH, so that 
the gender was predicted prospectively in a blinded fashion.  A three-step enrichment 
method for sorting first-trimester fetal primitive erythroblasts from maternal blood was 
carried out (section 4.6).  Subsequently, the cells from the upper and the lower layer were 
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separately cytospun on the glass slides and underwent Wright staining (section 2.2.5) and 
were viewed under light microscope for morphological visualisation and count of 
nucleated erythroblasts.  Slides which showed the presence of NRBCs, were 
subsequently processed for combined immunohistochemistry, AMCA and cFISH using ε-
globin as a fetal cell specific marker (section 2.2.14).   
 
Data Analysis:  The data was analysed by SPSS (Statistical Package for Social Sciences) 
version 11.5.  Non-parametric Wilcoxon signed rank test for paired samples was applied 
for the comparison of the number of NRBCs isolated from each layer after the three-step 
enrichment method as the samples did not have a Gaussian distribution.  A p value of 
<0.05 was considered to be statistically significant.  Results are reported as means, 
median and ranges, though in a non-Gaussian distribution, the median is the best 
representative of all value in the series.  The significance of the correlation was analysed 
using Spearman Rank analysis.    
 
Results:  The mean maternal age was 24 years (SD 3.92) (Table 5.1).  The mean 
gestational age at the time of termination of pregnancy was 9+3 weeks (SD 1.53).  After 
first-step density gradient centrifugation in the pre-termination samples, significantly 
greater number of mononuclear cells were found in the upper layer compared to the lower 
layer (p = 0.007).  On the other hand, significant contamination with red blood cells was 
noted in the lower layer (p = 0.009) compared to the upper (Table 5.2).  Although, a 
three-fold increase in the number o f NRBCs and  ε-globin positive nucleated cells was 
observed in the upper compared to the lower layer after the three-step enrichment 
method, the distribution of NRBCs (p = 0.31) and ε-globin positive nucleated cells (p = 
0.53) in the upper layer were not significantly different from that of the lower layer 
(Table 5.1). 
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In the post-termination samples, the number of mononuclear cells was also significantly 
higher in the upper layer (p = 0.005) with no significant difference in the distribution of 
red blood cells (p = 0.06) across the two layers (Table 5.2).  Despite a 1.3- and 1.4-fold 
increase in NRBCs and ε-positive nucleated cells in the upper compared to the lower 
layer, the number of NRBCs and the primitive fetal nucleated erythroblasts retrieved in 
the upper layer were not significantly different (p = 0.64) and (p = 0.53) from that of the 
lower layer after the three-step enrichment protocol (Table 5.1).   
 
An average of 3 and 10 ε-globin positive fetal primitive erythroblasts were recovered 
from the three-step enrichment method per 20 ml maternal blood before and after the 
first-trimester termination of pregnancy, respectively.  A significant increase in NRBCs 
(p = 0.005) and ε-globin positive nucleated erythroblasts (p = 0.005) were observed after 
termination of pregnancy.  A 3- and 2.8-fold increase in NRBCs and ε-globin positive 
fetal nucleated cells were noted after the invasive procedure, respectively, which were 
statistically significant (p = 0.005) (Table 5.2).  Fold increase in NRBCs after termination 
of pregnancy was associated with an increase in ε-globin positive nucleated cells and a 
significant positive correlation was noted between the two (r = 0.82; p = 0.004) (Figure 
5.1).  A significant positive correlation was also observed in the increase of NRBCs (r = 
0.66; p = 0.03) and ε-globin positive cells (r = 0.65; p = 0.04) as gestational age advanced 
in pre-termination maternal blood samples (Figure 5.2 and 5.3)   
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Table 5.1:  Enrichment of NRBCs and ε-globin positive primitive fetal erythroblasts 
after three-step protocol  
 
                   
                                Patients No    Maternal age    Gestation at blood   Pre-TOP NRBCs    Pre-TOP ε+ cells    Post-TOP NRBCs   Post-TOP ε+ cells   Fetal              AMCA/     
                                (years)              collection day         1st layer/2nd layer    1st layer/2nd layer     1st layer/2nd layer    1st layer/2nd layer      karyotype      cFISH    
                              (weeks/days)    
   
   1.      22  8+5  6             0             6              0        7 0              7         0    XY         XY    
 
   2.      24  9+4 2              0            2        0       6 0             4         0    XY                   XY        
 
   3.      27   7+3 0             2            0        1       1 4             0         2    XY                   XY     
   
   4.      18  10+4 3             3            3        1       0 12           0       10    XX                   XX        
 
   5.      23  12 4             7            0        7     22 3           15         3    XY                   XY   
       
   6.      20  8+2 0             3            0        3       9 0             9         0    XY         XY   
      
   7.      25  11+5 7             0            7        0     15 6           15         6    XY         XY        
 
   8.      32  8+5 3              0            3        0     17 7             6         5             XX         XX        
 
   9.      24  9+1 13            0            1        0      2 39           0         4             XY         XY        
 
   10.      21  8+2  0             2            0        2      2 10          1        10   XY         XY       
      
 
Total                        38         17             22       14    81  81        57            40         
                                                                                                     ___________________________________________________________ 
Minimum          18   7+3    0            0              0        0    0 0            0            0              
Maximum          32  12 13           7             7                7 22                39          15         10         
Mean      23.6  9+3 3.80       1.70         2.20          1.40 8.10             8.10       5.70        4.00          
Median    3.00       1.00         1.50           0.50 6.50             5.00      5.00         3.50          
SD        3.92  1.53 4.05       2.26         2.57           2.22 7.58             11.64    5.85         3.80           
     __________________________________________________________ 






Table 5.2:  Enrichment of NRBCs and ε-globin positive primitive fetal erythroblasts 




   Minimum Maximum    Mean     Median       Standard Deviation   p-value   
 
Pre-top upper layer MNCs  1.90 x 107 6.09 x 107       3.57 x 107       3.41 x 107             1.25 x 107     0.007 
             
Pre-top lower layer MNCs  1.22 x 107 5.04 x 107       2.29 x 107       2.28 x 10              1.10 x 107  
  
Pre-top upper layer RBCs      0 1.05 x 107       3.72 x 106       2.76 x 106                 4.04 x 106 
             
Pre-top lower layer RBCs             3.96 x 106    2.88 x 108       9.00 x 107       7.44 x 107                8.77 x 107    0.009 
 
Post-top upper layer MNCs       1.92 x 107    6.60 x 107       4.22 x 107       3.87 x 107               1.26 x 107    0.005 
 
Post-top lower layer MNCs   6.0 x 106     3.45 x 107       2.17 x 107       2.50 x 107          1.21 x 107 
                                                                                                                                                                                             
Post-top upper layer RBCs   6.0 x 105      2.40 x 107        6.04 x 106        3.0 x 106            7.24 x 106                
             0.06 
Post-top lower layer RBCs                    6.0 x 105      2.75 x 107      1.34 x 107       1.44 x 107               9.58 x 106   
 
Pre-top NRBCs (total)  2 13     5.50       4.50              3.92 
 
Post-top NRBCs (total)   5                  41   16.20                12             11.44    0.005 
  
Fold increase in NRBCs   1.17 8   3.41        3               2.04    0.005  
  
Pre-top ε-globin+ cells  1 7   3.60        3               2.32 
 
Post-top ε-globin+ cells   2 21   9.70        9.50               6.07     0.005 
 
Fold increase in ε-globin+ cells  1.17 5.50   2.94       2.79               1.22     0.005 
 
 
Top:  Termination of pregnancy; MNCs: Mononuclear cells; RBCs: Red blood cells; NRBCs: 
Nucleated red blood cells
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            Figure 5.1 Correlation between fold increase in nucleated red blood cells and ε-  
            globin positive primitive fetal nucleated erythroblasts after termination of   































































































































Figure 5.3 Correlation between pre-termination enriched ε-globin positive primitive 















The predicted fetal gender on AMCA and cFISH matched that confirmed by cFISH on 
samples of trophoblast tissue in each case:  (two females and eight male fetuses).  The 
morphology of enriched cells was clearly visible on AMCA and the gender signals could 
be clearly visualised on cFISH analysis (Figure 5.4 and 5.5).  No ε-globin positive XX 
cells were noted among male fetuses.  Similarly, no ε-Hb-NRBCs were observed in the 















































Figure 5.4 Immunofluorescence staining and cFISH on male fetal primitive 
nucleated erythroblasts enriched from first-trimester maternal blood 
 







Figure A-D shows immunofluorescence staining with cFISH (red signal:X 
chromosome; green signal:Y chromosome: Male fetus) within the nucleus and 
accumulation of AMCA around the nucleus and staining of intracytoplasmic ε-
globin positive primitive fetal nucleated erythroblasts, depicting the morphology of 
the entire cell (20 x magnifications) 
 
Figure 5.5 Immunofluorescence staining and cFISH on female fetal primitive 
nucleated erythroblasts enriched from first-trimester maternal blood 
 
       
Figure A,B shows immunofluorescence staining with cFISH (red signal:XX 
chromosome: Female fetus) within the nucleus and accumulation of AMCA around 
the nucleus and staining of intracytoplasmic ε-globin positive primitive fetal 








Interpretation:  The data show that application of the three-step enrichment protocol 
recovered on an average 3 fetal primitive nucleated erythroblasts cells before and 10 after 
termination of pregnancy per 20 ml maternal blood, respectively.  The procedure also led 
to an approximately three-fold increase in ε-globin positive primitive fetal nucleated 
erythroblasts following termination.  A significant increase in mononuclear cells was 
obtained in the upper layer as compared to the lower layer after first-step Percoll 1118 
density gradient centrifugation implying more recovery of NRBCs and primitive fetal 
nucleated erythroblasts was to be expected in the upper layer.  Although, a three-fold 
increase was noted in the recovery of both NRBCs and primitive fetal nucleated 
erythroblasts from the upper layer, no significant difference was observed in their 
distribution in the upper as compared to the lower layer after the three-step enrichment 
method.   
 
In the post-termination samples, despite a significant increase in mononuclear cells in the 
upper as compared to the lower layer, the number of NRBCs and primitive fetal 
nucleated erythroblasts retrieved were not significantly increased compared with that of 
the lower layer.  The frequency of NRBCs and primitive fetal erythroblasts in maternal 
blood increased progressively as the gestational age advanced from 7+3 weeks to 12 
weeks gestation.   
 
Based on the above results, a mathematical model was constructed.  The relationship 
between the observed number of pre- and post-termination enriched primitive fetal 
nucleated erythroblasts determined by linear regression is: 
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Observed number of pre-termination primitive FNRBCs = co-efficient between pre and 
post-termination primitive FNRBCs x observed number of post-termination primitive 
FNRBCs 
 
The co-efficient for our model = 0.354 (95% CI, 0.264% - 0.444%) 
 
The 89.8% of the variability in the number of fetal primitive nucleated erythroblasts 
observed in the pre-termination samples is determined by the number of cells obtained in 
the post-termination samples (R2 =0.898).  Therefore, the accuracy of our in-vivo model 
is approximately 90%.  With 37% efficiency, we could enrich 3 and 10 cells before and 
after termination of pregnancy, respectively.  Therefore, the actual number of primitive 
fetal nucleated erythroblasts likely to be circulating before and after termination of 
pregnancy would be 8 and 27 per 20 ml maternal blood, respectively. 
 
Thus, the following mathematical relationship for the prediction of number of pre-
termination primitive FNRBCs to be obtained through an enrichment system is 
postulated: 
 
Expected number of enriched fetal nucleated erythroblast in pre-  
            termination sample = efficiency of the enrichment system x enriched  
           fetal nucleated erythroblast in post-termination sample / 100 
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5.3 Conclusion   
 
This chapter examines the use of maternal blood obtained post-surgical termination of 
pregnancy as a suitable in-vivo model to test the efficiency of the three-step enrichment 
method for first-trimester non-invasive prenatal diagnosis.  The protocol was able to 
enrich 3 and 10 ε-globin positive primitive fetal nucleated erythroblasts per 20 ml 
maternal blood before and after termination of pregnancy, respectively.  The data also 
suggest that termination of pregnancy can lead to an approximately three-fold increase in 
the trafficking of embryonic ε-globin positive fetal primitive nucleated erythroblasts cells 
into maternal blood and hence, is a biological model for fetomaternal haemorrhage as that 
not only FRNBCs is raised but so as our target cell types. 
 
The results demonstrate that surgical termination of pregnancy can be used as a model, 
both in-vitro and in-vivo for the study of first-trimester non-invasive prenatal diagnosis.  
We show that post-termination of pregnancy enrichment of ε-globin positive primitive 
fetal erythroblasts can estimate the efficiency of that particular enrichment system in on-
going pregnancies. Earlier studies have used post-termination maternal blood to evaluate 
the usefulness of fetal cell enrichment methods, but none have been able to indicate how 
this correlates with on-going pregnancies (Samura et al., 2000; Wang et al., 2000; 
Choolani et al., 2003). Our study shows that an enrichment protocol can expect three-fold 
fewer fetal cells in an ongoing first trimester pregnancy than the number of cells enriched 
from first trimester maternal blood obtained after surgical termination of pregnancy. 
 
This study is unique as the factors such as the timing of drawing of the blood before and 
after invasive procedure, recruiting only those pregnant women who had no episode of 
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bleeding, and drawing blood before the insertion of pessary were taken into account 
during the design phase of the study.  Further, the blood samples were taken from the 
same women before and after the invasive procedure.   
 
There is no study in the current literature which has used termination of pregnancy as a 
model for first-trimester non-invasive prenatal diagnosis.  This is the first time such a 
procedure has been used and proven as a model for the study of non-invasive prenatal 
diagnosis.  Voullaire et al. (2001) tried to use first-trimester CVS as a model to study 
non-invasive prenatal diagnosis.  The efficiency of their enrichment protocol was 70% in 
in-vitro model.  However, when applied on the patient samples before and after CVS, no 
first-trimester FNRBCs could be enriched from the pre-CVS samples (Voullaire et al., 
2003).  This could be because the numbers of first-trimester FNRBCs obtained from the 
CVS washings were too small to test the efficiency of an enrichment system in an in-vitro 
model.   
 
The three-step enrichment system can be applied on patient samples in an ongoing 
pregnancy in the first-trimester to calculate the number of epsilon-globin positive 
primitive fetal nucleated erythroblasts present.  Surgical termination of pregnancy can be 
used to evaluate efficiency of an enrichment method in in-vitro model by other 
investigators to test the efficiency of their protocol for first-trimester non-invasive 
prenatal diagnosis.  Once the efficiency of their enrichment system is determined, the 
procedure can be used as an in-vivo model where the enrichment method could be applied 
only to post-termination maternal blood samples.  The number of cells circulating in the 
post-termination samples can be calculated.  The mathematical model mentioned above 
can then be used to predict the number of pre-termination target cells present in the 
maternal blood.  The predicted numbers can help the investigators decide, whether the 
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enrichment system is efficient enough to be used on patient samples in an ongoing 
pregnancy in the first trimester for non-invasive prenatal diagnosis.   
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Chapter 6: Termination of pregnancy as a model system 
to study first-trimester non-invasive prenatal diagnosis 




The recent demonstration of relatively large amounts of circulating cell-free fetal DNA in 
maternal blood (Lo et al., 1997) has revealed another source of fetal genetic material that 
could be used for non-invasive prenatal diagnosis.  Recently, few investigators have tried 
to determine whether cell-free fetal DNA can be used as a marker of fetomaternal 
haemorrhage using invasive procedures such as second-trimester amniocentesis (Samura 
et al., 2003) or first-trimester termination of pregnancy (Wataganara et al., 2004; 
Wataganara et al.,  2005) as a biological model.  Samura et al. (2003) were able to 
quantify and show a significant increase in the cell-free fetal DNA levels after 
amniocentesis.  However, the result could have been influenced by (1) the inclusion of a 
single outlier which should have been excluded from final analysis so as to help 
understand the data distribution and (2) mean has been reported as a measure of central 
tendency instead of median.  Wataganara et al. reported conflicting results.  In their 
earlier study (2004) the authors demonstrated an increase in post-procedure cell-free fetal 
DNA levels while in their later report (2005), they did not observe significant difference 
in the post-termination DNA levels over the pre-termination in the first trimester.   
 
It was demonstrated in chapter 5, that termination of pregnancy is a biological model for 
fetomaternal haemorrhage.  A post-procedure three-fold increase in fetal primitive 
nucleated erythroblasts trafficking was observed.  This chapter examines whether first-
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trimester termination of pregnancy can be used to quantify cell-free fetal DNA as a 
marker of fetomaternal haemorrhage.  If proven, the procedure can be used as a model 
system to study non-invasive prenatal diagnosis using cell-free fetal DNA as a biological 
marker.   
 
6.2 Effect of first-trimester termination of pregnancy on cell-
free fetal DNA levels in maternal blood   
 
Aim: To determine whether an increase in cell-free fetal DNA levels in maternal blood 
can be obtained after first-trimester termination of pregnancy. 
 
Investigation: Paired blood samples (3 ml) were obtained 2 hours before and within 5 
minutes of elective first-trimester surgical termination of pregnancy from 10 patients for 
quantitative analysis of cell-free fetal DNA (section 2.2.15).  Twenty millilitre of blood 
sample both before and after the procedure had been obtained from the same group of 
patients for fetal cell enrichment and identification (Chapter 5, section 5.2).  The data 
were analysed by SPSS (Statistical Package for Social Sciences) version 11.5.  Non-
parametric Wilcoxon signed rank test for paired samples was applied for the comparison 
of the concentration of cell-free fetal DNA levels before and after the procedure.  A p 
value of <0.05 was considered to be statistically significant.  Results are reported as 
means, median and ranges, though in a non-Gaussian distribution, the median is the best 
representative of all value in the series.   
 
Result: There were 8 male fetuses as determined by the amplification curve using SRY 
sequence (Figure 6.1).  The gender was confirmed with cFISH on trophoblast cells.  
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Among these pregnancies with male fetus (n = 8), a significant increase in NRBCs (p = 
0.01) and ε-globin positive fetal nucleated erythroblasts (p = 0.01) were observed after 
the termination of pregnancy (Table 6.1).  A significantly three-fold and a 2.79 fold 
increase in NRBCs (p = 0.01) and ε-globin positive primitive fetal nucleated erythroblasts 
(p = 0.01) respectively, were also observed after the invasive procedure (Table 6.2).  A 
significant positive correlation exist between the fold increase in post-termination 
NRBCs and ε-globin positive primitive fetal nucleated erythroblasts (r = 0.864; p = 
0.006) (Figure 6.2).  No significant difference was noted in the concentration of cell-free 
fetal DNA levels after the termination of pregnancy compared to before the procedure (p 
= 0.52) (Table 6.1).  Although a 1.16 fold increase in cell-free fetal DNA after the 
invasive procedure was observed, it was not statistically significant (p = 0.77) (Table 
6.2).   
 
Figure 6.1 Amplification curve of SRY on cell-free fetal DNA from maternal plasma 
 
Delta Rn 
No. of cycles 
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Table 6.1:  Cell-free fetal DNA concentration before and after termination of 




                   
                            Patients No    Maternal age    Gestation  age    Pre-TOP   Post-TOP    Pre-TOP    Post-TOP     Pre-TOP        Post-TOP        Pre-TOP          Post-TOP 
                                (years)          (weeks/days)      NRBCs      NRBCs      ε+ cells       ε+ cells       β-globin        β-globin        DNA levels     DNA levels 
                                                                                                                                                   (total DNA)   (total DNA)    (GE/ml)            (GE/ml)  
     (GE/ml)        (GE/ml) 
 
   














   
    4.      23             12               11           25              7              18      1083.60          3263.40               8.62                6.22 
 
   
 
       
   5.      20               8+2                  3             9              3           9              1213.60         1797.40             23.60              20.80 
 
   
 
      










   8.      21               8+2                  2           12              2              11      1309.80         1536.00              5.94                8.74 
 
     
 
                  _____________________________________________________________________________________________________________________ 
 
 
Minimum          20                 7+3                         2             5                   1           2               1022               808.53              1.55                0.01 
 
 
Maximum          27                12                13           41                   7                21              4779.40         5077.60            23.60              75.20 
 
 
Mean      23.25                  9.27           5.75        15.75             3.63            9.50           1872.75         2481.54              9.99              18.71    
 
 
Median        -                   -               4.50        10.50             2.50            8.00            1315.50         2425.90             8.02                9.81   
 
 
SD       2.25               1.65             4.33        12.52            2.62            6.87            1262.99         1429.08             7.74              24.69    
 
 
                                  ________________________________________________________________________________ 
 
 




 Table 6.2 Fold-increase in NRBCs, ε-globin positive primitive fetal nucleated 
erythroblasts and cell-free fetal DNA concentration after termination of pregnancy 
in the first-trimester 
 
       Minimum   Maximum Mean          Median SD         p-value 
Fold increase in NRBCs              1.17         6                3.01           3.00 1.37    0.01  
Fold increase in ε-globin+ cells 1.17     5.50                2.90           2.79 1.35         0.01 
 
         Fold increase in β-globin         0.33     3.01                1.53           1.33 0.85    0.06 
  
Fold increase in cell-free        0.01   28.83                 4.36              1.16         9.91         0.77 
fetal DNA levels                        
 
 
Figure 6.2 Correlation between fold increase in NRBCs and ε-globin positive 















No significant correlation was found to exist between the number of NRBCs obtained in 
these fetuses and the corresponding concentration of cell-free fetal DNA after the 
termination of pregnancy (r = -0.262; p = 0.53) (Figure 6.3).  

















































Figure 6.3 Lack of correlation between numbers of post-termination enriched 















However, a significantly strong negative correlation was observed between the number of 
primitive fetal nucleated erythroblasts recovered after the invasive procedure and the 
post-termination levels of cell-free fetal DNA (r = -0.790; p = 0.02) (Figure 6.4).    
 
 
Interpretation: A significant increase in NRBCs and ε-globin positive primitive fetal 
nucleated erythroblasts were observed after the invasive procedure in women carrying 
eight male fetuses.  Increases in post-procedure NRBCs were associated with significant 
concomitant increase in ε-globin positive primitive FNRBCs.  No significant increase 




Number of nucleated red blood cells enriched 
































Figure 6.4 Negative correlation between numbers of post-termination enriched ε- 

















No significant relationship could be demonstrated between the post-termination NRBCs 
number and levels of cell-free fetal DNA.  On the other hand, after termination of 
pregnancy, the number of ε-globin positive fetal nucleated erythroblasts cells obtained 




The data from this chapter show that cell-free fetal DNA levels cannot be used as a 
marker to demonstrate fetomaternal haemorrhage using first-trimester termination of 
pregnancy as a biological model.  Although, an approximately three-fold increase in 
Number of epsilon-globin positive primitive fetal nucleated 

































NRBCs and epsilon-globin positive primitive fetal nucleated erythroblasts were observed 
following termination of pregnancy, no significant increase in cell-free fetal DNA levels 
were observed.  Both fetal primitive nucleated red blood cells and cell-free fetal DNA are 
concurrently present in the circulation of all pregnant women in the first trimester.  
Fetomaternal haemorrhage after termination of pregnancy can be expected as early as 7 
weeks of gestation, unlike the results reported by Wataganara et al. (2005), who 
suggested that fetomaternal haemorrhage is likely to occur only after 8 weeks gestation.  
Despite an increase in the trafficking of fetal primitive nucleated erythroblasts following 
termination of pregnancy, and assuming that many of these cells traversing the 
fetomaternal interface are readily undergoing programmed cell death and are likely to 
deliver fetal genetic material into maternal circulation, a significant decrease in the post-
procedure fetal DNA levels was observed.  The mechanism for such an increase in fetal 
cell trafficking following first-trimester termination of pregnancy with no significant 
increase in cell-free fetal DNA remains unknown.  Therefore, termination of pregnancy 
cannot be used as a model system for the study of first-trimester non-invasive prenatal 
diagnosis using cell-free fetal DNA.   
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Chapter 7: General Discussion 
 
This thesis aimed to determine (i) if embryonic ε-globin positive fetal nucleated 
erythroblasts persists beyond the first-trimester in trisomy 18 fetus and at birth in trisomy 
18 neonates and (ii) if termination of pregnancy can be used as a model system to study 
efficiency of a three-step enrichment protocol for first-trimester non-invasive prenatal 
diagnosis. 
   
In this chapter, I examine if the hypotheses put forward can be accepted or must be 
rejected, assess the clinical implications of these results within the field of non-invasive 
prenatal diagnosis, crticically evaluate the limitations of these data, and propose potential 




Epsilon-globin positive primitive fetal nucleated erythroblast was found to persist not 
only in the second trimester in trisomy 18 fetus but also at term in these neonates.  
Therefore hypothesis 1 which states that: “Embryonic epsilon-globin positive nucleated 
red blood cells persists beyond the second trimester using trisomy 18 as a model” can be 
accepted. 
 
Most investigators attempted fetal cell recovery directly from maternal blood without 
first demonstrating the efficiency of their enrichment protocol in model mixtures. This 
assumes 100% recovery and no variation. We show this is not the case. Using one 
protocol we get only 37% recovery on a consistent basis, with some variation (95% CI, 
28.5%-45.6%; n=8).  In studies that have attempted model mixture evaluation, the spiked 
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cells did not always represent the exact target for non-invasive prenatal diagnosis, which 
in the first trimester would be fetal primitive NRBCs. Cells that have been used include 
cord blood NRBCs, cord blood derived expanded erythroid cells, and fetal liver cells 
(Gan-Shirt et al., 1998; Bhat et al., 1993; Troeger et al., 1999; Smits et al., 2000; Bianchi 
et al., 1996).  We used our exact target cells (first trimester FNRBCs) in our model 
mixtures so that we could determine accurately how our protocol would perform when 
using first trimester maternal blood.  Large numbers of primitive fetal nucleated 
erythroblasts was successfully enriched from termination of pregnancy tissue for this 
purpose (section 4.2).  The target cells were spiked in model mixture and the efficiency 
of the three-step enrichment system, Percoll 1118, anti-CD45/anti-GPA and ammonium 
chloride/acetzolamide was effectively tested using termination of pregnancy as an in-
vitro model (section 4.6).   
 
To date, there is no biological model to determine the in vivo efficiency of any new fetal 
cell enrichment protocol. Ideally, a procedure that causes increased fetal cell trafficking 
could allow evaluation of the in-vivo enrichment efficiency of new such protocols by 
studying their enrichment in maternal blood obtained post-procedure.  Furthermore, the 
model should closely reflect the average-risk maternal population, and not bias the 
enrichment efficiency by studying only high risk pregnancies. We show that maternal 
blood obtained post surgical termination of pregnancy is a suitable in-vivo biological 
model for new fetal cell enrichment protocols and methods. We have demonstrated that 
three fold fewer fetal cells would be enriched from maternal blood in ongoing 
pregnancies than those isolated from post termination maternal blood.  Thus hypothesis 2 
which states that surgical termination of pregnancy can be used to evaluate efficiency of 
a new fetal cell enrichment protocol in in-vitro model system and it can be used as an in-
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vivo model to study enrichment efficiency of a novel non-invasive prenatal diagnosis 
method in the first trimester can be accepted. 
 
Cell-free fetal DNA in maternal blood has been investigated as a marker of FMH (Lau et 
al., 2000; Bianchi et al., 2001; Wataganara et al., 2004; 2005). Surprisingly, we did not 
observe any change in cffDNA and total DNA levels in maternal plasma within 5 min 
after surgical TOP. Earlier studies had suggested an increase in these levels within 
maternal blood samples taken after surgical TOP, but the sampling times had varied 
(Bianchi et al., 2001; Wataganara et al., 2004; 2005). Recently, Jeong et al. (2007) 
reported a linear increase in both total DNA and cffDNA levels in maternal plasma at 
different time points after elective first trimester surgical TOP. DNA levels were 
significantly higher at 90 min after the procedure.  It was suggested that this may be due 
to the slow release of cell-free nucleic acids from the fetal cells that had entered into the 
maternal circulation after the procedure. These data by Jeong et al. (2007) may explain 
the insignificant change in total DNA and cffDNA levels we observed in our study where 
maternal blood was collected immediately after surgical TOP. 
 
7.2 Implication of results in the context of non-invasive 
prenatal diagnosis 
 
New protocols and novel methods of non-invasive prenatal diagnosis are difficult to 
compare because the in-vivo model has not been standardized. We propose an ideal in- 
vivo model where new systems can be tested because a greater number of fetal cells are 
circulating in maternal blood after surgical termination of pregnancy. The results 
obtained from this model can be extrapolated to obtain likely efficiency of the system in 
both healthy and at-risk pregnancies. This model can be readily standardized within and 
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between research groups, so that the data can now be compared. We believe this in-vivo 
model is a useful addition that would bring non-invasive prenatal diagnosis closer to 
clinical service.  
 
This thesis also shows that the three-step enrichment protocol is able to enrich 37% of the 
ε-globin positive primitive fetal nucleated erythroblasts circulating in the maternal blood 
in the first trimester and that such cells are likely to persists beyond the first-trimester and 
upto term in trisomy 18 newborns.  The number of cells enriched may not allow the 
applicability of the technique as an independent diagnostic test for non-invasive prenatal 
diagnosis in the first-trimester in near future, as even the gold standard tests such as 
amniocentesis and chorionic villus sampling requires analysis of at least 20 cells from 
two different flask cultures (Guetta et al., 2004).  However, it can be used as an additional 
screening marker and can represent a new approach to screening for Down syndrome.  
The current non-invasive screening test gives a risk estimate to the couples.  At the same 
time an independent test can be carried out on maternal blood for the number of ε-globin 
positive nucleated cells using the three-step enrichment protocol.  An increase in the 
number of cells in the first-trimester maternal blood and the persistence of such cells in 
the second-trimester could indicate the pregnant women at risk of carrying an aneuploidy 
fetus.  The decision to go on to invasive procedure could then be based on the results of 
two independent non-invasive screening tests.   
 
Embryonic ε-globin is a specific fetal cell identification marker and the three-step method 
gives a pure population of nucleated and anucleated red blood cells with no maternal 
contamination of white cells.  Therefore, a combined immunohistochemistry together 
with AMCA and cFISH for chromosome-21 can be performed on ε-globin nucleated cells 
enriched from those women who are identified at high-risk after two non-invasive 
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independent screening tests.  AMCA being a fetal cell identifier would help in depicting 
the morphology and therefore, would help in the identification of the fetal cells with three 
copies of chromosome 21. 
 
7.3 Using epsilon-globin positive primitive fetal nucleated 
erythroblasts for diagnosis of genetic disorders at single cell 
level 
 
The numbers of primitive fetal nucleated erythroblasts obtained from the three-step 
protocol may be low enough to preclude its usage for first-trimester non-invasive prenatal 
diagnosis of chromosomal disorders for the time being, micromanipulation is one strategy 
that could allow its utilisation for the diagnosis of genetic disorders.  Sekizawa et al. 
(1996) demonstrated that it was possible to select single fetal NRBCs by 
micromanipulation and potentially diagnose genetic conditions such as Duchenne 
muscular dystrophy (DMD) by PCR.  In one of six cases studied, DMD was suspected 
when four out of seven exons within the DMD gene were not amplified but the diagnosis 
was not confirmed since all seven exons were subsequently amplified from another 
sample obtained from the same slide.  To show that their technique could have identified 
DMD if present, they tested one lymphocyte from a patient with DMD and demonstrated, 
by PCR, the correct deletion in exon 50.  One limitation of the study was that erythroblast 
identified by morphology alone was presumed to be fetal in origin.  Though Watanabe et 
al. (1998) demonstrated the prenatal diagnosis of the X-linked ornithine transcarbamylase 
deficiency syndrome, NRBCs were picked up based on their morphology rather then fetal 
in origin.  Martel-Petit et al. (2001) identified NRBCs based on Kleihauer test and 
applied micromanipulation to a pregnancy at risk for cystic fibrosis.  However, one cell 
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demonstrated a heterozygous genotype, which could have resulted from selection and 
analysis of a maternal cell.   Therefore, using non-specific fetal cell marker could lead to 
the procedure to be labour intensive and time consuming as it is not clear whether the 
cells picked up are indeed fetal or maternal NRBCs.  In contrast, Chueng et al. (1996) 
used micromanipulation to pick ζ-globin positive fetal NRBCs and diagnosed fetal 
haemoglobinopathy in two pregnancies between 10-12 weeks.  However, ζ-chain is not 
absolutely fetal specific and has been reported in adult carriers of α-thalassaemia 
(Cheung et al., 1984; Chui et al., 1986, Tang et al., 1992).  On the other hand, ε-globin is 
a highly specific fetal cell marker and under the current circumstance whereby low 
numbers of these cells are obtained from maternal blood, primitive fetal erythroblasts 
staining positive for ε-chain can be isolated by micromanipulation technique and utilised 
for PCR based diagnosis of genetic disorders.  Figure 7.1 shows the usage of 
micromanipulation technique on first trimester fetal primitive nucleated erythroblasts 
enriched from termination of pregnancy tissue and Figure 7.2 demonstrates ε-globin fetal 
cell identification marker and cFISH signals on these cells which were fixed on the glass 
slides.  It can be seen that the morphology of the cells are clearly intact after 
micromanipulation.   
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Figure 7.1 Application of micromanipulation technique on first-trimester 




Figure A-D indicates primitive fetal nucleated erythroblasts being picked using 
micromanipulator at a single cell level (20 x magnifications) 
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7.4 Limitations of this research 
 
The low number of cells retrieved using the three-step enrichment protocol could have 
been likely due to too many steps involved in the enrichment process.  Sixty-three 
percent of the target cells are expected to be lost after the three-step enrichment process 
Figure 7.2 Immunofluorescence staining of ε-globin and cFISH for gender 





Figure A-D shows immunofluorescence staining with cFISH (red signal:XX 
chromosome: Female fetus) within the nucleus and accumulation of AMCA 
around the nucleus and staining of intracytoplasmic ε-globin positive primitive 
fetal nucleated erythroblasts, depicting the morphology of the entire cell (60 x 
magnifications).  Morphology of the cells are well preserved after 
micromanipulation at the single cell level 
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(section 4.6).  Besides, the enrichment procedure is time-consuming, as each of the two 
layers was processed separately after the first-step density gradient centrifugation.   
 
Although, a very short exposure to ice-cold ammonium chloride/acetazolamide was 
incorporated into the enrichment protocol for in-vitro model system and clinical samples, 
it is expected that 7% of fetal cells may have been lost during this step after the first two 
step of enrichment process (section 4.3).  If a surface antigen-based immunselection 
strategy were available, both the density gradient centrifugation and the lysis step would 
preferably be omitted. 
 
7.5 Directions for future research 
 
The three-step enrichment protocol using ε-globin as a fetal cell specific marker applied 
in this thesis, retrieves a small number of fetal primitive nucleated erythroblasts from 
pretermination maternal blood samples.  The future work should aim to involve 
incorporation of ζ-globin together with the application of ε-globin as a fetal cell 
identification marker so as to increase the number of target cells.   
 
The one step during the enrichment process that is associated with the greatest cell loss is 
density gradient centrifugation (Choolani et al., 2003).  It is recognised that elimination 
of this mechanical step and replacement by an immunsorting strategy would enhance rare 
fetal cell recovery.  Thus, identification of unique, differentially expressed surface 
membrane proteins and antigens is the key to improved enrichment protocols.  A 
proteomic approach can be utilised to address this issue.  Comparing membrane protein 
profiling of RBCs and FNRBCs using the complimentary techniques of one and two-
dimensional electrophoresis and Surface Enhanced Laser Desorption and Ionisation mass 
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spectrometry (SELDI-TOF/MS) could be useful.  Matrix Assisted Laser Desorption and 
Ionisation mass spectrometry (MALDI-TOF/MS) could also be used for peptide mapping 
and identification.  Finding surface antigens that could be used to differentiate fetal 
erythroblasts from adult anucleate erythrocytes would eventually be ideal, so that the use 
of density gradient centrifugation and selective erythrocyte lysis can be avoided.  This in 
turn could cut down the number of steps involved in the enrichment method and therefore 
the cell loss.   
 
As adult anucleate erythrocytes are smaller and more deformable than fetal primitive 
erythroblasts, these properties could be exploited to deplete maternal erythrocytes and 
eliminate the need for density gradient centrifugation.  One such technique that could be 
beneficial is the designing and development of microelectromechanical systems (MEMS) 
filters for size-based filtration of fetal and maternal cells.  
 
Finally, for clinical applicability, once all aspects of the non-invasive prenatal diagnostic 
technique have been optimised, these can be automated including locating ε-globin 
positive erythroblasts on the microscope slides and capturing the images for evaluation 
by a technician at a convenient time.  This could in future may cut down the number of 
steps involved in enrichment process, as purity would not be seen as an utmost criteria 
and therefore contamination with maternal nucleated cells would not interfere with the 
automated scanning system, as it would capture only AMCA positive embryonic ε-globin 
primitive fetal erythroblasts.  However, such an automated diagnostic technique would 
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